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Abstract
Understanding the stock market in the 21st century is very important to investors as well as
company executives. All publicly traded companies get most of their financing by issuing stock
on the various stock markets of the world. These stocks are then brought and sold to investors.
The research in this dissertation used the event study methodology to evaluate the United States
stock market rate of return for pharmaceutical stocks impacted by pandemics in 2009 and 2020.
Using the stocks' historical data before and after the announcement of a pandemic by the World
Health Organization, this event study will see if the pandemic affects the stocks' rate of return.
Key words: pandemic, rate of return, abnormal return, expected return, and actual return.
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Section 1: Foundation of the Study
Event studies are used to test how the stock market incorporates information about a
specific event and with empirical evidence, support or disprove the basic assumptions of the
event study. Event study findings could be profitable for both the company (Alrgaibat, 2015) and
an investor. At the same time, the opposite holds that the market will respond unfavorably if the
information is not profitable. Hence, event studies are used to determine if an event is of value to
an investor in making an investment decision in the future (Thaler & Shiller, 2015).
Following in the basic steps of Wang (2016), who investigated the impact of an event as
a dependent variable, it was concluded that the stock market is always efficient. This is different
from research by Daniel and Hirshleifer (2015), who studied the impact of an event and
statistically revealed that abnormal returns followed an event caused by investor behavior and
outside forces. Compared to other researchers like Charron (2015) and Daniel and Hirshleifer
(2015), whose research concluded that the stock market does not react to an event. Their research
concluded no difference in the average Rate of Return (ROR) before or after an event. Wang
(2016) suggested that the market’s reaction to an event is just considered a normal equity
reaction.
Background of the Problem
The average person is an investor in the stock market, either as a single stockholder,
401K holder, a mutual fund owner or a purchaser of goods sold by companies that offer stocks
(Alrgaibat, 2015; Dalbar Associates, 2020; Wenjing, 2017). If you are involved in the purchase
or selling of equity, the question arises as to how much the investor can make by buying and
selling equity. By buying or selling an asset, an investor hopes to make a reasonable ROR. The
money to be made is the ROR multiplied by the investment. When it comes to buying and selling
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stock, information is critical to both the company and the investor. Of course, information can
move a stock price in either a good or bad way resulting in sales, buys, holds, gains and losses.
How this information is interpreted is always in question and can either have a negative
or positive effect on the stock price, depending on the recipient. Information usually takes the
form of dividends, company takeovers, elections, laws passed at either the federal or state level,
or an unplanned event such as an earthquake (Ball & Brown, 1968). The research of this event
study is to see the effect of the announcement of a pandemic by the World Health Organization
(WHO) on pharmaceutical sector stock prices on the NYSE. This research also looked to see if
the Efficient Market Hypothesis (EMH) (Fama, 1970; Pilkington, 2017) consistently holds,
resulting in investors generating statistically significant abnormal returns because of the
announcement of a pandemic by the WHO. The EMH states that share prices reflect all available
information, and consistent alpha generation is impossible (Fama, 1970). In its simplest form, the
EMH states that the market cannot be beaten over the long haul (Charron, 2015), but no research
validates that with repetitive market anomalies caused by pandemics. Also, according to Thaler
and Shiller (2015), Charron (2015), and Daniel and Hirshleifer (2015), no research attempted to
look at a small subsection of the market and not a market in general. Therefore, this research is
unique because it looks for patterns in a specifically targeted sub-section of the stock market to
see if Thaler and Shiller (2015), Charron (2015), and Daniel and Hirshleifer's (2015) findings
hold that there is a flaw in the EMH.
Problem Statement
The general problem to be addressed is the failure of the EMH to hold consistently,
resulting in investors being able to generate statistically significant abnormal returns. Charron
(2017) asserted that the EMH does not hold and is flawed in it is very fundamental wording. This
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problem was validated by Daniel and Hirshleifer (2015), Pung and Lee (2020), and Wang
(2016), who also disagreed with the EMH holding true because of investor behaviors and outside
forces. The problem with the EMH holding true is further explained by the research of Thaler
and Shiller (2015), who, like Charron (2015) and Daniel and Hirshleifer (2015), found that the
EMH does not hold true based on another idea, which is the premise of explaining rational
behavior in the markets. The specific problem to be addressed is the failure of the EMH to hold
consistently, resulting in investors being able to generate statistically significant positive
abnormal returns in the pharmaceutical sector of the United States’ stock market following the
announcement of a pandemic by the World Health Organization (WHO).
Purpose Statement
The purpose of this event study research was to evaluate the potential impacts of
pandemics on the financial performance of the United States stock markets, specifically, the
pharmaceutical sector of the New York Stock Exchange (NYSE) after the announcement of a
pandemic (Thaler & Shiller, 2015; Wang, 2016). This event study was a fixed design using
quantitative methods to examine the cause and effect of the announcement of a pandemic on the
stock market (Babones, 2016). This event study used a t-Test, portfolio theory, and market model
to determine the abnormal return of the 26 pharmaceutical stocks compared to the Standard and
Poor (S&P) 500 (Morgan et al., 2013) (Appendix B).
This event study was a fixed design using the quantitative method because it is
exploratory, deductive, and has hypotheses (Babones, 2016; Creswell, 2014; Yin, 2018). The
qualitative research method alone is not appropriate for this event study because it has a
hypothesis. The quantitative method alone is also not appropriate for this research because the
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research is comparing and interpreting data from multiple theories on one event, looking for data
not presented in one set of findings from one theory (Babones, 2016; Creswell, 2014; Yin, 2018).
Nature of the Study
The nature of the study was a fixed design using quantitative methods, specifically
causal-comparative ex post facto quantitative research because the objective was to test an
existing theory and examine the relationship between the actual return to their expected return
after the announcement of a pandemic by WHO compared to the estimation period and the S&P
500 (Creswell, 2014; Yin, 2018). The market model was used to determine the abnormal return
of the healthcare sector pharmaceutical stocks to do the causal-comparative analysis.
The healthcare sector of the NYSE is made up of 196 companies as of January 2020
(NYSE, 2020). For this event study, a sample of 26 pharmaceutical companies was chosen. This
sample size was also the same as the population of pharmaceutical companies that have existed
since 2009, before the first pandemic in this study. This sample size was validated by a power
analysis that exceeded the 95% confidence level and the 5% confidence interval requirement for
a research project with a 0% error rate of proving the hypothesis. The reason for choosing the
pharmaceutical sector of the market was because there was an expectation that pharmaceutical
firms would exhibit abnormal positive returns on the announcement of a pandemic by the WHO
since they may have been the ones to produce a treatment, cure, and/or vaccine for a pandemic
(Center for Disease Control [CDC], 2020; Pung & Lee, 2020; WHO, 2020). This was because
most of the market was losing funding; the pharmaceutical sector was gaining funding. This
increased funding for research leads to a secondary effect of studying what the pharmaceutical
sector had to do with the problem of the EMH consistently holding, resulting in investors being
able to generate statistically significant positive abnormal returns (Thaler & Shiller, 2015). They
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argued that the stock market is inefficient, has bubbles, and exhibits anomalies, which is the case
of specific funding of a sub-section of the market during a crisis. Yet, according to Fama (1970),
the whole stock market responds the same way because it takes in all information and responds
accordingly (Freihat, 2019; Wenjing, 2017).
An event study is either an event-history analysis or an interrupted time series analysis
(Alrgaibat, 2015; Wenjing, 2017). An event-history analysis uses time as the dependent variable
and then looks for variables that explain the duration of an event or the time until an event
occurs. The interrupted time series analysis compared a before and after or a cause and effect of
an event to explain how and to what degree the event changed something. In this study, we
looked at how the announcement of a pandemic by the WHO impacts the pharmaceutical stock
price on the NYSE. Therefore, this event study was a time series analysis of the effect of the
announcement of a pandemic by the WHO on pharmaceutical stock actual ROR versus the
expected return of the stock compared to the movement of the entire market represented by the
S&P 500.
A causal comparative study examines the relationship between the variables the
researcher cannot manipulate and events that have already occurred before the research is started.
Then the researcher tries to explain the cause of the difference in the variables by looking at
outside factors that lead to an observed difference (Creswell, 2014; Yin, 2018). To use this
methodology, the researcher identified two groups that were similar in every way except for the
difference being studied. As stated earlier, this research was looking to see if the announcement
of a pandemic (independent variable) makes a difference in stock price (dependent variable)
using a logical argument, persuasion, and statistics (Creswell, 2014; Yin, 2018;
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thefreedictionary.com, nd). The market model was used to determine the abnormal return of the
pharmaceutical stocks compared to the S&P 500 to recalculate ROR.
Discussion of Method
Event studies are designed to investigate the effect of an event on a specific dependent
variable using statistics. The most commonly used dependent variable in event studies is the
company's stock return. In an event study, the goal is to study the changes in stock return beyond
expectation or what is called an abnormal return (Beladi et al., 2016; Charron, 2017; Daniel &
Hirshleifer, 2015; Thaler & Shiller, 2015). The change in stock returns occurs over a time called
an event window (Beladi et al., 2016), and the researcher can infer the significance of the event
on the stock ROR.
Cumulative abnormal return (CAR) is abnormal for an event study. A CAR is merely an
average of the time (TP) to compare to the actual expected return of the stock and compared to
the S&P 500 of the NYSE to see how the actual returns differ from the estimated return of the
stock and the movement of the stock market itself. CAR is required for research because over a
small-time window of hours or days, abnormal returns by themselves can lead to bias in result
findings (Thaler & Shiller, 2015). Therefore, CAR is a better indicator of abnormal return since
it is the average of the ROR over some time. In this study, the CAR would look at the 21 days
and seven-day pre- and post-event windows for the announcement of a pandemic by the WHO
on the pharmaceutical companies in the healthcare sector of the NYSE (Chen et al., 1986).
The data used in this research about stock prices will come from the historical data of the
NYSE (2020). Since the stock price data is readily available for the public, there should be no
ethical concerns about collecting or analyzing this readily available public data. Also, all
information about stock prices have been validated by outside sources and through multiple
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research criterion, legal compliance and typically audited. Reliability and validity of the online
stock price data from reputable sources should not be an issue for this research project. This
event study has research questions (RQs) and supporting hypotheses. Both the RQs and
hypotheses are used to formulate and propose statistics for validation and for supporting the
findings.
The research questions and hypotheses are based on the question of the failure of the
EMH to hold consistently, resulting in investors being able to generate statistically significant
positive abnormal returns in pharmaceutical stocks from the healthcare sector of the NYSE due
to the announcement of a pandemic by the WHO. Leading to the idea that an investor can
outperform the overall stock market through specific stock selection or specific market timing on
stock purchases because of an event (Wenjing, 2017). While the hypothesis does not have to be
correct, it does have to have a choice of outcomes that are either true or false. Therefore, this
event study has two scientifically testable predictions about the relationship between the stock
ROR and the announcement of a pandemic by the WHO. The first hypothesis looks for a direct
relationship between the stocks ROR; before and after the announcement of a pandemic by the
WHO. The second hypothesis looks to see if the EMH is supported by the behavior of the overall
market in the volume of stock actually traded.
These hypotheses are based on the work of Fama (1970) and Pilkington (2017), who said
the market is efficient and that prices are directly reflective of events and will trade at their fair
market value. Daniel and Hirshleifer (2015) argued that the market is affected by outside events.
This is the premise behind hypothesis one (H10), which states there is no statistically significant
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difference in the aggregate pharmaceutical sector stock(s) rate of return after announcing a
pandemic by the WHO.
The second hypothesis (H20) looks to support the work of Thaler and Shiller (2015) who,
like Charron (2015) and Daniel and Hirshleifer (2015), looked to explain the rational market.
The second hypothesis (H20) determines if a flaw exists in the EMH, which does not look at
stock prices, but stock volume. When a stock is trading in larger than normal stock volume, it
would be an indicator of a flaw in the market that could be exploited and used to predict the
movement of a stock and hence a flaw in the EMH (Wenjing, 2017). This in itself is the basis of
supply and demand, which is an underlying basis of EMH. Supply and demand say low
availability and high demand with increase a stock price; whereas the opposite is true and high
availability and low demand will decrease the stock price. So, increased movement of the
volume of stock would indicate a potential area to exploit or an anomaly in the market (Wang,
2016). Therefore, H2a states there is no statistically significant difference in the volume of
aggregate pharmaceutical stock traded after the announcement of a pandemic by the WHO.
Summary of the Nature of the Study
The market model describes the relationship of the expected ROR over a period of time
for an asset(s), where the ROI is how much one plans to get back from an investment that was
purchased (Alrgaibat, 2015; Freihat, 2019; Wenjing, 2017). This event study will analyze the
EMH, employ the market model, and use t-Tests to statistically prove whether or not the
announcement of a pandemic by the WHO does or does not affect stock price(s) in the
pharmaceutical sector.
Research Questions
This event study has two research questions (RQs) which are,
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RQ1. What is the difference between the pharmaceutical stocks’ rate of return before and
after the announcement of a pandemic by the WHO?
RQ2. What is the difference in the volume of pharmaceutical stock traded before and after
the announcement of a pandemic by the WHO?
Hypotheses
There must be a hypothesis related to the research, as with any quantitative scientific
research. The hypothesis uses statistics to help prove or disprove a theory. The following
hypotheses are proposed for this event study to complement the previous research questions.
Hypothesis 1
H10 - There is no statistically significant difference in the pharmaceutical stocks’ rate of
return after the announcement of a pandemic by the WHO.
H1a - There is a statistically significant difference in the pharmaceutical stocks’ rate of
returns after the announcement of a pandemic by the WHO.
Hypothesis 2
H20 - There is no statistically significant difference in the volume of pharmaceutical
stock traded after the announcement of a pandemic by the WHO.
H2a - There is a statistically significant difference in the volume of pharmaceutical stock
traded after the announcement of a pandemic by the WHO.
Theoretical Framework
Conceptual Framework
At its simplest form, a conceptualized framework of an event study can be defined as a
representation of a theory if the theory has a solid and logical rationale (Palache et al., 2017).
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According to Shoemaker et al. (2003), this idea is supported by the belief that a theory can
explain or predict an outcome; but a model merely describes something. This model ideology,
however, does not reveal why the relationship exists between the events being studied.
Shoemaker et al. (2003) also stated, though a model is not a theory, a model can be used to
represent a theory (p. 112) and continues that a research model helps describe a process, but a
research theory is needed if the author intends to understand how the actual research process
works. The question to be addressed is if there is a failure of the EMH to hold consistently,
resulting in investors being able to generate statistically significant positive abnormal returns in
pharmaceutical stocks due to the announcement of a pandemic by the WHO.
Framework
While all sectors of a stock market are affected by a pandemic, some areas are hit harder
than others. Historically, some sectors of the life sciences/ pharmaceutical companies do better
than the normal equity stocks (EY Analytics, 2020). There is a two-fold reason for this anomaly.
First, the world hopes pharmaceutical companies produce a cure, treatment, or vaccine for the
pathogen (CDC, 2020; Palache et al., 2017). Secondly, governments typically invest in
pharmaceutical companies for treatments for the population and the military (FDA, 2020).
According to EY Analytics (2020), the pharmaceutical sector has outperformed the
market in the last three financial crises of the twentieth century. These financial crises are the
savings and loan crisis of 1991, the dot.com bubble of 2001, and the financial crisis of 2008 (EY
Analytics, 2020). Based on this data, this event study hypothesizes that pharmaceutical
companies would have positive abnormal returns because of the announcement of a pandemic by
the WHO because people are looking to pharmaceutical companies for the solution to a
pandemic (Palache et al., 2017). Once a treatment or a vaccine is available, governmental
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agencies are the first and sometimes largest buyers (CDC, 2020). This can be because the role
and mission of the CDC are to protect America from health, safety, and security threats, in the
U.S. Whether diseases start at home or abroad, are chronic or acute, curable, or preventable,
human error or deliberate attack, CDC fights disease and supports communities to do the same.
(CDC, 2020). This can be seen in the CDC financials, where they brought $4.1 billion on the
Vaccines for Children program (CDC, 2020) or where the National Vaccine Program spent $102
million according to the Health and Human Services United States Government (2019).
EY Analytics (2020) conducted research that said pharmaceutical company stock prices
showed significant wealth creation with positive news about tests and product delivery.
However, losses from the same study were much larger following bad news for pharmaceutical
companies. Other research by Himmelmann and Schiereck (2012) identified certain causes for
the changes in stock price because of the media's increased attention. The wealth creation or
destruction is reflected in the stock price and stock volume traded. Himmelmann and Schiereck
(2012) also found that the smaller the pharmaceutical company, the larger the stock price
increase.
Two predominant empirical models measure the ROR in an event study examining
pharmaceutical companies’ stock prices. They are the market model and CAPM (Alrgaibat,
2015; Freihat, 2019). These theories are typically used independently and have resulted in mixed
findings. This framework follows the idea of Babones (2016), who takes on a mixed method
approach for the positivist standpoint and uses it quantitatively, not the qualitative manner with
which researchers normally associate positivism. Babones (2016) uses interpretivism or social
constructivism from a positivist perspective. The only difference is that typically a social
constructivist/ interpretivist is part of the study, not an outside observer.
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Therefore, the market model is employed in this research to see if an abnormal return is
generated. A market model predicts the theoretical ROR of the pharmaceutical sector stock. The
final theory is a Nobel Prize winner by Markowitz (1952) called the Modern Portfolio Theory
(MPT). MPT is based not on an asset but on a group of assets called a portfolio (Markowitz,
1952), which means that in a t-Test of data from a group of stocks, prices might cancel out or not
reveal an abnormal return. The one factor that will not change is the total number of trades,
which means that using Markowitz's (1952) MPT may show an increased volume of stock
traded.
The final piece of the event study framework is the variables. This event study has
independent, dependent, and intervening variables and mentions possible extraneous variables
(Creswell, 2014; Yin, 2018). The announcement of a pandemic is the proposed independent
variable that affects the dependent variable of the pharmaceutical stock prices of the healthcare
sector of the NYSE. Other variables in research are extraneous variables (Creswell, 2014; Yin,
2018). This event study attempts to mention some extraneous variables, but these variables are
just mentioned and may or may not affect the outcome. This event study has an intervening
variable of the WHO. This is because the announcement of a pandemic by the WHO is the
determining factor of if a disease/ pathogen/epidemic becomes a pandemic (WHO, 2020).
Summary of Conceptual Framework
Existing pharmaceutical research almost exclusively focuses on stock price clinical trial
studies and company announcements made by the Food and Drug Administration. Research on
stock price responses of public pharmaceutical companies listed on the NYSE or other stock
exchanges is very limited. In this event study, I will try to fill this void in research by analyzing
twenty-six long-term pharmaceutical companies to see if they exhibit a positive abnormal return
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because of the announcement by the WHO. The choice of companies is based on these being the
only NYSE companies to exist during both pandemics. Twenty-six pharmaceutical companies
from the healthcare sector of the NYSE were selected as the sample and the only existing
population, which exceeds the ninety-five percent confidence level and the five percent
confidence interval requirement for a research project.
Because the sample is one hundred percent of the population, the hypotheses can be
accepted or rejected with a margin of error of 0%. This is the first of the kind research for this
topic since there have only been two pandemics since 2003 when the WHO started issuing
Public Health Emergency of International Concern and only six pandemics in the last 120 years.
There has been a multitude of pathogens and epidemics in the United States and the World,
according to the WHO (2020). However, the WHO is the only group that can make a disease/
pathogen/ epidemic a pandemic and, therefore, an intervening variable that can affect the
pharmaceutical stocks of the healthcare sector of the NYSE.
Definition of Terms
Fairly
To a degree or extent. Reasonable or moderately. Conforming to the laws and rules. Fair,
just, and honestly and right. (thefreedictionary.com, nd)
Finance Ethics
The concept of right and wrong in financial/ accounting methods (Mintz & Morris,
2011).
Irrational
Not having the ability to reason, not logical, non-sensical, poor judgment, not of sound
mind, incoherent, no mental clarity (thefreedictionary.com, nd)
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Rate of Return (ROR) achieved (actual) in the market during the holding period
(Alrgaibat, 2015; Fama, 1970; Freihat, 2019; Ragsdale, 2015; Wenjing, 2017).
Rational
Having the ability to reason, logical, good judgment, and sound mind.
(thefreedictionary.com, nd)
Realized Rate of Return
Return of Investment (ROI) gained on the equity during the holding time adjusted due to
inflation and other factors (Alrgaibat, 2015; Fama & MacBeth, 1973; Freihat, 2019; Ragsdale,
2015; Wenjing, 2017)
Risk-free ROR
A return that can be earned without bearing any risk. This ROI is represented by returns
on treasury bills (T-bills) issued by the Federal Reserve and or Central Bank of the United States.
T-bills are better than bonds because they do not fluctuate daily like bond rates (Alqisie &
Alqurran, 2016).
Religion
For purposes of this event study, the word can briefly describe ANY religion unless
otherwise specified. Examples are Atheism, Buddhism, Christianity, Hinduism, Islamic,
Judaism, and Wicca.
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Table 1
Abbreviations
Abbreviation
AHT
AKA
AM
AUM
CAPM
CBO
CDC
DAX
ECN
EIS
GAAP
GDD
GDP
HIPAA
IBRD
ICSID
IDA
IFC
MIGA
MLP
NASDAQ
NYSE
PEF
PHEIC
PM
REIT
RET
ROI
ROR
RRR
SARS
SE
SEC
S&P
T-bills
UNDP
WHO

Meaning
After Hours Trading
Also Known As
Ante Meridian
Assets Under Management
Capital Asset Pricing Model
Congressional Budget Office
Center for Disease Control
Deutscher Aktienindex – German stock market list of 30 stocks
Electronic Communication Networks
Epidemic Intelligence Service
Generally Accepted Accounting Principle
Global Disease Detection Program
Gross Domestic Product
Health Insurance Portability and Accountability Act
International Bank for Reconstruction and Development
International Centre for Settlement of Investment Disputes
International Development Association
International Finance Corporation
Multilateral Investment Guarantee Agency
Master Limited Partnership
National Association of Securities Dealers Automated Quotations Exchange
New York Stock Exchange
Pandemic Emergency Financing Facility
Public Health Emergency of International Concern
Post Meridiem
Real Estate Investment Trust
Rational Expectations Theory
Return on Investment
Rate of Return – (has various meanings depending on application)
Required Rate of Return
Severe Acute Respiratory Syndrome
Stock Exchange
Securities and Exchange Commission
Standard and Poor’s
Treasury Bills
United Nations Development Program
World Health Organization
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Assumptions, Limitations, Delimitations
This researcher believes in the statement made by Leedy and Ormond (2010), who
asserted that assumptions are so basic that without them, the research problem itself could not
exist (p. 62). Because of this, assumptions should be said to be probably true; otherwise, the
study cannot move forward. All data were collected via electronic records posted on the internet
on websites managed by the NYSE, Bloomberg, various company/ government websites, the
WHO, and the CDC. Also, all websites are reliable and accurate for the pharmaceutical stock
market ROR.
Assumptions
The assumption is that all data collected and presented by the NYSE (2020), the WHO
(2020), the CDC (2020), and Bloomberg (2020) is correct and accurate as of the date the data
was collected. This event study and research also assume that all data collected and presented by
the various company financials are correct and accurate as the data was collected. This study was
limited to the collection of data readily available as public records on the collection date.
Limitations
The first limitation is reporting time and dates for this study. All dates and times may be
uncoordinated due to the International Date Line. The dateline or timeline moves a clock one
hour for every 15 degrees of travel longitude around the globe when one moves East to West
(Lamont, 1921). There is a possibility of seconds, minutes, or hours of variance in when or
where someone heard the announcement of a pandemic by the WHO. This limitation affects the
reporting time of pandemic events but is impossible to control from a research perspective. This
limitation is best addressed by reporting all dates and times reported in research articles.
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The next limitation was that the methodology depended on the assumption of an efficient
market (Fama, 1970). This assumption is not valid in many situations, as Poser (2003) pointed
out. Poser (2003) pointed out the length of time required for individual investors to respond to
the event(s) is random, and therefore the implication is that the markets could exhibit
inefficiencies because prices do not instantly or fully reflect all available information. This is
because stock prices usually increase in a series of steps as investors respond in waves. This is
referred to as the Elliott Wave Principle or Elliott Wave Theory (Poser, 2003). This limitation of
an efficient market is beyond the scope of this research but is a component of this event study.
Another limitation is that the researcher has no control of stock prices for the
pharmaceutical sector or any stock in the stock market. In addition, the S&P 500 index was used
as a proxy for the market. This index includes the most liquid and largest market companies
(NYSE, 2020). Based on this information, the S&P 500 index may not represent all stocks in the
market. The S&P 500 could not be the most representative index by some researchers due to the
definition of terms and variables. Even if we assume away the problems of the EMH, we might
have other problems if the companies under study are contaminated by other concurrent, preexisting, or short-term ensuing events not found from a simple company inquiry during the event
window time frame. Concurrent events and studied events in different stock sectors might
weaken or reinforce the event, generating an abnormal return not caused by the specific event
being studied (Beladi et al., 2016). This limitation is mitigated by reporting all prices accurately
from the historical data of the NYSE.
Delimitations
The delimitations of this research are that it is focused on the stock ROR of
pharmaceutical stock in the healthcare sector stocks of the NYSE from April 2009 to March

18
2020 to see if the pandemic affected the ROR of the stocks. The research is also limited to these
actual research questions and hypotheses. Changing the research question and hypothesis could
change the findings of this event study. At the same time, changing the equity database(s) to
other stock, stock sectors, events, dates, or other equities could also change the data and findings
of this research.
Significance of the Study
The EMH is a stock market investment theory that Fama created (1970) that said it is
impossible to beat the market and make an investment that outperforms the overall market. The
problem of the EMH consistently holds; results in investors being able to generate statistically
significant abnormal returns (Beladi et al., 2016; Charron, 2017; Daniel & Hirshleifer, 2015;
Thaler & Shiller, 2015), which is the underlying premise of this event study. Couple these
problems of the EMH with the use of the market model and MPT (Aldaarmi et al., 2015; Bajpai
& Sharma, 2015; Wenjing, 2017), which by themselves are the basis of many studies for
corporate financial theory. This study may contribute to the existing body of knowledge by
presenting a valid model that can be used in future theoretical event study problems in which just
the traditional market model is used to see if an event has a bearing on the stock market ROR.
Reduction of Gaps
Gap is a term used to imply what the research learns (Beladi et al., 2016). This research
paper serves to bridge the gap between the event study and the actual event of the announcement
of a pandemic by the WHO on the NYSE pharmaceutical stocks ROR. Secondly, this research
examines whether different results can be derived from the same data using the market model
and MPT. Finally, if positive abnormal returns are found, this research may assist hedge fund
and mutual fund portfolio managers as to where to direct some of their investments in future
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pandemics. The interpretation and repercussions between these two pandemic events and the
expectations of the outcomes in standards and practices are the gap in this research (Beladi et al.,
2016).
Implications for Biblical Integration
The King James Version of the Bible is specific in three verses that sum up the basis of
this event study. Luke 16:11 says. “And if you are untrustworthy about worldly wealth, who will
trust you with the true riches of heaven?” Luke 12:34: “Where your treasure is, there your heart
will be also.” Then Revelations 3:17-18: “You say, 'I am rich, with everything I want; I don't
need a thing!' And you do not realize that spiritually you are wretched, miserable, poor, blind,
and naked.”
Relationship to Field of Study
This event study looks at the financial aspect of the financial calculation of the United
States pharmaceutical stocks of the NYSE and if the announcement of a pandemic by the WHO
affected the pharmaceutical stocks ROR. Finance also relates to the market model (Aldaarmi et
al., 2015; Bajpai & Sharma, 2015) because it is the most frequently used stock price expected
return model. The market model builds on the actual returns of a reference market return and the
correlation of the firm's stock return with the reference market return.
Summary of the Significance of the Study.
In modern finance, findings are required to be backed up by generally accepted
accounting principles (GAAP) and supported by proven numbers and statistical data (Morgan et
al., 2013). The readers and peer reviewers of research should easily follow logically and
unbiasedly. The nature of the study is a fixed design with quantitative methods. The quality of
the data from the research was as important as the interpretations of the data. Therefore, the
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usefulness of the data is qualitative, using feelings and meanings to offer a holistic professional
evidence-informed decision for the effect of the announcement of a pandemic by the WHO on
the ROR of pharmaceutical stocks of the NYSE.
A Review of the Professional and Academic Literature
Event Study
An event study is an analysis performed on a security or a combination of securities that
examines the impact of an event on the value of that security (Beladi et al., 2016; Chan et al.,
1997; Charron, 2017; Daniel & Hirshleifer, 2015; Thaler & Shiller, 2015). An event study will
reveal how a security is likely to react to said catalyst occurrence (the event) or contingent event.
According to Binder (1998) and Fama et al. (1969), the event study does the following uses
information from a specific time about a stock price and, using the event study methodology,
calculates the normal return and then possibly an abnormal return.
Three time points are needed to calculate the findings of an event study. They are a
period before the event (pre-event) or the (estimation period), the time of the event or (event
day), and a time after the event (post-event) or (observation period) (Binder, 1998; Fama et al.,
1969) these time collectively are called an event window (Ball & Brown, 1968). The researcher
can infer the event's significance on the stock from these findings. However, the basic premise of
event study must be true for this to be true: the market is efficient (Fama, 1970). If the market is
efficient, the event's effect will be reflected immediately in the stock price of the company being
studied (Fama et al., 1969). The event study methodology works to calculate the normal return of
stock from the pre-event window and the new actual return of stock during and after an event.
Then the actual return of the event and post-event time are deducted from the pre-event findings,
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and an abnormal return is attributed to the event (Beladi et al., 2016; Chan et al., 1997; Charron,
2017; Daniel & Hirshleifer, 2015; Thaler & Shiller, 2015).
The researcher hypothesized this abnormal return, and research questions and hypotheses
are proved or disproved. This can be seen in the following research, as many researchers have
found problems with the EMH. For example, Thaler and Shiller (2015) and Chan et al. (1997)
argued that the stock market is inefficient, has bubbles, and exhibits anomalies. These bubbles
and anomalies in the stock market allow investors to make money if they specifically buy a stock
based on known or hypothesized information that will affect the stock or the stock market
overall.
Charron (2017) found that small-capitalization stocks outperform large-capitalization
stocks. As Beladi et al. (2016) described, the January Effect is a stock market anomaly whereby
a stock that performed badly in the last quarter of a year performs better in January of the next
year. Chan et al. (1997) and Charron (2017) found that companies with low-price book ratios
outperform the market. Charron (2017) studied reversals and found that stocks that performed
well or poorly in one year typically performed the opposite in the subsequent year.
Daniel and Hirshleifer (2015) also discussed other market anomalies caused by outside
forces. Other events around the world like bankruptcies, mergers, defaulting on debt, changes in
management, weather, terrorist attacks, and presidential tweets have shown, on occasions, that
anomalous events can result in statistically significant positive or negative abnormal the United
States stock market returns (Elbe, 2008; Karolyi, & Martell, 2010; Wang, 2016). Event studies
look for relationships between the selected equity prices and the chosen catalyst and how the two
factors interact.
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Bias
A bias is a preference or an inclination. Something that someone does affects their
judgment (thefreedictionary.com, nd). With this in mind, every researcher must know that not
every person can have and invest in equity with the same amount of information. Every person
will read, experience, and observe different things and view the things they see and read
differently (Rieger, 2012). Rieger (2012) concluded that behavioral biases lead investors to make
bad estimates on the probability of the ROR from investments. Other researchers like Kahneman
and Sahi et al. (2013) attempted to list a series of biases by investors. These biases included:
preferring known risks over unknown risks, relying on something as a point of reference, making
investment decisions based on easily available and known information, playing it safe with risk,
investing differently in an asset-based on yearly income, trying to be social responsibility, invest
in familiar equities, say they learn from their past decisions, are adverse to losses, often feel
regret, overconfident in their ability, rely on family and friends, and follow current trends
(Kahneman & Riepe, 1998; Rieger, 2012; Sahi et al., 2013).
Apart from investor bias is research bias. Research bias is not just found in conclusions
from the research. It is drawn in every aspect of research. It can be found in the event study’s
design, data collection, and data analysis (Smith & Noble, 2014). Understanding bias allows the
reader and the writer of research to review the literature and findings critically and independently
to remove any potentially harmful opinions. At the same time, it keeps the research evidence
based. Most bias in research is based on the fact that researchers are unwilling to publish results
that show unfavorable findings. This is because researchers fear negativity towards their work or
findings (García-González et al., 2019; Smith & Noble, 2014). Research work, whether good or
bad, is still research. Edison was quoted by the World Bank in the 1994 Infrastructure for
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Development Report as saying, I have not failed 10,000 times. I have successfully found 10,000
ways that will not work. (World Bank, 2020). This is the same mentality a researcher has to
have. It is not a failure. It is more about learning what does not work so that others can know
what not to try and move on and try something else.
World Bank
The World Bank is a part of the World Bank Group and is made up of the International
Bank for Reconstruction and Development (IBRD) and the International Development
Association (IDA) (Fernandes, & Sridhar, 2017; World Bank, 2020). The World Bank provides
loans to poor developing countries to pursue capital projects. The World Bank is made up of five
organizations. These organizations are the International Bank for Reconstruction and
Development (IBRD), the International Development Association (IDA), the International
Finance Corporation (IFC), the Multilateral Investment Guarantee Agency (MIGA) and the
International Centre for Settlement of Investment Disputes (ICSID) (Fernandes & Sridhar, 2017;
World Bank, 2020). The World Bank is located in Washington, DC and has financing with all
193 countries involved in the United Nations (World Bank, 2020). The World Bank’s goal is to
reduce poverty, and its largest benefactors are the countries of China and India (Fernandes, &
Sridhar, 2017; World Bank, 2020).
The World Bank has a unique relationship with pandemics. The World Bank, through the
IBRD, has created the Pandemic Emergency Financing Facility (PEF). The PEF is a facility
designed to channel emergency funding to developing countries facing the risk of a pandemic.
On June 28, 2017, the Word Bank started selling a specialized $500 million bond fund to
investors to raise money. Set to mature on June 28, 2020, Germany and Japan (World Bank,
2020) primarily funded these bonds. The PEF is comprised of two parts. The first part is
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insurance, with premiums paid by bonds and swaps for immediate emergency funding of
pandemic research. The second part is a cash window available after 2018 to contain a disease
that is not eligible for funding by the insurance part (Fernandes & Sridhar, 2017; World Bank,
2020).
All of the handlings of funds and payouts are to be handled by the reinsurance companies
of Swiss Re and Munich Re. The pandemic bonds are only used for the pandemics declared by
WHO. The PEF covers six viruses that are most likely to cause a pandemic declared by WHO.
These viruses include orthomyxoviruses (new influenza pandemic Virus A), coronaviridae
(SARS, MERS, or coronaviruses), filoviridae (Ebola and Marburg) and other zoonotic diseases
(Crimean Congo, Rift Valley, and Lassa fever). The declaration of a pandemic by WHO allows
governments to activate preparedness plans and possibly take emergency procedures to protect
the public, regulate banking and finance, including military use, and issue travel and trade
restrictions (Fernandes & Sridhar, 2017; World Bank, 2020).
United States Government and Pandemics
The United States Congressional Budget Office (CBO) assessed the Macroeconomic
Effects of a Pandemic Flu in 2005 and followed up in 2006 in their research (CDC, 2020). In the
study, the CBO concluded there would be about a 4.25% reduction in Gross Domestic Product
(GDP) reduction in a severe pandemic and about a 1% in a mild pandemic. On the supply side of
a potential pandemic, there would be 2.25% percent in the severe pandemic scenario, the supply
side of a potential pandemic and about 0.05% in the mild pandemic. The final side of the study
was the impact on the demand side.
The demand side of a pandemic would depend on the industry, and those that depend on
intense interpersonal contact would suffer more than those that do not require person-to-person
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contact, except for the healthcare industry, which would show an increase in demand. In both the
severe and mild pandemic models, it was concluded by the CBO that economic activity would
rebound in the post-pandemic period to pre-pandemic levels; but this number would have to be
adjusted by the overall effect of the pandemic on the population. The economy would return to
normal. However, in a severe case scenario, a pandemic that causes a loss of 5% of the
population would see economic activity return to normal minus 5%, meaning in a mild pandemic
with no major losses of life or long-term effects (CDC, 2020; Fitzgerald et al.,2017; Hsieh et al.,
2013).
Equity Markets
According to the NYSE data (January 2020), the entire world’s stock exchanges have a
value of over $80 trillion United States Dollars (USD). The two largest players in the global
stock markets are the NYSE and NASDAQ. The NYSE and NASDAQ combined are bigger
than the next seven global equity exchanges combined. These other equity exchanges are Japan,
China, Euronext, London, Hong Kong, Germany, and Canada (Jeanneret, 2017; NYSE, 2020;
Roseman et al., 2018) (Table 2).
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Table 2
Exchange Market Values in United States Dollars 2019
EXCHANGE
TOP 10 US COMPANIES
FANG + Microsoft
Tokyo - Japan
Shanghai - China
Hong Kong - China
Euronet- EU
London SE
Deutsche Borse SE -Germany

Billion (USD)
5,986
4,406
5,689
4,026
3,936
3,927
3,767
1,864

The top 10 United States companies and FAANG plus Microsoft (Figure 1).
Figure 1
Exchange Values Graph
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The top 10 US companies are Walmart, Exxon, Apple, Berkshire Hathaway, Amazon,
United Health Group, McKesson, CVS. Health, AT&T, and AmerisourceBergen. FAANG stands
for: Facebook, Amazon, Apple, Netflix, and Google plus Microsoft (NYSE, 2020) (Table 2).
Most people say the stock market is too risky and that individual stock ownership is even riskier.
However, owning an index fund on a major world index in the long term is proven to yield a
good profit (Fama & MacBeth, 1973; Jeanneret, 2017; Roseman et al., 2018).
From 1999 to 2020, the best indexes of the NASDAQ 100 have an average ROI of over
300% percent. The Dow Jones Industrial Average followed this with a 196% ROI, the German
DAX with 150% ROI, and the S&P 500 with 154% ROI. Compared to the stock market in the
United Kingdom, the ROI of just 36% percent and the Nikkei 225 stock exchange ROI of 48%
(NYSE, 2020) (Figure 2, Table 3).
Figure 2
Sector Percentage of the Market Graph 1-2-2020 (NYSE, 2020)
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Table 3
Stock Market Sectors and Values are in Billions (NYSE, 2020)
Stock Market Sector

MARKET CAP 1-2-2020

Information Technology

18%

9.29

Financials

15%

7.72

Health Care

12%

6.12

Industrials

9%

4.5

Consumer Discretionary

11%

5.79

Consumer Stables

8%

4.1

Communication Services

10%

4.92

Energy

6%

3.28

Materials

4%

2.01

Utilities

3%

1.5

Real Estate

3%

1.38

100%

50.61

TOTALS

Stock-market history shows that the market and investors react to epidemics and
pandemics. The reactions are usually based on the severity of the epidemic/ pandemic (NYSE,
2020). This is just not a Unites States NYSE problem. For example, the Avian Flu epidemic of
1997 coincided with the Asian stock market crisis. The Asian Stock market problems preceded
the Russian Market collapse of 1998 (World Bank, 2020). The Dow Jones Market also has data
on the effects of epidemic/ pandemics on the NYSE. According to the Sert et al. (2020), there is
always an effect on the market based on epidemics and pandemics (Table 4).
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Table 4
Dow Jones Market Data 2020
Epidemic

June 1981

6-month
% Change of
S&P
-0.20

12-month
% Change of
S&P
-10.73

September 1994

8.22

26.31

SARS

April 2003

14.59

20.76

Avian flu

June 2006

11.66

18.36

September 2006

6.36

14.29

Swine flu

April 2009

18.72

35.96

Cholera

November 2010

13.95

5.63

MERS

May 2013

10.74

17.96

Ebola

March 2014

5.34

10.44

December 2014

0.20

-0.73

January 2016

12.03

17.45

June 2019

9.82

N/A

HIV/AIDS
Pneumonic plague

Dengue Fever

Measles/Rubeola
Zika
Measles/Rubeola

Month End

The S&P 500 also has the following chart about epidemic/ pandemic history and the
Unites States Stock Market (Figure 3).
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Figure 3
Epidemic/ Pandemic History in US Stock Market

Federal Security Rules and Regulations
The United States has various rules, laws, and regulations that govern the establishment
of and the buying and selling of equities. These laws are enforced by one of 52 regulatory
agencies. The United States Securities and Exchange Commission (SEC) (SEC, 2020) is the
largest enforcer of finance rules and laws related to equities on the NYSE. The first major
finance law was the Sherman Anti-Trust act of 1890, followed by the Securities Act of 1933, the
Glass Steagall Act of 1933, which was repealed in 1999, the Securities Exchange Act of 1934,
the Investment Company Act and the Investment Advisors Act of 1940, Securities Investor
Protection Act of 1970, and the National Securities Markets Improvement Act of 1996 which
amended the Security Exchange act of 1934 section 15 (h). This was later followed by the
Sarbanes-Oxley Act of 2002 and the Dodd-Frank Wall Street Reform and Consumer Protection
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Act of 2010 (Dyer, 2016; Jeanneret, 2017; Roseman et al., 2018; United States Government,
2019).
All of these laws are in place to help protect the average investor (Alrgaibat, 2015;
Dalbar Associates, 2020; Wenjing, 2017) in the stock market and to make sure the companies are
doing what they are supposed to do, reporting all information that would have a bearing on the
company and their stock price. Because of these laws, all information is made public as soon as
possible (Fama (1970). This information would change stock prices accordingly. We have an
efficient market (Fama, 1970), and no one can benefit from anomalies in the market.
Securities and Exchange Commission
The United States Securities and Exchange Commission (SEC) is the primary
government agency that oversees the United States stock market. According to the SEC (2020),
stocks are a type of security or equity that gives the shareholder ownership in a company (Dyer,
2016; Jeanneret, 2017; Roseman et al., 2018; United States Government, 2019). To buy or sell
stock, a stock owner or equity buyer has to go to a stock market to buy or sell stocks. A stock
market is where companies sell stocks and investors buy/ sell stock (Dyer, 2016; Jeanneret,
2017; Roseman et al., 2018; United States Government, 2019). Stock is broken down into two
categories of common stock and preferred stock. These two categories can be broken down into
other categories. These stock categories are growth, income, value, and blue-chip (SEC, 2020).
Growth stocks have earnings that increase faster than the market average and do not pay
dividends, but investors hope the stock will appreciate and be sold for more money later (SEC,
2020). Income stocks are company stocks that pay dividends. Investors buy them because of the
dividends they generate (SEC, 2020). Value stocks have low price-to-earnings ratios (SEC,
2020). Finally, there are blue-chip stocks. Blue-chip stocks are a combination of value and
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growth. Typically, blue-chip stocks are well-known companies that usually all pay dividends
(SEC, 2020).
Companies issue stocks for several reasons. One is to pay off debt. The second is to raise
money to launch a new product or expand into a new market locally or internationally. By
buying stock, stock owners or investors get a capital appreciation of hoping the stock price goes
up, earns dividends, and has voting rights for the board of directors or influences company
decisions. Preferred stock owners do not have voting rights (Dyer, 2016; Jeanneret, 2017;
Roseman et al., 2018; United States Government, 2019). Buying and selling stocks come with
some inherent problems. These problems are called risk or market volatility. These uncertainties
can affect the amount of return on investment (ROI) (Dyer, 2016; Jeanneret, 2017; Roseman et
al., 2018; SEC, 2020).
Epidemic
An epidemic is a rapid spread of an infectious disease to a large number of people in a
given area within a short time, usually two weeks or less (CDC, 2020; Crossley et al., 2012;
Gilbert, 2014; Lofgren & Rapazzo, 2017; WHO, 2020). Epidemics are generally caused by a
change in the ecology of the host population, a genetic change in the pathogen itself, or the
introduction of a new pathogen to a new host population. An epidemic occurs when the host’s
immunity to the pathogen is reduced below the endemic equilibrium, and the transmission
spreads into the host’s body. An epidemic may be restricted to one area; however, it may spread
to other countries or areas and cross international boundaries. Depending on the severity of the
epidemic, it might be classified as a pandemic by the World Health Organization, but it must
meet the criteria of a pandemic. All pandemics usually start as an epidemic (CDC, 2020;
Crossley et al., 2012; Gilbert, 2014; Lofgren & Rapazzo, 2017; WHO, 2020).
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There are two types of epidemics or pandemics. First is the common source outbreak
epidemic. This is where an affected individual(s) had an exposure to a common disease-causing
agent. A person can get it from a single exposure occurrence or an incubation period from
multiple long-term exposures if this is the case. It is a point source outbreak (CDC, 2020). The
second type of exposure is the propagated outbreak. The pathogen-causing disease is spread from
person to person, usually by a single exposure. However, the one person moved around and
exposed multiple people who continue to move around and affect others (CDC, 2020; Crossley
et al., 2012; Gilbert, 2014; Lofgren & Rapazzo, 2017; WHO, 2020).
Therefore, in a propagates outbreak, each person is the reservoir of disease, and either is
affected and becomes sick or has immunity and just carries the disease-causing pathogen and
infects others. Each person becomes sick at their rate. However, this time from exposure to
showing symptoms of the disease is called the disease incubation period (CDC, 2020; Crossley
et al., 2012; Gilbert, 2014; Lofgren & Rapazzo, 2017; WHO, 2020). The propagated outbreak is
the most common form of epidemic/ pandemic transmission since the carrier(s) do not know they
are sick or infected with a pathogen. This is usually how an epidemic becomes a pandemic is
because in the twenty-first century, we are an interconnected world, and travel is common with
international airports and frequent travel for a job(s) or personal leisure.
Pandemic
All over the world, there are deadly infectious diseases. There are two ways to think
about diseases. The first is diseases that threaten under-developed countries, either small or large
scale. Then some diseases threaten more developed countries like the United States.
Alternatively, other industrialized countries. Outside of the Unites States, according to WHO
(2020) and the CDC (2020), there is cholera, tuberculosis, malaria, dengue fever, pneumonia,
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diarrheal diseases and a litany of other epidemics and problems. These diseases account for over
34.4% of all deaths, according to the World Bank (2020), which is quite large considering the
World Bank also says that war only accounts for .64% percent of all deaths.
As far as pandemics go, the Spanish Flu of 1918 killed more Americans in one year than
all of the Unites States fought in the 20th century. This includes World War II, Korea, and
Vietnam (World Bank, 2020). At the same time, the CDC and WHO are not prepared for a largescale pandemic of the next unknown disease. According to the CDC (2020), there are drugresistant strains of existing infections and new mutated strains of influenza, tuberculosis, malaria,
dengue fever, and Methicillin-Resistant Staphylococcus Aerus (MRSA). The full extent of a
human pandemic’s economic, social, and political impacts depends critically on a number of
factors. The first factor of a pandemic is the number of people who 1) become infected, 2) can
transmit the disease, 3) develop symptoms, 4) cannot work for a certain time either because they
are ill or because they are at home caring for the sick and finally, and 5) the number of people
who eventually die (CDC, 2020; Crossley et al., 2012; Gilbert, 2014; Lofgren & Rapazzo, 2017;
WHO, 2020).
A pandemic is an epidemic; that scale is bigger than an epidemic. A pandemic also
crosses international borders, affects a large number of people, and can be contagious or
infectious, usually in less than a year where it starts small, increases then decreases in cases and
severity (CDC, 2020; Crossley et al., 2012; Gilbert, 2014; Lofgren & Rapazzo, 2017; WHO,
2020). Pandemics are not a disease that makes people sick. It is widespread globally and kills
people. If this were the case, one could argue that cancer is a pandemic. Cancer is a disease that
crosses borders, makes people sick, kills some people, but has been around for generations and
has not decreased in volume or severity since it was first recorded. However, cancer is not
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infectious or contagious (CDC, 2020; Crossley et al., 2012; Gilbert, 2014; Lofgren & Rapazzo,
2017; WHO, 2020). Another distinction that must be made for pandemics is that it is not
seasonal. The best example of this is influenza or the flu (CDC, 2020), which occurs yearly but is
not a pandemic or epidemic.
The influenza virus causes influenza or the flu (CDC, 2020; Crossley et al., 2012; Gilbert,
2014; Lofgren & Rapazzo, 2017; WHO, 2020). There are four types of influenza viruses. Only
three affect humans: Type A, Type B, and Type C. The fourth type is Type D which is not
known to affect humans (CDC, 2020; WHO, 2020). The flu is a virus spread through the air from
coughs or sneezes or touching surfaces contaminated by the virus and then touching the eyes,
nose, or mouth. An infected person can be infectious to others before and when they show
symptoms. Usually, the flu is tested by looking at the spectrum of a person and checking for
influenza ribonucleic acid (RNA) (CDC, 2020; WHO, 2020). Most flu cases are seasonal and are
generally Type B influenza virus. The Spanish Flu of 1918, as with any other epidemic or
pandemic flu, was a Type A influenza virus (CDC, 2020; (Karlsson et al., 2014; WHO, 2020).
World Health Organization (WHO)
The World Health Organization (WHO) was founded in 1948 and is a part of the United
Nations specializing in international health. The WHO is located in Geneva, Switzerland, and
has 150 offices worldwide. The WHO has members from all 194 participating states of the
United Nations and provides essential functions of monitoring public health, responding to
health emergencies, advocating for universal healthcare, and promoting general health and wellbeing (Pandemic, 2009; Pung & Lee, 2020; Villarreal, 2016; WHO, 2020).
According to the WHO, classifying pandemics as a future global shock factor is
consistent with considering certain aspects of public health and infectious diseases as an
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existential threat to society and human security. This is an expansion on the United Nations
Development Program (UNDP) of 1994 (WHO, 2020). The UNDP was reaffirmed in the 2003
United Nations Commission on Human Security. The premise behind the UNDP conceptualizes
the security of society and humans as human-centric rather than the traditional state-centric
belief system. This ideology’s goal is to protect society and human safety and welfare from such
things as disease, hunger, unemployment, crime, social conflict (war), political repression, and
environmental hazards (Pandemic, 2009; Pung & Lee, 2020; Villarreal, 2016; WHO, 2020).
WHO says there are four major things learned from studying epidemics and pandemics?
There is insufficient globally shared information available in real-time about pandemic risk
inventories, hazards, or threats (WHO, 2020). 2) There is a lack of forward-thinking and
planning for creating and distributing medicines and vaccines. This is caused by the lack of
shared information (WHO, 2020). 3) There is not an international harmonization of regulations
across the globe for identifying and treating a pandemic (WHO, 2020). 4) There needs to be
sustainable basic research efforts required before, during and after a pandemic (WHO, 2020).
The WHO and the CDC acknowledge and post all known pandemics and epidemics on
their website. Pandemics are nothing new and have been around for as long as people kept
records. Some non-recent pandemics, according to WHO (2020), are the Plague of Athens (430
BCE) caused by typhus or perhaps typhoid fever; the Antonine Plague (165-180 CE) caused by
either smallpox or measles; and the Bubonic Plague caused by the bacterium yersinia pestis, (540
BCE). Then there is cholera, caused by vibrio cholerae (1816-1826 ad), Barua (1992) in Angola,
Ethiopia, Somalia, Sudan, Zambia, South Africa, and Northern Vietnam.
These are not the only pandemic agents. There are also other documented pandemics
causing agents, which are typhus, measles, smallpox, tuberculosis, malaria, yellow fever, viral

37
hemorrhagic fever, antibiotic-resistant bacteria including staphylococcus aureus, enterococcus
species, Mycobacterium tuberculosis, Serratia marcescens, e. coli, pseudomonas aeruginosa, and
Acinetobacter baumannii (CDC, 2020, Pandemic, 2009; Pung & Lee, 2020; Villarreal, 2016;
WHO, 2020). In addition to these known pandemic-causing agents, there is the dreadful threat of
engineered or synthetic bioterrorist agents on the immediate horizon, which are manufactured
chemically engineered forms of the above agents according to the CDC (2020) in their
bioterrorist’s articles. Finally, the severe acute respiratory syndrome (SARS) virus did not meet
the criteria for a pandemic but was an epidemic. The SARS virus (COV-2) of 2002-2003 (CDC,
2020) is also a corona virus that, just like the corona virus of 2020, affects the respiratory system
of its hosts, causing breathing problems and death in some cases (Crossley et al., 2012; Gilbert,
2014; Lofgren & Rapazzo, 2017; WHO, 2020).
According to WHO, the declaration of a pandemic has profound social, political, and
economic consequences worldwide and even on the agency itself. WHO (2020) defines a disease
as an epidemic when there are more cases of a particular disease than normal in an area(s). A
pandemic is where the disease leaves one area and affects others in other countries or globally. A
pandemic can range from mild to severe, with the level of severity changing over time. These
changes usually start small and increase, then shrink back down after the pandemic has run its
course. According to the older WHO guidelines which are no longer used, there were six phases
of a pandemic, and also what is a Post Peak Period and a Post Pandemic Period (Pandemic,
2009; Pung & Lee, 2020; Villarreal, 2016; WHO, 2020).
These six phases are:
Phase 1
No animals have been reported to cause infection in humans
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Phase 2
An animal is known to have caused human infection and is therefore considered a
specific potential pandemic threat.
Phase 3
An animal or human-animal has caused sporadic cases or small clusters of
diseases in people but has not resulted in human-to-human transmission sufficient to
sustain community-level outbreaks
Phase 4
Human to human transmission of an animal or human-animal virus able to sustain
community-level outbreaks has been verified.
Phase 5
The same identified virus has caused sustained community-level outbreaks in two
or more countries in one WHO region.
Phase 6
In addition to the criteria defined in Phase 5, the same virus has caused sustained
community-level outbreaks in at least one other country in another WHO region.
Post Peak Period
The pandemic cases in most countries with adequate surveillance have dropped
below peak levels; additional pandemic waves may recur during this period.
Post Pandemic Period
Levels of case activity have returned to the levels seen for seasonal cases in most
countries with adequate surveillance. (WHO, 2020). Prior to declaring a pandemic, the WHO
normally declares a Public Health Emergency of International Concern (PHEIC) (WHO, 2020).
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A PHEIC is a formal declaration by the World Health Organization (WHO) for an exceptional
incident that has been found to pose a public health danger to neighboring nations as a result of
the worldwide transmission of illness and to need a coordinated international response, including
the possibility of a nuclear war (WHO, 2020). When a situation arises, that is sudden, unusual,
serious, or unexpected. It is proposed to cross international borders and require an immediate
international response (Crossley et al., 2012; Gilbert, 2014; Lofgren & Rapazzo, 2017; WHO,
2020). The PHEIC was formulated in response to the SARS outbreak of 2003 under the 2005
International Health Regulations. The WHO has only used the PHEIC six times as of 2009 and
until January 2020 (WHO, 2020). These six times were the 2009 swine flu pandemic, the 2014
polio declaration, the 2014 Ebola outbreak in Africa, the Zika epidemic of 2015, the 2018 Kivu
Ebola epidemic, and the 2020 Coronavirus COVID-19 (Crossley et al., 2012; Gilbert, 2014;
Lofgren & Rapazzo, 2017; WHO, 2020).
The WHO has it is own criteria for defining words related to pandemics. WHO defines
risk as some measure of the probability of an event (disease-causing agent) and its consequence
to animals, humans, or society. The word threat is the basis, origin, or agent of an unwanted
impact by disease to a system. Lastly, vulnerability is any condition or weakness that makes an
animal or human susceptible to a threat. Then to assess risk, we have four more terms. There four
basic terms for assessing risk are 1) inventory, 2) hazard, 3) vulnerability and 4) loss (Crossley et
al., 2012; Gilbert, 2014; Lofgren & Rapazzo, 2017; WHO, 2020). Inventory considers the
inventory of properties, humans, physical environment, and society’s critical infrastructures at
risk. In the term hazard, we will consider the geographic origin of pandemics, the pathway to
spread, and the spread rate of the disease. The words hazard and inventory allow consideration of
the population’s vulnerability to being affected combining these two terms. This then leads to the
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build and natural resources affected, leading to and allowing for an estimation of loss (Crossley
et al., 2012; Gilbert, 2014; Lofgren & Rapazzo, 2017; WHO, 2020). These words play into how
a disease is classified in its phase and whether or not it is in a post-peak or post-pandemic period.
The Center for Disease Control (CDC) rates pandemics by the severity of deaths caused
by a pathogenic agent, which scales pandemics as a Category 1 to Category 5. The CDC says
that HIV/AIDS is a pandemic and the WHO does not. The WHO does acknowledge it as a
pandemic in the following article Vatican: condoms don’t stop Aids by The Guardian in October
2003 when the WHO condemned the Vatican’s views about HIV/AIDS by saying: These
incorrect statements about condoms and HIV are dangerous when we are facing a global
pandemic which has already killed more than 20 million people, and currently affects at least 42
million.
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Figure 4
Pandemic Categories (CDC, 2020)

Since the 19th century, there has only been a small list of pandemics, according to WHO
(2020). The list can be seen below in WHO’s list of Pandemics (WHO, 2020). This list is not the
only pandemics but is a list of all pandemics by WHO in the last 120 years (Table 5).
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Table 5
List of Pandemics (WHO, 2020)
Pandemic

Dates

Sixth Cholera Pandemic

1899-1923

Spanish Flu

1918-1920

Seventh Cholera Pandemic

1961-1975

HIV/AIDS Pandemic

1960-Present

Swine Flu

2009-2010

Coronavirus Covid-19

2019- 2020

Center for Disease Control (CDC)
The Center for Disease Control is the United States government agency founded in 1946
to protect United States citizens’ public health and safety through controlling and preventing
disease, injury, and disability (CDC, 2020; Fitzgerald et al., 2017; Hsieh et al., 2013). The
CDC’s main focus is to educate, train, inform and monitor infectious disease, food borne
pathogens, environmental health, occupational safety and health, health promotion, injury
prevention and educational activities. It is a United States federal agency with headquarters in
Atlanta, Georgia, controlled by the Department of Health and Human Services.
The CDC has a specialized group of employees who work as part of the Epidemic
Intelligence Service (EIS). It is a specialized hands-on group of employees investigating public
health problems domestically and globally (CDC, 2020; Fitzgerald et al., 2017; Hsieh et al.,
2013). The EIS, when deployed, do short-term epidemiological assistance assignments to
provide technical epidemiology expertise in containing and investigating disease outbreaks. The
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CDC has information on over 400 diseases and has investigated all recent epidemics and
pandemics. The CDC is partners with WHO and 196 countries to help monitor, educate, prevent,
and control infectious diseases through the use of the Global Disease Detection Program (GDD)
(CDC, 2020; Fitzgerald et al., 2017; Hsieh et al., 2013). Information for and about the CDC and
its efforts are readily available through its many reports, including State of CDC Report, CDC
Programs in Brief, Morbidity and Mortality Weekly Report, Emerging Infectious Diseases, the
Preventing Chronic Disease, and the Vital Statistics Report (CDC, 2020; Fitzgerald et al., 2017;
Hsieh et al., 2013).
Healthcare Sector
The healthcare sector of the NYSE is normally the largest sector of the NYSE (NYSE,
2020) until the year 2018 when the economy and stock market had a record-breaking two years,
which saw the development of its first trillion-dollar technology companies starting in 2019 what
is referred to as FAANG plus Microsoft (NYSE, 2020). This can be seen in Figure 1
Exchange Values Graph. Because of these changes and the management of the funds of
these companies, the healthcare sector in January 2020 was the third largest sector of the market
at that time (NYSE, 2020). The healthcare sector of the NYSE comprises 196 companies as of
January 2020 (NYSE, 2020) and includes the pharmaceutical companies used. The NYSE
healthcare sector also includes companies from managed healthcare, biotech, pharmaceutical
companies, and medical supplies.
A great deal of thought and planning has focused on the problem of medical care and
laboratory support during a pandemic (Hanfling, 2016; Hick et al., 2007, 2020; Meltzer &
McNeill, 2010). This sector would be critically impaired in the event of a severe pandemic, with
the obvious demand for care. However, this surge in demand would require supplies and help
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affected by the pandemic. Even if supplies and finances are there to carry out healthcare, the
effects of absenteeism and uncertainty of long-term effects would probably cripple the healthcare
sector (Hanfling, 2016; Hick et al., 2007, 2020; Meltzer & McNeill, 2010).
The financial impact on the healthcare sector would primarily be caused by the impact of
the insurance industry, which is in the financial sector of the NYSE (NYSE, 2020). This is
because of two reasons. The first is the general downturn in the economy and, secondly, more
specifically, a result of increased insurance claims. These claims would hit the health insurance,
life insurance, and pension insurance sectors especially hard, while the nonlife insurance sectors
would not be severely impacted. Also, the market sector that writes insurance policies would be
hit because insurance companies know they cannot make money, so they would not sell policies
(Weisbart, 2006).
This data about the effects of a pandemic can be supported by the Department of Homeland
Security, which did a study in 2007. They estimated the effects of a pandemic on the financial
markets of the NYSE by sector. They found that manufacturing would suffer the largest hit
losing $95 billion in output, finance and insurance would lose $40 billion, other services,
including healthcare, would be $18 billion, and retail trade would lose $32 billion. This can be
seen in Error! Not a valid bookmark self-reference. below.
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Figure 5
Average GDP losses Department of Homeland Security October 15, 2007

Ironically, for all of this research, the pharmaceutical sector is the one area that a person,
country, or government would look for to find a treatment, cure, or vaccine to the pandemic
(CDC, 2020; FDA, 2020). The pharmaceutical sector in healthcare discovers, develops,
produces, and markets drugs, medicines, and vaccines to the general population to either be selfadministered or administered by a healthcare professional (NYSE, 2020) to treat or cure a
medical problem. Any sick person would seek treatment by themselves or through another
healthcare sector and potentially be given something (medicine, vaccine) to treat them. During a
pandemic, the sick would seek treatment(s), and some pharmaceutical companies would have to
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provide it in theory, meaning that when the rest of the world, businesses are potentially affected
negatively by a pandemic. The pharmaceutical sector should show opposite positive results
based simply on supply and demand. Sick people demand treatment, and pharmaceutical
companies are the supplier of the treatment, not necessarily the administrator of the treatment
(Palache et al., 2017). The administer of the treatment would be someone/ something (business)
in the healthcare sector.
Spanish Flu 1918
In the last 120 years, the world has had six pandemics. The first pandemic in the
twentieth century was the Flu Pandemic of 1918, called the Spanish Flu (Karlsson et al., 2014;
WHO, 2020). This was preceded by the first pandemic listed by the WHO, called the Sixth
Cholera Pandemic of 1899. The Spanish Flu got its name because the world was coming out of
World War I, and the government regulated how newspapers could print about the flu epidemic.
Spain was a neutral country during this time, and it appeared from reading the news that Spain
was hit hard by the flu compared to other countries at the time and hence the name Spanish Flu
that stuck to this first twentieth-century pandemic (CDC, 2020; Karlsson et al., 2014; WHO,
2020). The H1N1 influenza virus caused the Spanish Flu, the same virus type that caused the
Swine Flu of 2009, just a different virus strain.
The Spanish Flu is mentioned because it is a pandemic but was disqualified as there were
not enough pharmaceutical companies in existence then and now on the NYSE to make it a
viable candidate for study. The Spanish Flu is also mentioned as a reference to the H1N1 virus
that caused the Swine flu of 2009 (CDC, 2020; Karlsson et al., 2014; WHO, 2020), used in this
study. Finally, this pandemic was disqualified as a viable study candidate since the WHO did not
exist until April 7, 1948 (WHO, 2020); therefore, the WHO could not announce the pandemic.
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Seventh Cholera Pandemic
The Seventh Cholera Pandemic is the second pandemic of the twentieth century from
1961-to 1975 (Ramamurthy et al., 2019; WHO, 2020). It is the seventh outbreak of cholera in the
world, and this outbreak was caused by the El Tor strain (name of where it was first discovered
in El Tor, Egypt) of the bacterium Vibrio cholerae (CDC, 2020; Ramamurthy et al., 2019; WHO,
2020) or cholera. Cholera is an intestinal disease that is preventable with clean water and basic
sanitation. This pathogenic disease was primarily around 1961 to 1975 but still exists in thirdworld countries today. The seventh cholera pandemic is caused by a mutated form of cholera on
the genetic level and is distinguished by the fact that it produces hemolysins (CDC, 2020;
Ramamurthy et al., 2019; WHO, 2020). Basic general treatment is access to clean water. The
Seventh Cholera Pandemic is mentioned as a pandemic because it is only the third of six
pandemics in the last 120 years but is also disqualified because it has also never had an actual
declaration as a pandemic by WHO; even though this was the first pandemic to exist after the
creation of the World Health Organization. The Seventh Cholera Pandemic was also disqualified
because a very small population of pharmaceutical stocks existed from the 1960s until 2020.
HIV/ AIDS Pandemic 1960 to Present
The fourth pandemic of the twentieth century is the HIV/AIDS pandemic. HIV was first
identified in the Democratic Republic of the Congo in 1960. It has killed more than 36 million
people (CDC, 2020; Silva & Cueto, 2018; WHO, 2020). HIV peaked in 2005 and 2012 with an
annual global death rate of 2.2 million people (CDC, 2020) and currently holds at about 1.6
million people per year. Human immunodeficiency syndrome (HIV) is the disease that causes
acquired immune deficiency syndrome, AIDS, and is typically a sexually transmitted disease
(CDC, 2020; Silva & Cueto, 2018). There are other cases where HIV/AIDS is transferred via
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blood, semen, vaginal fluids, and saliva from mother to child (CDC, 2020; Silva & Cueto, 2018;
WHO, 2020). HIV is a retrovirus species of Lentivirus that cause the immune system to fail, and
an infected person catches other infections and cancers which can kill you. HIV/AIDS does not
usually kill its host; some other disease kills the host. Normal life expectance is up to 11 years
(CDC, 2020; WHO, 2020). HIV infects vital cells in the human immune system with the help of
a T cell called CD4T (CDC, 2020; Silva & Cueto, 2018). When the t cell numbers decrease
below a certain point, the cell is compromised, and immunity is lost. Any opportunistic
infections can then infect the host. These infections and the infected host now have AIDS (CDC,
2020; Silva & Cueto, 2018).
HIV/AIDS has been classified as a pandemic since the early 1980s (CDC, 2020).
HIV/AIDS is a pandemic because of the number of deaths it has caused and its sporadic effects
in certain geographic populations (CDC, 2020; Silva & Cueto, 2018, WHO, 2020). Africa
currently has at least a 5% population with HIV/AIDS (CDC, 2020). However, advances in
managing and treating HIV/AIDS with retroviruses are manageable, and those infected can live
relatively normal lives. It may one day be treatable like the human papillomavirus (HPV), or a
vaccine will be found for measles, mumps, and rubella (CDC, 2020).
HIV/AIDS is the longest-running and even current pandemic (CDC, 2020; Cohen et al.,
2008). Because of HIV/AIDS, the actual term to classify HIV/AIDS should be an endemic, not a
pandemic. An endemic is an infectious disease that stays in a population and maintains a
consistent baseline with small increases and decreases (CDC, 2020) but never goes away. The
HIV/AIDS Pandemic originated in 1960 as an epidemic and changed to a pandemic on
December 1, 1988, by WHO, which declared Worlds Aids Day (WHO, 2020). As mentioned
earlier, the pandemic of HIV/AIDS is different from most pandemics in the fact that it is a
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pandemic by CDC standards; but not by WHO standards with the official declaration of a Public
Health Emergency of International Concern (PHEIC) of a pandemic (CDC, 2020; Silva & Cueto,
2018). The term PHEIC did not start till 2003 (WHO, 2020). WHO acknowledges HIV/AIDS as
a pandemic in its writings and statements! This can be seen in their statement when WHO
condemned the Vatican’s views about HIV/AIDS by saying: These incorrect statements about
condoms and HIV are dangerous when we are facing a global pandemic which has already killed
more than 20 million people and currently affects at least 42 million HIV/AIDS is mentioned as
a pandemic because it is only the fourth of six pandemics in the last 102 years but is also
disqualified. It has never had an actual declaration as a pandemic by the WHO because the
PHEIC did not exist until 2003. HIV/AIDS is also disqualified because a very small population
of pharmaceutical stocks existed from the 1980s until 2020.
Influenza
There are four types of influenza viruses Type A, Type B, Type C, and Type D. Type D
is not known to infect humans (CDC, 2020). Influenza or the flu is a virus spread through the air
from coughs or sneezes for relatively short distances. It can also be spread by touching surfaces
contaminated by the host-virus and then touching the eyes, nose, or mouth. Influenza is different
from the seasonal FLU (CDC, 2020). An infected person can be a host both before and when
they show symptoms. Tests are usually performed to determine the type of flu a person has, but
the tests often give false-negative results (CDC, 2020).
The flu can be stopped by washing hands and wearing surgical masks. The flu can be
treated, and some vaccines change yearly that treat up to three or four different strains. The
season flu virus mutates rapidly, and there is no current cure. The WHO and the CDC
recommend the yearly vaccine, but the vaccine does not treat or prevent influenza. Influenza is a
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Type A virus, and the yearly flu is usually a Type A or Type B. Most people who have it are
asymptomatic (CDC, 2020). The seasonal variety of influenza spreads worldwide in yearly
outbreaks, resulting in millions of illnesses and from 250,000 to 750,000 deaths per year. The flu
is typically present in the winter months, depending on a person’s location of the globe and
anytime they are located near the equator (CDC, 2020). Deaths occur mostly in high-risk
humans, with the most killed in the young and old age groups and hosts with other health issues
(CDC, 2020). The symptoms of influenza can appear as soon as one or two days after exposure
are seen with present with chills and body aches, fevers of up to 103-degree Fahrenheit or
39.4444 degrees Celsius. Most people with the flu are confined to bed for days with body aches
and pains as other symptoms (CDC, 2020).
Swine Flu Pandemic 2009 to 2010
The 2009 Swine Flu H1N1 was an influenza pandemic that lasted from 2009 to 2010 and
was the same type of influenza virus that caused the first pandemic of the Twenty-first Century
called the Spanish Flu. This was a new strain of the H1N1 flu virus which mutated and combined
with another form of influenza found in pigs. This is where the term swine flu originated (CDC,
2020). The Swine Flu was the first PHEIC ever declared by WHO. This version of the flu was a
combination of Type A and Type C influenza (CDC, 2020; WHO, 2020). Unlike another version
of the flu known as the Spanish Flu of 1918, the Swine flu had a very high infection rate; but a
low mortality rate (CDC, 2020; WHO, 2020). The swine flu was officially declared on June 11,
2009, and was declared over by WHO in August 2010 (WHO, 2020). The swine flu affected 700
million to 104 billion humans and caused up to a little over 550,000 deaths (CDC, 2020; WHO,
2020).
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Swine Flu Timeline
o March 2009 - Mexico In La Gloria, Veracruz H1N1 first appears
o March 28 - first care of H1N1 in the United States
o April 14 – CDC confirmed H1N1 in the United States
o April 24 – WHO issues an outbreak notice
o April 25 - The Schertz-Cibolo-Universal City Independent School District outside San
Antonio, Texas, is closed
o April 28 – WHO has cases in four regions
o April 29 – WHO now has cases in nine regions
o May 1- 331 cases of the H1N1 in the United States
o May 2 -WHO has 15 countries and 615 cases of H1N1
o May 3 – WHO has 17 countries and 787 cases
o May 5 – WHO 21 countries and 1,124
The United States has second confirmed death
o May 12 – WHO has 30 countries have officially reported 5,251 cases
o May 15 – WHO has 34 countries have officially reported 7,520 cases
o May 17 – WHO has 37 countries have officially reported 8,480 cases
o May 20 – WHO has 40 countries have officially reported 10,243 cases
o May 25 – WHO has 46 countries have officially reported 12,515 cases
o May 29 – WHO has 53 countries have officially reported 15,510
o June 1 – WHO has 62 countries have officially reported 17,410
o June 5 – WHO has 69 countries have officially reported 21,940 cases
o June 6 – FLU week 22: H1NI reported in 8 states of the United States
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o June 11, 2009 – WHO declares a pandemic (WHO, 2020)
o June 12 - WHO has 74 countries with 29,669 cases
o June 24 – FLU week 24: H1N1 reported in 12 states of the United States
o July 18 - FLU week 28: H1N1 reported in 13 states of the United States
o July 23 – WHO stops tracking individual H1N1 cases
Other Events in the Swine Flu Timeline 2009
Time is not a thing that is only affected by one event. For reference purposes, other
notable events that happened in the event window must be mentioned for the world that could
affect the NYSE of the United States. These are not the only events, but some notable events
may affect the NYSE stock prices. Those coexisting events are:
o May 17, 2009 - the video game Minecraft is released to the public
o May 20 – Mexico officially says it is in recession
o May 25 – North Korea conducts its second nuclear test and launches missiles
o June 1 – General Motors files for bankruptcy
o June 11 – Bulgaria officially says it is in recession
o June 12 – All United States televisions switched from analog to digital signals
o June 29 – Bernie Madoff is sentenced to 150 years in prison
o July 15 – Harry Potter and the Half-Blood Prince is released worldwide
o July 23, 2009 – The Bank of Canada announced the recession’s end.
Coronavirus Covid-19
A coronavirus is a group of viruses that cause diseases in mammals and birds. It is
typically an upper respiratory disease that is mild or potentially lethal in humans. Other
symptoms are gastro-intestinal problems (WHO, 2020). There are no known vaccines or antiviral
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drugs approved for the prevention or treatment of a coronavirus as of May 2020. Coronaviruses
were first discovered in the 1960s, with the earliest form of the virus discovered in chickens.
Later two coronaviruses were discovered in the nasal cavities of human patients who had a
common cold. This human coronavirus was called 229E and human coronavirus OC43 (WHO,
2020). The most famous case of coronavirus is the SAR(s) outbreak in 2003 called SARS-CoV
(WHO, 2020). A new form of coronavirus was found and reported to the WHO in December
2019 in Wuhan, China. On January 9, 2020, the coronavirus was named 2019-nCoV or (Covid19) by WHO (2020). At the time of this event study, there is speculation of the original starting
spot of the Covid-19 pandemic. All early news reports place their origins in China and WHO
reporting data indicates China was the origin’s spot in March 2020 (WHO, 2020). Since that
date, this has been a highly contested issue, with the virus’s origins being earlier than December
and in different countries.
Coronavirus Pandemic 2020 Timeline
o Dec 8, 2019 – 28 people went to the hospital with an unknown pneumonia infection
o Dec 31, 2019 – WHO is alerted to the Chinese outbreak
o Jan 1, 2020 – videos start showing on Weibo about sick people in China.
o Jan 9 – WHO names the coronavirus 2019-nCoV
o Jan 11 - first death caused by the coronavirus
o Jan 14 – first case of coronavirus reported outside of China
o Jan 16 – first case reported in Japan
o Jan 17 – second death reported in China by a coronavirus. Airports start screening flyers
rdered by the Center for Disease Control (CDC).
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o Jan 20 – three deaths, and now the coronavirus is in three countries (South Korea, United
States, and Japan).
o Jan 21 – first report of coronavirus in the United States by WHO. Death total 17.
o Jan 22 – China goes on lockdown (Includes Disney and McDonalds)
o Jan 23 – Twenty-Five (25) deceased worldwide
o Jan 24 – second case of coronavirus reported in the United States. The Senate health
committee has a closed-door meeting. Four members of Congress sell millions in stock
(USA Today, March 2020)
o Jan 25 – 41 reported dead
o Jan 26 - third confirmed case in the United States. Fifty-Six (56) are now deceased.
o Jan 30 – WHO declares a Corvid-19 a pandemic
o Feb 29 – United States has 2 confirmed deaths.
o March 9 – United States has 26 confirmed deaths. Italy has 463 confirmed deaths.
o March 11 – Coronavirus is officially declared a pandemic by WHO.
o March 20 – NYSE closes floor. All electronic trading starting on 3/23/20
The United States has 273 confirmed deaths
o March 21 – United States has 346 confirmed deaths
o March 22 - United States has 468 confirmed deaths.
o March 23- United States has 554 confirmed deaths
o March 24 -United States has 783 confirmed deaths. Italy has 6820 confirmed deaths.
Other Events of the Event Window
There were also coexisting events.
o January 8, 2020 – Duke and Duchess of Sussex step down as senior royals
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o Jan 15 – Phase 1 of United States the China Trade war signed
o Jan 15 – Articles of impeachment were formally delivered to Senate for President Donald
Trump
o Jan 20 – Martin Luther King Holiday
o Jan 21 – Formal impeachment of President Donald Trump began
o Jan 28 – Middle East Peace plan released by President Donald Trump
o Feb 5 - Donald Trump was acquitted by a 51- 49 vote in Congress
o Feb 18 – Boy Scouts of America files for bankruptcy
o Feb 27 – Dow Jones suffers biggest point fall in history
o March 16 - Congress proposes a Coronavirus bailout bill
o March 27 – Congress passes a two (2) trillion-dollar Coronavirus bailout bill.

Single Asset Pricing Model
The Single Asset Pricing Model or Single-Index Model or (SIM) is simply a correlation
equation between 2 variables, which are (Ri - Rf) and (Rm - Rf). The preceding must always be
true. Also, the SIM tells you a lot less than CAPM; specifically, it does not say anything about
the magnitude of the expected ROI, which of course, is the purpose of financial research by
finance professionals (Santos, 2017; Yip, 2005). The Sim can be expressed as:
Rei = αi + βi * (Rm) + ei
Where:
Rei – the return of stock i.
Alpha (α) – the constant of stock i or abnormal return
Beta (β) – measure indicating the correlation between the stock i and the index
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Rm – the return of the market
E(ei) – the residual return with a zero mean or 0.

The above must be true for any two random variables in the equation. The equation says
that the ROI to a random variable is the correlation (βi) with another variable multiplied by the
ROI to the other variable plus a trend (αi) plus an unbiased error. If the error was not unbiased,
simply remove the bias and add it to αi. Factoring in all other finance theories (Markovitz’s
diversification, Von Neumann and Morgenstern expected utilities) leads one to CAPM, which
says alpha of -i = 0. For SIM to be true, the variant covariance must be diagonal (Yip, 2005). The
problem with SIM is that a stock in relation to the market directly correlates. As the market goes
up, typically, a stock goes up. If the stock market goes down, a stock price typically goes down.
In most cases, this holds for the market except in situations where incidents happen to a single
stock, such as bad press or accidents (Santos, 2017).
History of Capital Asset Pricing Model (CAPM)
Ever since introducing the stock market in the United States in 1792, investors have tried
to develop theories about explaining or predicting the historical and future equity returns. The
biggest part of this endeavor is to produce an equity pricing model that best reflects the simple
cost of equity of an asset (Ward & Muller, 2012). To calculate the price of an asset such as a
stock or bond that trades in an equity market is one of the most important areas of finance. This
valuation of assets affects all economic life of both the individual and the business world.
According to economic theory, the value of an asset depends on four factors. These factors are a)
the cash flow or expected future cash flow, b) the timing of the cash flow, c) the required ROI or
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expected ROI from that asset now or in the future, and d) the discount used to help purchase the
equity (Cochrane, 2001).
Asset classes are the grouping of investments with similar characteristics and are subject
to various governmental agencies’ same laws and regulations. Assets classes are generally
divided into three main classes: equities (stocks), fixed income (bonds), and cash equivalent/
money market. Other items include real estate, commodities, futures, derivatives, and
cryptocurrencies. Investment assets are both tangible and intangible, which people/ businesses/
investors buy and sell to generate additional income on either a short or a long-term basis
(Cochrane, 2001).
Because assets can be similar in one aspect, they can be different. This difference usually
has to do with cash flow and the risk associated with the equity. At the same time, there is an
expected ROI for buying and selling this asset over a certain time. The CAPM is the main focus
and is the most referenced theory that individuals use and investors to explain balancing.
Ethics
A distinction must be made between ethics, morals, or morality. Even the most
uncivilized and uncultured person has their morality or sum of prescriptions that govern its moral
conduct. Nature has provided that each man establishes a code of moral concepts and principles
that apply to the details of practical life, without the necessity of the conclusions of science.
Ethics is the scientific or philosophical treatment of morality. The subject matter of ethics is
man’s deliberate, free actions, for these alone are in our power (Ayer, 1946). The study of ethics
is called axiology.
When businesses speak about ethics, they usually mean one of three things: 1) avoid
breaking the criminal law in one’s work-related activity; 2) avoid action that may result in civil
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lawsuits against the company; and 3) avoid actions that are bad for the company image.
Businesses are especially concerned with these three things since they involve losing money and
company reputation. In theory, a business could address these three concerns by assigning
corporate attorneys and public relations experts to escort employees on their daily activities
(Hare, 1952, 1981; Trevino, 1986, 1990, 1992; Trevino & Brown, 2004; Trevino et al., 1998,
2006).
The sources of ethics are partly man’s own experience and partly the principles and trust
proposed by other philosophical disciplines (logic and metaphysics). Ethics takes its origin from
the fact that certain general principles and concepts of the moral order are common to all people
at all times (Moore, 1903). This fact has indeed been frequently disputed, but recent ethnological
research has placed it beyond the possibility of doubt. All nations distinguish between what is
good and bad, between good men and bad men, between virtue and vice; they have all agreed
that the good is worth striving for, and that evil must be shunned, that the one deserves praise,
the other, blame. Though they may not be the same thing in individual cases, good or evil, they
agree to the general principle that good is to be done and evil avoided (Kant, 1971, 1985, 1985).
Financial business is immediately concerned with man’s social activity since the
treatment of production, distribution, and consumption of material commodities. However, this
activity is not independent of ethics; industrial life must develop following the moral law and be
dominated by justice equity love. Businesses are wholly wrong in trying to emancipate
themselves from the ethics requirements. (MacIntyre, 1984; Noddings, 1990, 2002; Plato’s
Republic (as cited in Cooper, 1997).
An example was shown in business financial ethics when the Ford Motor Company in
1970 valued human life compared to the sale of cars and death or several injuries caused by such
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cars. The company said it was too expensive to put $11 parts on a gas tank to make it safe. These
cars caught fire and killed or injured many people. Ford did a financial comparison to compare
the value of the money made and the value of payout from lawsuits. A human life was valued at
$200,000. There is a clash between two opposing cultural perspectives: A corporate financial
culture mindset that prioritizes profit as the highest value and an ethical perspective seen as a
social norm to value human life above financial gain. It is reasonable to assume that the average
person would find it unethical to take the life of another human being for financial gain. Legally,
it is a punishable offense to take the life of another human being, but because of advertising and
profits, white-collar crime is viewed in a different light than when an individual commits
homicide. A corporation’s legal obligation to prioritize the financial interests of its shareholders
primarily has created very opposing cultural values in our society (Bennett, 1990).
We value human life as a social agreement that we each value our own life and therefore
have a duty to respect the lives of others to preserve the right to our own. On the other hand, we
have designed an economic system that incentivizes social progress with personal gain and
competition, differentiating our work values. In order to sustain the corporations that provide us
with stuff, we embrace the corporate value of maximizing profit and disregard personal values
that contradict many decisions made in the name of profit. Kant’s categorical imperative says we
act only in our best interest. Based on our rights and expectations of society, we have a duty to
maintain a sense of social responsibility in our personal lives as well as our work lives; even to
the extent of resisting when an unethical decision is being executed, that endangers the lives of
others (Kant, 1971).
Ethics is defined as the discipline dealing with good, bad, moral duty and obligation
(thefreedictionary.com, nd). It can be a theory or system of moral principles or values. It is the
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principles of conduct governing an individual or a group. It can also be a guiding philosophy. By
definition, there is no clear explanation of what is and what is not ethical. We receive guidance
first from our families, society, individual religious beliefs, and codes of conduct at organizations
where we are employed. Though laws have been made to govern what is explicitly wrong, each
person must choose for themselves what path to follow and how close to the edge they will
remain. While what is right or wrong is not always clear, we must always remember that we are
responsible for our actions and the outcome of those actions in many instances.
Traditional approaches to morality have sought to find grounds for moral claims about
right and wrong. This search is because the demands of morality are sought to exist beyond
man’s everyday interests and selfish considerations. This relationship has been conceived in
several different ways, but perhaps the most relevant is the continuing debate over moral agency
within organizations, closely examining the debate on psychological and sociological
perspectives (McDonald & Victor, 1988). Today’s most generally accepted concept seems to be
that the individual within the organization is the moral agent, but that the firm exerts significant
influence on the ethical behavior within its boundaries (Sims, 1992). The issue of business
morality is, and cannot avoid being, both a personal and an institutional matter for every
corporate executive and for every employee who does not mean to surrender his integrity, his
honor, his very soul to an organization (Silk & Vogel, 1976, p. 231).
Personal Ethics
The real goal of life is to work in God’s kingdom and be right before Him. God created
man for a purpose. Life is meaningless unless we fulfill that purpose (Matthew 6:19-24).
Personal ethics could be defined as what a person thinks is right. However, this would vary from
person to person based on factors such as culture, beliefs, personal experience(s), law(s), and

61
religion(s), to name a few. An example of one’s ethics could be being honest, telling the truth,
what to spend time on or how much time to spend on a topic, what to eat, or how much to eat.
These actions become habits. The habits become character, and character becomes values and
morals (Bindman, 2015; Brennan, 1971; Brennan & Magness, 2018; Luce, 2019; Shulman,
2019; Trevino, 1999).
People will sacrifice their values and morals for work or the sake of not being rude or
doing their job. Imagine for a moment that you work for the government and have been sworn to
secrecy for a military topic. These people do not tell what they know or all that they know
because it is part of their job, yet they say they are honest. How about your coworkers who say
what a great presentation or idea is so that a meeting will end, and you do not get fired for saying
what you think? These two examples point out where a person’s ethics and business ethics can
collide and not be harmonious. The same could be the opposite if a person has no personal
ethics. If a person thinks it is ok to lie, cheat, and steal in their life, then working at a company
will have no problem doing the same at a job. Some examples of ethical lapses might be the
Bernie Madoff Ponzi Scheme, Enron, or Martha Steward (Bindman, 2015; Brennan, 1971;
Brennan & Magness, 2018; Luce, 2019; Shulman, 2019).
Problems with Ethics
Forcing ethical behavior on professionals, called applied ethics, has seen difficulties.
Bayles (1987) stated that applied ethics has not lived up to its original promise for many
observers as it has emerged in the last decade. Some outsiders, for example, have questioned the
need for ethics, while others have questioned if having a code of ethics will do any good. A
major criticism from applied fields is that much of applied ethics has been too abstract, rigid, and
divorced from the concrete problems practitioners face in fields considered by applied ethics. A
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strong case can be made if ethical reasoning is to influence others; ethics must be communicated
to them in a form workers can understand (Bayles, 1987).
In general terms, identification of the problem is the first step in the problem-solving
process, without which no further reflection or action can take place. As a determinant of moral
behavior, Rest (1986, 1988), Rest and Rest et al. (1999) stated that moral cognition must occur
before moral judgment can begin. A consequence of this idea is that moral action can occur
without prior moral awareness of a situation (i.e., one can do something that affects others in a
morally significant way without being aware beforehand of the moral implications of the action).
However, doing so precludes any possibility of moral deliberation about the action. This type of
scenario is precisely what most businesspeople attempt to avoid, acting without knowing the
ramifications of the action. In short, perception is the setting for action (Blum, 1991). Blasi
(1980) noted that almost any action could be relevant to morality if perceived as relevant by a
person, whereas no action is appropriate if a person does not see it as morally important to them.
The inherent complexity of business situations makes recognizing a moral component
difficult, and business decisions involving a moral component are arguably even more complex
than the average (Jones & Ryan, 1997). Perhaps unethical choices in organizations are often
made not because of human evil or un-ethicality but because ethical decision-making is
cognitively complex and strongly affected by organization design. The inherent complexity of
business situations makes recognizing a moral component difficult. Business decisions involving
a moral component are arguably even more complex than the average (Jones & Ryan, 1997).
Ethics in finance relates to the concept of financial allocation of resources. Finance is
intertwined with ethics because the resources of any business unit are finite. This allocation of
resources is both on the macro and micro levels. The microfinance level is the individual investor
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equity, and the macro-level finance is the actual CAPM of equity. This is a manifestation of
ethical theory and justice, whereas efficiency, competition, and profit-making are ethical. This is
what businesses do. They ration the scarce resources between all that is involved. Ethics become
problematic and unethical when people are not responsible for the money. Leading others is
unethical by seeing a problem and doing nothing about it (Rogers, 2003). In actuality, this is
morals because morals in the actions of an induvial in an ethical situation (Rest, 1986, 1988)
Law
The philosophy of law called jurisprudence implies there is a question as to what law is
and has been argued by Aristotle (1958, 1984) and Kant (1971, 1985, 1996) that there must be a
reason and moral action to require such things. At the same time, there is no common meaning of
law except that it reflects the use of the word law in such context of its usage. This is because the
law is broken down into many categories to include but not limited to common, civil, religious,
binding, criminal, legal, Sharia (Ahmad, 2009), religious, and canon. Law can be the art and
science of justice (Lord Lloyd of Hampstead, 1972). The principles of law are for the betterment
of society because humankind cannot always do this on their own in a moral fashion (Younger,
2017).
Law pertains to people’s health and pandemics because it protects all people affected by a
pandemic. Law gives the government the right to enforce quarantines during an emergency
(CDC, 2020) and other general issues such as smoke-free air quality laws the ability to issue
temporary detention orders for those with psychological issues. Most people are not aware of
how the law affects people’s health. In the United States, the Public Health Authority is the
managing authority for the CDC and the Occupational Safety and Health Department of the
United States government and gets their authority from the 45 CFR 164.512 (CDC, 2020).
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These laws give those acting in the legal capacity to report, control, prevent, and educate
about diseases, injuries and things that cause disabilities. For patients’ laws are in place to
protect those affected by diseases and injuries with the Health Insurance Portability and
Accountability Act (HIPAA) of 1996 (CDC, 2020). This law can be overridden by 45 CFR
165.512 (b) (1) (IV) when a health care professional deems a person exposed to a communicable
disease and has or can spread the disease to others. When this occurs, the individual affected
must be notified that his or her information has been shared. This information sharing is not
limited from doctor to local government agency, but from a doctor, all the way up to foreign
governmental agencies is deemed appropriate. This is what happens when a potential pathogen is
identified. The CDC has a list of known pathogenic diseases that must be reported in writing and
found on their website (CDC, 2020). The CDC is the government agency that reports potential
pathogens to the World Health Organization and foreign governments. Knowing when to report
to others becomes an ethical and moral issue for a doctor or clinical practitioner. Because making
a clinical decision for a patient also involves making an ethical decision, whether consciously or
not. This is why the American Medical Association has its codes of ethics (CDC, 2020).
Morality
Morality is a system of beliefs, values, and underlying judgments about the rightness or
wrongness of acts (Zimbardo, 1995). Moral sensitivity is the awareness of how our actions affect
other people. It involves being aware of different possible lines of action and how each line of
action could affect other parties. It involves imaginatively constructing possible scenarios and
guessing cause and effect consequences in the real world (Rest et al., 1999).
Butterfield et al. (1996, 1997, 2000) and Trevino and Weaver (1996) believe that
morality occurs when a person realizes that their response to a given issue could affect the
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interests, welfare, or expectations of others in a manner that may conflict with one or more
ethical standards or norms. Rest et al. (1999) stated that morality is aware of how our actions
affect others. One significant difference between the definition and others is the notion of degree.
Butterfield et al. (1996, 1997, 2000) noted that one sees’ morality as an either/or state. The moral
person is either aware of the moral components of a situation or is not aware (Blum, 1991).
Morality is more complex than other definitions imply (Trevino & Youngblood, 1990).
Jones and Ryan (1997) pointed out that the moral person must first recognize the moral
issue. A person who does not recognize the moral aspects of an issue will certainly rely on ‘nonmoral’ criteria in deciding. Ramifications for businesses acting without moral awareness can be
disastrous (Butterfield et al., 1997). Rogers (2003) stated that moral awareness is a moral
obligation to fix an issue before it becomes an ethical decision.
Justice, Fairness, and Mercy
Justice and fairness are two words that are used as synonyms and are part of the
definition of the other. However, they are not the same and have complex meanings for those
that use them. Kant (1996) made an argument that every living person has a conscience and finds
himself watched, scared, and inspired by an internal authority that watches over and guides a
person; like a law, but something designed into a person, that they did not make (Kant, 1985,
1996). Rawl defined autonomy or self-ownership as the right of an individual to govern and reap
the benefits of their actions, choose their life plans, and pursue their particular definitions of
happiness without the interference of others (Younger, 2017). Rawl’s view is similar to Kant’s
view in which free will and morality are the same things (Kant, 1985, 1996).
Kant’s view indicates that a person can choose to be happy because they are free, which
implies that a person can choose their moral definition of right and wrong by those actions; by
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the sheer nature of choice because they are free. Justice is fairness, according to Rawl (Younger,
2017). Rawl had two basic ideas that came from this idea of justice is fairness. The first is that
each person has a right to the basic concept of liberties as long as there is an acknowledgment of
the liberties of others. Secondly, the first idea is that the gains of the best-off in society are
related to the improvements and betterment of the worst-off in society. Which means that for a
decision to be just, it must because the greatest benefit to the least advantaged in society,
compared to the most advantaged? Otherwise, the most advantaged have put themselves above
others, which is not just (Steiner, 1977; Younger, 2017).
Kant (1996) argued that for a person to act morally, rather than by accident, it must be a
sense, independent of circumstance nature, and act with the objectivity of all rational laws.
Hence, the practice of free wills and choice. Therefore, since we can choose, we are by definition
free and can exert free will. Free means that we choose, but our choices are not independent
unless we set ourselves above others. This interplay of free individuals lays the groundwork for
community and that an individual is part of something bigger than oneself. This is similar to the
ideas shared by Plato (as cited in Cooper, 1997) and Brown (2017). When an individual makes
moral decisions; and does things that bring out the best in themselves. Then their actions are just
and fair. Very similar to input versus output ratios related to work in what is referred to as
distributive justice, equality, or equity theory (Adams, 1963).
Fair is defined by thefreedictionary.com (nd) as just and honest, one of twenty definitions
of the word. However, being just and honest implies an ethical sense of right and wrong and
disregarding one’s interest. However, justice and fairness do not mean treating everyone the
same, like criminals and victims. Fairness super imposes a belief that everyone is treated the
same; unless someone does something that results in them being treated differently. The
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difference in treatment that applies to one must be applied to all in the community resulting in
fairness is the measure of justice (Gillis, 2018).
Justice means ensuring that people receive what they deserve according to
thefreedictionary.com (nd) as described above; a criminal receives the appropriate punishment,
for example. Mercy is also a countervailing principle that promotes being less harsh than one is
entitled to (thefreedictionary.com, nd). Whereas fairness was the measure of justice, balancing
the three is key for dealing with people morally from an ethical standpoint. A lack of justice is
wrong, but a lack of mercy can be just as wrong. Christianity in the King James Version of the
Bible mentions these three times. In Micah 6:8 (KJV), He has shown you, O man, what is good;
and what does the LORD require of you but to do justly, to love mercy, and to walk humbly with
your God?
In Zechariah 7:9 (KJV), Thus, says the Lord of hosts ‘Execute true justice, show mercy,
and compassion everyone to his brother.’ Finally, Matthew 23:23 (KJV) states, Woe to you,
scribes and Pharisees, hypocrites. For you pay tithe of mint, anise, and cumin and have neglected
the weightier matters of the law: justice, mercy, and faith. These you ought to have done without
leaving the others undone. Justice is a distribution of the burdens and benefits of society. These
distributions should be based on needs, effort, and contributions for everyone to receive their fair
and just share (Adams, 1963; Gillis, 2018).
Knowledge and Wisdom
Wisdom is defined as the accumulated philosophic or scientific learning-knowledge; the
ability to discern inner qualities and relationships-insight, a good sense-judgment, the generally
accepted belief challenges what has become accepted wisdom among many historians, a wise
attitude, belief, or course of action, and lastly the teachings of the ancient wise men
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(thefreedictionary.com, nd). Psychologists regard wisdom as distinct from the cognitive abilities
measured by standardized intelligence tests. Wisdom is often considered a trait developed by
experience but not taught. When applied to practical matters, the term wisdom is synonymous
with prudence. Some see wisdom as a quality that even a child, otherwise immature, may possess
independent of experience or complete knowledge. The status of wisdom or prudence as a virtue
is recognized in cultural, philosophical, and religious sources. Some define wisdom in a
utilitarian sense as foreseeing consequences and maximizing the long-term common good.
(Carter, 2017; Grimm, 2015).
Knowledge is expertise and skills acquired by a person through experience or education,
the theoretical or practical understanding of a subject, what is known in a particular field or is a
total of facts and information, awareness, or familiarity gained by experience of a fact or
situation (thefreedictionary.com, nd). Philosophical debates in general start with Plato’s
formulation of knowledge as justified true belief (Plato’s Republic as cited in Cooper, 1997).
Knowledge acquisition involves complex cognitive processes: perception, learning,
communication, association, and reasoning. The term knowledge is also used to mean the
confident understanding of a subject with the ability to use it for a specific purpose.
(thefreedictionary.com, nd). Wisdom is the ability to understand and recognize the value. It is not
knowledge. Knowledge recognizes cause and effect, which is independent of value. An example
is realizing that a man will die if he has his head removed is knowledge. Deciding if the
decapitation is an accident, a crime, or upholding justice is wisdom (Carter, 2017; Grimm, 2015).
Aristotle’s Solution
One of the clearest and most useful ethical absolutism came from Aristotle. Aristotle
realized that what people desire is what they regard as good. To say no more than this is that all
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desires are good no matter how much they conflict. Consequently, there can be no standards
(Aristotle, 1958). Aristotle solved this problem by delineating two types of desire: natural and
acquired. Natural desires are those needs that are common to all human beings, such as food and
shelter. Beyond these, people also desire health, knowledge, and a measure of prosperity. By
being natural, these desires, or needs, are good for everyone. Since there can be no wrong basic
needs, there can be no wrong desire for these needs (Aristotle, 1958).
However, there are other desires as well. These are not the needs of a person but the
wants of a person. At the level of wants, the nature of good becomes clouded. Individuals may
want something they desire as a good, but it may be bad for them. People with sound judgment
should decide what is good, unlike an apparent good. This sound judgment comes with
experience. Young children have little experience of what is good or bad for them, so they must
be guided by parents and other adults. Mature adults, however, should be able to decide what is
good for them (Aristotle, 1958). People must decide what is good for others as well as for
themselves. They expect that goods for them apply equally to other people. Aristotle (1958) said
it is necessary to have the three virtues of practical wisdom: temperance, courage, and justice to
treat others in the same way one treats oneself.
Value
In the early twentieth century, Alfred North Whitehead did research on values. His ideas
were in sharp contrast to the existing dualistic and materialistic worldviews. He proposed that
some individuals are void of any value but affirmed that every individual is valuable in and for
itself. For Whitehead, no matter how fleeting or trivial, every living thing is unique and subject
to experience. Every individual is a unique achievement of value. So, value and existence are
coexistence. If a value is limited exclusively to the subject, then there is no warrant for affirming
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the value of others. However, since living, things know that others exist, and each has its
intrinsic value; then there has to be respect for the value of others (Whitehead, 1920, 1925, 1927,
1929a, 1929b, 1933, 1938, 1948, 1951a, 1951b, 1978, 1996).
Value is no longer something one finds in the world; it places on the world. To exist; is
prima fascia, to being internally related to others. In this relation and fulfillment of needs, each
subject starts to place value on itself against the values of all other living and non-living subjects
(Whitehead, 1920, 1925, 1927, 1929a, 1929b, 1933, 1938, 1948, 1951a, 1951b, 1978, 1996).
Things gain value based on work; based on the un-pleasantness, difficulty, stability, and
responsibility generated by the work.
Value is the word Whitehead (1925) uses for the intrinsic reality of an event. Value is an
element that permeates through and thinks for a poetic view of nature. We have only to transfer
to the very textures of realization in itself that value which we recognize so readily in terms of
human life (Whitehead, 1925). Are not five sparrows sold for two farthings, and not one of them
is forgotten before God? Nevertheless, even the very hairs of your head are all numbered. Fear
not, therefore: ye are of more value than many sparrows. Also, I say unto you, whosoever shall
confess me before men. He shall the Son of man also confess before the angels of God. (Luke
12: 6-8. KJV).
Value is where every subject has to decide whether its intrinsic value is worth more than
the intrinsic value of the other subject whose value that one subject takes from another in
fulfillment of its own needs. This interaction is the basis for humans to lay the groundwork of
ethics and morality where the extrinsic value would be something that brings one joy or
happiness like a family (Whitehead, 1920, 1925, 1927, 1929a, 1929b, 1933, 1938, 1948, 1951a,
1951b, 1978, 1996).
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Efficiency
Fama (1970) developed what is known as the efficient market hypothesis (EMH). To
understand this, one has actually to understand efficiency at its core. Efficiency is defined as a
way to avoid waste, energy, money, and time by doing something (thefreedictionary.com, nd). In
Fama et al.’s (1969) EMH, he explained an ideology of testable efficiency based on an
equilibrium model. His idea is that the market takes in all information, and the price reflects that
information. This is equilibrium. Equilibrium is when two opposing forces are balanced, supply
and demand are matched, and a stable price (thefreedictionary.com. nd). If the price is not stable
and balanced, an abnormal return would be generated.
Efficiency is comprised of two different models. These models are technical efficiency
and fundamental efficiency. Both of these models look at a relationship between information and
price. Fama (1970) uses technical efficiency to say that information is instantly reflected in the
price. Therefore, an investor cannot use the information to predict stock prices. The idea of
fundamental efficiency lies in the idea that the price of an equity is in its intrinsic value (what an
investor thinks) equity is worth (Thaler & Shiller, 2015). In both examples, a study is conducted
to study the relationship between the price of equity and information. In technical efficiency, a
researcher looks at information as the study’s starting point and sees a relationship between the
information and the equity price. In the fundamental efficiency relationship, the price is the
starting point, and we look to see if the information explains how the equity price reacts (Thaler
& Shiller, 2015).
This event study is a fundamental efficiency analysis since we know stock prices and
want to see if we have explained the equity price. This leads to a technical efficiency question for
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an investor: Can I profit from information? The opposite question can be proposed for
fundamental efficiency: Do equity prices deviate from the intrinsic value?
We have to ask ourselves: Where do we stand concerning the company with these two
questions? Are we an investor in a company, or are we a part of the company? Fama et al.’s
(1969) EMH is based on technical efficiency for investors to make money from an investment.
Whereas the company is concerned with fundamental efficiency and does the purchasers of an
equity value it worth more or less than what the company owners say it is worth. This leads us to
other efficiency studies: weak-form, semi-strong, and strong-form efficiency (Baker & Bloom,
2013; Peón et al., 2019). Weak-form efficiency asserts that prices of the equity instantly reflect
all information. Future equity price movements cannot be predicted using past prices. Semistrong efficiency asserts that equity prices fully reflect all publicly available information. Only
investors with additional non-public (inside) information could have an advantage in purchasing
equity (Baker & Bloom, 2013; Peón et al., 2019). The downside is that the equity price will
adjust accordingly when this information is made public, bringing a strong-form efficiency.
Finally, the strong-form efficiency asserts that equity prices fully reflect all public and private
information available. This model of efficiency implies that no one can have an advantage in the
market and that there is no data that would provide any additional value to the investors and
generate an abnormal return (Baker & Bloom, 2013; Peón et al., 2019).
According to Thaler and Shiller (2015), the idea of technical efficiency implies that an
investor should not try to guess what the market will or will not do. However, the best thing an
investor can do is build a portfolio (Markowitz, 1952) that represents their goal and attempt to
replicate the market overall as best as possible. At the same time, Thaler and Shiller (2015) have
a different opinion on fundamental efficiency. This implies that any intervention by the public
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(an event study) or laws and regulations by the government to weigh, measure or predict the
price of an equity is harmful to the market. The idea of the price generated by the market is the
best price for the equity. Thaler and Shiller (2015) also discussed critiques of efficiency. If critics
say fundamental efficiency does not hold, then advocates of technical efficiency did hold. Or
vice versa. However, according to Thaler and Shiller (2015), the only logical explanation is that
for these advocates, technical efficiency implies fundamental efficiency or vice versa (Thaler &
Shiller, 2015).
Assets Under Management
Assets Under Management (AUM) is a legal term from the Securities and Exchange
Commission (SEC) (SEC, 2020). Any time a company has 30 million in AUM, it must register
with the SEC. An equity management company takes in equities (cash, deposits, stocks, bonds,
mutual funds) and makes decisions for investors for their various equities. These management
companies usually charge a fee and trade equities for their benefactors in a hopeful way to make
more money than the investor can make on their own (SEC, 2020). According to Fama (2013),
80% percent of all mutual funds are in wealth management accounts. World Bank (2020)
estimates that over 15 to 19 trillion dollars in United States assets are managed worldwide from
2013 to 2018. Equities are managed, and management implications can forecast that future stock
returns. In contrast, Fama’s whole idea of efficiency says the market and equity prices cannot be
forecasted or controlled (Fama, 1970).
AUM matters are two-fold. One uses the information or financial dissertation to predict
equity movement. Secondly, the AUM implies using ethics and finance models/ theories to apply
efficiency to the market. Most equity managers follow Markowitz’s (1952) idea of a diversified
portfolio and lower the risk of loss for the investors. At the same time, the idea of managing
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equity says the market is controllable and contradicts the EMH (Fama, 2013). The average
investor, whether small or large (Alrgaibat, 2015; Brigham & Houston, 2009; Fama & MacBeth,
1973; Frase & Ormiston, 2004; Freihat, 2019; Mossin, 1966; Ragsdale, 2015; Ramadan, 2014;
Sharifzadeh, 2006; Wenjing, 2017) are always looking for a better ROR on investments.
Managed accounts have the mass appeal of the more a company has (Assets Under
Management), the more they can generate a better return. Otherwise, there would be no need for
someone else to let people manage their money, hold their equities, and buy and sell their stocks
for them.
This is where ethics/ morality comes into this event study. If, as Poser (2003) said that the
market moves in waves and investors respond to other investors, a large managed account would
swing equity prices or the market as a whole. Therefore, a managed asset fund, if mismanaged,
could create it is own anomaly in the market that could be exploited just like so many other
researchers have shown with other anomalies (Baker, & Bloom, 2013; Elbe, 2008; Fama et al.,
1969; Karolyi & Martell, 2010; Luo, 2012). Most managed accounts have set ROR from the
companies that offer them. Usually, the risk is a determining factor when calculating said risk
and ROR (SEC, 2020). The whole idea of a managed account and Markowitz’s (1952) idea of a
portfolio that can predict ROR contradicts the idea of Fama (1970) and the idea that the investor
can control and predict the ROR of a stock. Because if one can control the ROR, they are
predicting/ controlling what the market does, which contradicts the EMH.
Another factor with AUM is fees which range from 0 dollars up to as much as 25%
percent (Mauck & Salzsieder, 2015). With AUM, funds mimic a known index like the S&P 500
or generate a specific ROR. However, according to EMH, all funds should pay out the same
yield. So, a rational investor should find a fund with the cheapest fee and invest in that fund.
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Mauck and Salzsieder (2015) found that investors would invest in equities with the highest fees
because of investor bias in the diversification of equities, even though those investments had the
same ROR as cheaper or historically more successful funds. Mauck and Salzsieder (2015) argued
that this was a clear violation of EMH and the ability to have a rational investor. They also
hypothesized that companies that allowed investors to invest with higher fees and lower ROR
acted unethically with AUM. At the same time, companies are acting immorally because they do
what helps the companies that sell equities to generate funds for a company and pay themselves
fees generated by deceiving the average investor into buying and selling to generate funds that
help them (investment manages) and their investment companies’ profits.
Rational Investor
DALBAR, Inc., which started in 1976, is the financial community’s leading independent
expert for evaluating, auditing, and rating business practices, customer performance, product
quality and service (Dalbar Associates, 2020). DALBAR gives unbiased evaluations of
investment companies, financial advisors, insurance companies, broker/dealers, retirement plan
providers and financial professionals. DALBAR has done studies of what are rational and
emotional investors. DALBAR questions if people invest based on personal values, memories, or
what they hear in the news? DALBAR says you are an emotional investor in a 2016 study
(Dalbar Associates, 2020).
A rational investor or rational behavior is defined as a reason or logic
(thefreedictionary.com, nd). In finance, rational is making a logical decision with the optimum
benefit level (Sharpe, 1964). This cognitive bias can be seen in the gambler’s fallacy. Suppose
you flip a coin; it lands on tails six times. You assume that head is coming up, so you are
inclined to say tails are coming up. When in reality, it is still a 50/50 chance. The new coin toss
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is a new independent event. The new coin flip is not dependent on the prior coin flips like most
people emotionally feel. This is Fama’s (1970) whole idea with the EMH. You cannot determine
what the market will do based on prior information because the market will take in all
information and react accordingly. This is different from anything else in the market. However,
this idea supports Poser’s (2003) idea that investors buy stocks in waves and are emotional
investors because investors see what others are doing and follow other investors’ leads regardless
of whether they are rational. Neither of these assumptions about investors’ rationality can be
considered normal. It is a starting point for looking at the relationship between information and
equity price; because it is all about the market efficiency and how the market reacts to investors
purchasing stock.
According to the NYSE (2020) and the World Bank (2020), the time limit on investors
holding an investment is diminishing, which contradicts stock market investment advice (Sharpe,
1964). This is usually to buy and hold. The average holding period for stocks in 1960 was eight
years and four months. In the 1970s, it was five years and three months. The 1980s were two
years and nine months. The 1990s were two years and two months, and the 2000s saw one year
and two months, according to the NYSE Historical Market Reports (2020). Ned Davis Research
(2020) has the following graph to support these findings located as Figure 6.
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Figure 6
Stock Holding Periods 1929 to 2016 (Ned Davis Research, 2016)

Since 2000 there have been conflicting reports because of electronic trading. Most trades
are short-term (less than a year). The time limit for holding an investment can be as low as 22
seconds and longer (Harris, 2011; NYSE, 2020) World Bank, 2020). According to Harris (2011),
these short-term investments are considered long-term investments by the actual investors. The
World Bank from 2015 reported the average stock is traded four times a year from 2008 to 2014and 1.5-times a year after 2015. The Ned Davis Research group said 8.3 months was the average
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holding time in 2016 (Rowles, 2020). A potential reason for the changes in time for trading to
increase is because of the 1993 law called the Commercial Transaction Law Number 18, which
according to the Credit Swiss and World Bank cite the growth of E-trading and the fact that
financial companies’ bonuses of executives for meeting measurable performance goals can be
tax-deductible (World Bank, 2020). Other things proposed in the same report are that large
financial companies only make money buying or selling investments. Therefore, a financial
company that buys and holds assets cannot make short-term quarterly financial goals for the
companies without buying and selling AUM (World Bank, 2020).
For the average investor, this is defined by rational decisions when investing in equity
(Dalbar Associates, 2020). A trade-off between the plan’s choices or what you feel or think. This
is demonstrated in efficiency. Efficiency means you get the maximum benefit of resources
(Fama, 1970; thefreedictionary.com, nd). Equality means that benefits are shared equally among
society (thefreedictionary.com, nd). In finance, efficiency is the size of the economic pie, where
equality divides the pie into equal slices. This is seen in laws and how government policies are
designed. The rich are asked to pay more taxes for those who make less and do not pay taxes.
Unemployment is given to those who could work who are not working then. Hence,
unemployment helps people work less and as a country. We are not efficient because we produce
less. When cutting the finances into more equal slices, the smaller the pie gets is not fair and or
just for all.
This trade-off of finance is seen in investing, where investors choose when to buy and
sell. The question becomes what the investor thinks will achieve their financial goal. This
investor opinion is the trade-off between what they give up and what do they think the outcome
of their actions will be. An example is that stock prices start to drop. Do you hold or sell and get
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out of the stock? History teaches that stock prices will increase over time. This is demonstrated
in Figure 3 which shows that the market eventually goes up no matter what happens. The
question is can you wait for it to recover? The early twenties investor theoretically can wait for
the market to recover. However, a 75-year-old might not have years to wait. No matter what they
decide, their individual choices can be rationale as long as it fits into the investor’s financial
plan(s) (Sharpe, 1964). Only humans can say a financial plan is irrational or emotional because it
does not fit into their (another person/ investor) financial plan(s).
This whole idea plays into the Rational Expectations Theory (RET) (Muth, 1961). The
RET is the dominant assumption model used in finance as a cornerstone of the EMH. RET
implies the following:
o Individuals use their knowledge to rationalize when making a decision
o The average person has expectations
o Rational expectations are just a guess of tomorrow
o The average person is right most of the time
o People learn from their mistakes
o Equity (company) values are important (price, production, and employment)
o Investors behave in ways that give them enjoyment in life
o Investors seek to maximize profits
o These expectations about the future influence current decisions
o Investors create expectations based on all available information
o These market predictions are very close to the market value (Muth, 1961)
In RET (Muth, 1961), the investors’ expectations and, therefore, the outcomes of investor
actions influence each other. Hence, there is continual feedback from prior investments and
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current behavior. This behavior of RET either supports or disproves EMH (Fama et al., 1969) or
adds credence to the Elliott Wave Principle or Elliott Wave Theory discussed by Poser (2003) by
saying that people react accordingly to the new information. These ideas of waves and time are
supported by Swedroe (2013), Agrawal et al. (2010), and Smales (2013), who tested and reported
the effects of information on event windows and found that from the time information is
released, it takes 40 seconds for the NYSE to respond to information compared to 75 to 90
seconds for the London Stock Exchange to respond to the same event.
Momentum
To coincide with Elliott Wave Theory (Poser, 2003) is the idea of momentum.
Momentum is a phenomenon that behavioral finance has uncovered in the presence of bias in
investing (Daniel et al., 1998). Momentum comes from investors acquiring information and
reacting to it (buying or selling equity). Then the market reacts, and therefore the investor reacts
again (buying or selling equity) with a financial goal. The equity takes on its energy, and the
movement of the equity, either up or down, has its momentum repeating this process repeatedly.
Daniel et al. (1998) concluded that depending on the strength of the bias and how many biases an
investor had determined how long and how much equity could move. Their research was seminal
when it was written and explained the over and under reactions of the market.
Pharmaceutical Companies
The companies were chosen from the idea of looking at twenty-six pharmaceutical
companies in the healthcare sector of the NYSE because they potentially should react differently
than the surrounding market since investors would be looking for them (pharmaceutical
companies) to produce a treatment, vaccine, or cure to the pandemic (Palache et al., 2017).
However, choosing the actual companies because of the word pandemic was a problem. Many
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articles and research material described epidemics as pandemics in their writings. These
epidemics are described as pandemics because of WHO's public health declarations but not
WHO's PHEIC (2020). The list of epidemics in the twentieth century after the foundation of
WHO in 1948 is: Polio 1949 and 1952, Asian Flu of 1957, Hong Kong Flu of 1968, smallpox
and London flu of 1972, smallpox of 1974, the plagues of 1984 and 1994, meningitis of 1996,
Nipah Virus of 1998, Dengue fever of 2000, Cholera of 2001, SARS of 2002, the plague of
2003, Cholera, Dengue Fever, Ebola, Yellow Fever, and Leishmaniasis od 2004, Dengue fever
of 2005, Cholera, Plague, Malaria, Dengue Fever, and Rift Valley fever of 2006, Dengue fever,
Cholera, Plague, Hepatitis B, Mumps, Bubonic plague, and hand foot and mouth diseases of
2008, 2009, and 2011, MERS of 2012, the 2014 polio declaration, the 2014 Ebola outbreak in
Africa, the Zika epidemic of 2015, the 2018 Kivu Ebola epidemic, and 2017, 2018, 2019
encephalitis, measles, Dengue fever, Nipah Virus, and Yellow fever (WHO, 2020).
There have only been six pandemics in the last 120 years. They are the Sixth Cholera
Pandemic of 1899-1923, Spanish Flu of 1918-1920, Seventh Cholera Pandemic of 1961-1975,
the HIV/AIDS Pandemic of 1960-Present, the Swine Flu of 2009-2010, and the Coronavirus
Covid-19 of 2019- 2020 (WHO, 2020). However, HIV/ AIDS disqualified itself from the
research because it never announced a pandemic. This was because the idea of an announcement
of a pandemic did not exist until 2003 in response to the SARS epidemic of 2003. In 2003 the
WHO started declaring Public Health Emergency of International Concern (PHEIC) (WHO,
2020). Any epidemic or pandemic prior to 2003 had to be eliminated because of the term
pandemic; or because of the PHEIC by WHO, which could not have existed prior to 2003.
Pharmaceutical companies are a sub-category of the healthcare sector of the stock
market. Healthcare companies are the world's largest and fastest-growing part of most economies
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and usually consume as much as 10% of most developed nations' gross domestic product (GDP)
(World Bank, 2020). The healthcare sector provides goods and services to treat curative,
preventive, rehabilitative, and palliative care patients. Healthcare is typically divided into several
areas based on the United Nations International Standard Industrial Classification system. Most
healthcare is defined as hospital activities, medical and dental practice activities, and other
human health activities. The Global Industry Classification Standard and the Industry
Classification Benchmark further distinguish the industry into two main groups: healthcare
equipment and services, pharmaceuticals, biotechnology, and related life sciences (United
Nations, 2020).
Pharmaceutical companies research, develop, and market medicines made primarily from
artificial sources (Palache et al., 2017). Pharmaceutical companies take years to research,
manufacture, produce products and get the Food and Drug Administration's approval (FDA,
2020; Palache et al., 2017). This is slightly different from biotechnology (biotech) companies
that manufacture and make living organisms’ products. Both pharmaceutical and biotech
companies have the same overall goal and similarities with making medicines. Pharmaceutical
companies are usually more stable than biotech companies because they hold exclusive rights to
products and have other forms of income from their large size and mergers with other
companies. Most pharmaceutical companies have a biotech division or product line, whereas the
opposite is not true for biotech companies to have a pharmaceutical division (Palache et al.,
2017).
Pharmaceutical companies are considered defensive stocks (Krzeczewski, 2017).
Defensive stocks tend to do well during economic downtowns in the stock market than cyclical
stocks that tend to do well due to upswings in the overall economy. Defensive stocks should not
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be confused with defense stocks, which manufacture such as weapons, ammunition, and fighter
jets (Krzeczewski, 2017). A cyclical stock can be classified according to its reaction to business
cycles. Cyclical companies tend to make products or provide services in lower demand during
economic downturns and higher demand during upswings. The automobile, steel, and real estate
investment industries are examples of cyclical businesses.
Defensive stocks are the opposite of cyclical stocks because they do well during poor
economic conditions. Defensive stocks are companies whose products and services enjoy steady
demand. Examples of defensive stocks are food, medicines, and utilities stocks since people
typically do not cut back on their food, medicines, or electricity consumption during a downturn
in the economy (Krzeczewski, 2017). Even though defensive stocks tend to do well during
economic downturns, their performance during upswings in the economy is poor and tends to be
lackluster compared to cyclical stocks because they do not show great(er) demand as the
economy gets better.
To possibly identify a defensive stock, one can look at the stock's beta. Beta measures the
stock-price change compared to the overall stock market change (Chen & Chi, 2018). Defensive
stocks typically have a beta of less than 1. A beta of 1 means the stock price moves at the same
rate as the overall market, whereas a beta of less than 1 would mean that the stock would move
less than the market (Chen & Chi, 2018). Defensive stocks benefit from long-term gains with
lower risk than other stocks. Another way to identify a defensive stock is to look at its strong
cash flows. These companies usually have stable operations and pay dividends, which can lessen
a stock's price decrease during a market decline.
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Stock Prices
The stock prices used were the adjusted close price on the NYSE for each company. The
adjusted close is information acquired from a company’s historical data. Other data in the
historical data from the NYSE is the date, opening price, the high price of the day, the low price
of the day, the closing price, the adjusted closing price, and finally, the volume of that stock
traded during the day (NYSE, 2020). The opening and high and low price of the day was
removed from the data gathered from the NYSE historical data, which left three pieces of
information. Volume is removed as it is another part of the research.
The remaining information besides the date is the close and adjusted closing price of the
stock. The difference between the close and adjusted close is that the closing price is simply the
cash value of that specific stock at the end of a stock trading business day. The adjusted closing
price reflects the stock's closing price concerning other stock attributes like dividends, stock
splits, and new stock offerings (Heun et al., 2002; NYSE, 2020). The adjusted closing price is a
more accurate reflection of the stock's true value for a long-term investor. The adjusted closing
price time and effort are removed, which is one of the limitations of event studies. One drawback
to adjusted close is that an investor cannot buy stock at the adjusted close the next day. Stock is
typically priced following the prior day's closing price (NYSE, 2020) plus an adjustment for
after-hours trading.
The final consideration in stock prices is the electronic communication networks (ECNs)
and after-hours trading (AHT). AHT is information because the widely used ECNs move stock
prices from the close or adjusted close price to the opening market price (NYSE, 2020). Daily
trading on the NYSE is from 9 AM to 4 PM Eastern Standard Time (NYSE, 2020). Companies
have things happening after these hours that affect the stock price, called after-hours trading. An
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example here is a company that incurs a financial scandal. If the stock was trading at $100 at
close, it might only be worth three $3 at the morning open price because nobody will pay for a
scandal-ridden company. This happened with Lehman Brothers in 2008, which started the largest
world recession since World War II (Dullien et al., 2010; McKibbin & Stoeckel, 2009).
Dividends
One of the topics mentioned in the stock price section is dividends. Dividends are a
distribution of part of the company profits to investors/shareholders of company stock
(thefreedictionary.com, nd). Dividends are part of the reason for holding stock for long-term
investors (Chen & Chi, 2018). Besides hoping for an increase in stock prices, companies
typically pay out a portion of the profits quarterly to investors as a token reward. According to
the NYSE (2020) and Chen and Chi (2018), larger, more established companies with predictable
profits and losses are the best dividend-paying companies. According to the NYSE (2020), the
following industries are the best dividend payers: basic materials, oil and gas, banks and
financial, healthcare & pharmaceuticals, master limited partnerships (MLP), real estate
investment trusts (REIT) and utilities. Dividends are usually paid out quarterly unless a special
dividend is issued (Chen & Chi, 2018; NYSE, 2020).
There are rules for dividends to be paid to investors. According to the NYSE (2020),
dividends follow chronological order. First is the announcement date of the dividend. This is the
date that dividends are announced by company management and approved by shareholders.
Second is the ex-dividend date when eligibility expires for a dividend. Next is the record date,
which the company uses to which shareholders are eligible to receive a dividend. Then finally is
the payment date. This is when the company distributes the money, and investors get credit for
the funds in their accounts or books, depending on how or what dividend is paid (Chen & Chi,
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2018; NYSE, 2020). Dividends are usually paid as cash, and long-term investors use these funds
as part of the ROR calculation of their investment. Based on the adjusted close of the NYSE
historical data, dividends are pre-calculated into the adjusted close of stock prices (NYSE, 2020).
Mean vs. Median and Skewness
The term average or mean expresses that something is statistically normal
(thefreedictionary.com, nd). A value would be expected, middle, usual, or common in research.
In mathematics, the average is the sum of all values divided by the number of values added. The
mean is almost considered synonymous with average. However, a statistician will disagree
because mean is only a form of describing an average (Morgan et al., 2013). Median is different
from average as the median is the central point of a set of numbers (Morgan et al., 2013). In
statistics, the median is the number that occurs in the middle of a set of numbers. Median is
considered the most suitable way to describe the central tendency of a particular sample (Morgan
et al., 2013)
The term average encompasses several ways to measure what value best characterizes a
particular sample. The terms and measurements that are used will depend on the situation. It will
be based on how you want to describe a certain set of data or samples. This is where skewness
becomes a factor in interpreting data. Skewness is where the mean and median of a data set are
not the same or have a variance (Morgan et al., 2013). A skewness to the right or the left of
abnormal distribution is where the median and the mean are different. An example for mean,
median and skewness is the following collection of 10 numbers in numeric order: [1, 1, 1, 2, 2, 3,
5, 8, 12, 17]. The mean of the numbers is 5.2. Which is the total of the numbers 52 divided by 10
or {1+1+1+2+2+3+5+8+12+17 = 52 or 52/10 = 5.2].
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The median of the group of numbers is 2.5. This is calculated by finding the middle of
the number two and the number three set of numbers. This group has two middle numbers: five
numbers from the left and five numbers from the right. The number 2 plus 3 divided by 2 is 2.5
or (2+3 = 5 and 5/2 = 2.5). The group of numbers now has 5 numbers greater than 2.5 and 5
numbers less than 2.5. In this example, the mean (5.2) is greater than the median (2.5). This is
common for a skewed distribution to the right; the distribution can be skewed to the left when
the mean is less than the median. The mean of numbers is sensitive to outliers in number sets in
statistics. The median is not sensitive to outliers (Morgan et al., 2013). An outlier is a number
that is an extreme number that exists outside of a pattern or expectation (thefreedictionary.com,
nd).
In finance, the word average is thrown around in relation to the average investor (Dalbar
Associates, 2020), different from the concept of an average in numbers. This is seen in Fama’s
whole idea that an average investor cannot beat the market (Fama, 1970). However, at the same
time, most accounts are managed and get a set rate of return, which is as good as or better than
the market (Alrgaibat, 2015; Brigham & Houston, 2009; Fama & MacBeth, 1973; Frase &
Ormiston, 2004; Freihat, 2019; Mossin, 1966; Ragsdale, 2015; Ramadan, 2014; Sharifzadeh,
2006; Wenjing, 2017). Fama even acknowledges this with 80% of all mutual funds are in wealth
management accounts (Fama, 2013). In the same context, the average ballplayer does not play in
the NBA, or the average tennis player does not win a tennis match at Wimbledon. This does not
mean the average person cannot invest, nor should they not work on their jump shot or backhand.
The average investor is not a finance major, nor are they investing hours daily into
investing. The average investor is someone invested in the stock market and has the goal of a
decent ROR on their investment (Dalbar Associates, 2020). At the same time, the NYSE (2020)
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stated that the average stock market return was 10% which is quite different from Appendix C:
NYSE Composite Index Annual ROR, which ranges from -40.9% to 31.3% in 1995. The market
return is not always average. Since 2000 the market has beaten the average for a total of nine
times based on Appendix C: NYSE Composite Index Annual ROR (NYSE, 2020), which is not
even a 50% rate (9 returns/19 years data Appendix C = .4737). The average is not the best
number to show the relationship between the two numbers. The terms mean median and mode
are required to help one understand the relationship between two numbers (Morgan et al., 2013).
At the same time, average is not a good word for all investors. Dalbar Associates (2020)
implies some basic concepts about the average investor. These ideas are:
1. The average investor uses readily available stock information.
2. The average investor gets information from ads, commercials, magazines, friends, bosses,
random persons, and radio/television stock advice.
3. The average investor does not want to pay a lot for the advice.
4. The average investor has lost money in the market
5. The average investor does not make the S&P 500 return on their investment
6. The average investor is a BUY and HOLD for long term of more than a year on an
investment.
7. The average investor is afraid to sell when a stock price increases because of missing
more gains.
8. The average investor is afraid to sell when the stock price is down because it means
acknowledging losing investment money.
9. The average investor has not researched many stocks and does not plan when to sell or
what price. No clue how much they will make, but it will be a lot.
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10. The average investor has a 401K or another financial plan.
11. The average investor is concerned about social security and their future finances.
12. The average investor makes up the largest group of investors in the market. (Dalbar
Associates, 2020).
This can be seen in Dalbar’s 20-year study ending on 12/31/2015, which showed the S&P
500 Index averaged 9.85% a year, and the average investor had a market return of 5.19% (Dalbar
Associates, 2020).
Significant and Practical Statistics
Formal research pushes the idea that research should be statistically significant in its
findings. Whatever the researcher is studying did not happen by chance and is repeatable in
another scientific study using statistical, mathematical equations (Fisher, 1925; Morgan et al.,
2013; Peng, 2015; Trafimow & Marks, 2015). According to scientists and researchers, these
experimental findings must be at a rate of less than .05 or p <.05 in the statistical equation as the
alpha (Fisher, 1925; Morgan et al., 2013; Peng, 2015). Medical research pushes the idea of 0.01
or p <.01as the alpha (Peng, 2015; Trafimow & Marks, 2015). This ideology has made
researchers and scientists only believe that statistically significant findings should be published,
and all other research is faulty if their findings are not statistically significant (Peng, 2015;
Trafimow & Marks, 2015).
There is another type of statistics, according to some statisticians. That is the belief in
‘practical’ significance compared to ‘statistical’ significance in findings (Peng, 2015; Trafimow
& Marks, 2015). Practical statistics are used to describe the magnitude of the ‘effect’ and
whether research findings will make a difference in the real world with research findings (Peng,
2015). An example is a test score. The outcome of a test is studied using cost and test results as
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variables, looking for changes from a new study technique on the final test score results. Test
results from the test scores study show a statistically significant difference in the research study
findings. However, upon closer inspection, the actual difference, even though statistically
significant, is a three-point score difference in actual test score results. The cost of the new
program is $20,000. A good researcher should know that three points on a test are not worth
$20,000 in the real world, even though it is statistically significant in research results. The
opposite is true where a new math formula is added to the study guide at the cost of zero ($0)
dollars, and the test score goes up three points on final test scores, but the result findings on the
test study scores are now not statistically significant. The findings are practically significant, yet
the results are not statistically significant based on research criteria.
This is where the reader and researcher have to look at research data findings from a
statistically and a practical significant point of view (Peng, 2015; Trafimow & Marks, 2015). A
three-point test increase with zero cost is very practical for the average person (Alrgaibat, 2015),
even though it is not statistically significant to a researcher (Fisher, 1925). This idea of practical
vs. statistical findings is supported by the work of Peng (2015) and Trafimow and Marks (2015),
which shows the error in null hypothesis significance testing because of the use of statistics and
p-values P (T<=t) two-tail in result findings. In reality, no statistical test can tell whether the
effect of a study is large enough to be important in a field of study in real-world applications for
everyday purposes (Peng, 2015; Trafimow & Marks, 2015).
All statistical research does is show whether study findings are statistically significant in
a research context. All statistical data is truly up to interpretation. What has been forgotten is that
statistical significance is a continuous spectrum of mathematical data and not a yes or no answer
that is finite in the research results (Peng, 2015; Trafimow & Marks, 2015). Researchers ask a
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question based on their faulty understanding of the word significance, which is the concept of the
findings of this research be statistically significant in output from the research project? The
researcher should be asking a more sensible and reasonable question: How significant is the
finding (data) for a real-world application(s)? Because of this faulty understanding and logic in
interpreting the word significant by the scientist, researcher, or statistician, the true meaning of
the word significance is missed. Significance has a more technical and colloquial meaning which
is: impactful, important, and relevant (thefreedictionary.com, nd) which is where true research
should be founded; not in the ideology of an arbitrary number (.05 for alpha or p>.05) based on
research history or research criterion for saying something does not happen by chance (Fisher,
1925).
Summary of the Literature Review
This literature review has covered many topics and terms to define, explain, and interlink
various non-sequential points of view, research, and data. The culmination of the data will
become clear in the qualitative explanation of the findings of this research project, specifically in
the data analysis section in part two. As mentioned in the problem and purpose statement, this
research combines many pieces of a problem secondary to the actual research data collection
methodology. As with any other research, a researcher and consumer know there are always new
topics to be answered and new problems or results present when data is collected.
This section also has given credence to the problem and the background of the problem.
It describes many factors into the nature of the study about the EMH and the general problem to
be addressed the possible failure of the Efficient Market Hypothesis (EMH) to consistently hold,
resulting in investors being able to generate statistically significant abnormal returns. Charron
(2017) asserted that the EMH does not hold true and is flawed in its very fundamental wording.
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Daniel and Hirshleifer (2015) validated this problem and disagreed with the EMH holding true
because of investor behaviors and outside forces. The research further explains the problem with
the EMH holding true by Thaler and Shiller (2015); who, like Charron (2015) and Daniel and
Hirshleifer (2015), found that the EMH does not hold true based on another idea; which is the
premise of explaining rational behavior in the markets. The specific problem questions are if the
EMH consistently holds, resulting in investors being able to generate statistically significant
positive abnormal returns in the pharmaceutical sector of the United States NYSE stock market
following an announcement of a pandemic by WHO.
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Section 2: The Project
Purpose Statement
The purpose of this event study research was to evaluate the potential impacts of
pandemics on the financial performance of the United States stock markets, specifically, the
pharmaceutical sector of the NYSE after the announcement of a pandemic (Thaler & Shiller,
2015; Wang, 2016). This event study was a fixed design using quantitative methods to examine
the cause and effect of the announcement of a pandemic on the stock market (Babones, 2016).
This event study used a t-Test and portfolio theory to determine the abnormal return of the 26
pharmaceutical stocks compared to the S&P 500 (Morgan et al., 2013) (Appendix B: Used
Pharmaceutical Company List broken down by NYSE and NASDAQ categories).
This event study was a fixed design using the quantitative method because it was
exploratory, deductive, and had hypotheses (Babones, 2016; Creswell, 2014; Yin, 2018). The
qualitative research method alone was not appropriate because it had a hypothesis. The
quantitative method alone was also inappropriate because the research compared and interpreted
data from multiple theories on one event, looking for data not presented in one set of findings
(Babones, 2016; Creswell, 2014; Yin, 2018).
Role of the Researcher
According to Denzin and Lincoln (2003), research is considered an instrument of data
collection. The data went thru the human instrument (AKA: the researcher) rather than thru
questionnaires, machines, or piles of inventories. The research and the consumers of said
research need to know a little about the researcher (Greenbank, 2003). I, Ronald (Ron) Burnette,
am an employee of the State of Virginia and a Fortune 500 company. I hold no bias, nor gain any
benefit from the data, the compilation of data, or the outcome of this dissertation except to say I
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wrote a finance-related dissertation which will help me acquire my Doctorate in Business
Administration (DBA). I have presented all information based solely on the data’s face value,
hopefully without imposing any judgments,’ bias, or influence on said findings. This event was
exempt from the Liberty University Institutional Review Board (IRB) as it has no primary
instrument for data collection but is a collection and interpretation of second-hand data (Liberty
University Institutional Review Board Policies, 2019). I did, however, present this event study
from an interpretive quantitative method. This framework follows the idea of Babones (2016),
who used a mixed method approach for the positivist standpoint and used it quantitatively, not
the qualitative manner with which researchers normally associate positivism.
I present this data from an etic perspective as a researcher. Etic means from an outside
perspective compared to an emic or inside perspective (thefreedictionary.com, nd). I have
attempted to answer questions relevant to the market and portfolio theories and their effect on the
equity market related to pharmaceutical stock ROR. The research itself is important as the
outcome of the research. The fact that the data did or did not support the underlying problem(s)
or hypotheses is inconsequential. This research gives actual researched proof to any investor,
whether average or professional, which theory is an appropriate guide for looking at
pharmaceutical stock ROR and adding additional proof to the theory that the market is or is not
efficient.
Participants
The participants in this research project are all of the 2,800 plus publicly traded
companies of the NYSE, of which 296 are healthcare sector stocks listed as of March 2020
(NYSE, 2020). However, this event study focused only on 26 of the 47 pharmaceutical
companies from that list. This is because the 26 companies are the only companies that have
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existed for 11 years. Other participants were the sources of information about said companies or
other terms and factors used in the literature review for their contribution to this project.
These 26 pharmaceutical companies were not random. The participants in this study were
chosen for one reason. This reason was that the pharmaceutical sector of the stock market would
behave differently than the rest of the stock market, as demonstrated in Figure 3: Sources:
http://www.pandemicflu.gov. - An official U.S. Government Web site managed by the U.S.
Department of Health & Human Services. (1): S&P 500: US Data
http://www.econ.yale.edu/~shiller/data.htm. (2): UK Equity Market: Global Investment Returns
Yearbook 2005. Dimson et al. (2020) and Elgeti (2020) showed the pharmaceutical sector
performing better than the rest of the market because of its defensive investment nature.
However, the speculation to this research shown in the hypothesis is that the pharmaceutical
sector would behave differently due to the announcement of a pandemic by WHO.
Research Method and Design
The research method and design were primarily built around analyzing data from public
databases related to the NYSE equity markets. The purpose of this research was to paint a picture
of how the different finance theories have a bearing on how stock prices are viewed. This data
was then statistically analyzed, and the finding was presented in the results section. This results
in statistical information that will or will not support the null hypothesis and answers the
corresponding research questions.
Discussion of Method and Design
Event studies are designed to investigate the effect of an event on a specific dependent
variable using statistics. The most commonly used dependent variable in an event study was the
company's stock return. In an event study, the goal of it was to study the changes in stock return
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beyond expectation or what is called an ‘abnormal return(s)’ (Beladi et al., 2016; Charron, 2017;
Daniel & Hirshleifer, 2015; Thaler & Shiller, 2015). The change in stock returns occurs over a
time called an ‘event window’ (Beladi et al., 2016), and the researcher can infer the significance
of the event on the stock ROR.
Cumulative abnormal return (CAR) is abnormal for an event study. A CAR is merely an
average of the time (TP) to compare to the actual expected return (EP) of the stock and compared
to the S&P 500 of the NYSE to see how the actual returns differ from the EP of the stock and the
movement of the stock market itself. CAR is required for research because over a small-time
window of hours or days, abnormal returns by themselves can lead to bias in result findings
(Thaler & Shiller, 2015). Therefore, CAR was a better indicator of abnormal return since it is the
average of the ROR over some time. In this study, the CAR would look at the 21 days and 7days pre- and post-event windows and the day of the actual event (T0) for the announcement of a
pandemic by the WHO on the pharmaceutical companies in the healthcare sector of the NYSE
(Chen et al., 1986).
The data used in this research about stock prices came from the historical data of the
NYSE (2020). Since the stock price data is readily available for the public, there should be no
ethical concerns about collecting or analyzing this readily available public data. Also, all
information about stock prices had been validated by outside sources, and through multiple
research criteria, legal compliance and typically audited before publishing by outside sources; so,
reliability and validity of the online stock price data from reputable sources was not an issue
either for this research project. This event study has research questions (RQs) and supporting
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hypotheses. Both the RQs and hypotheses were used to formulate and propose statistics for
validation and for supporting the findings.
The RQs and hypotheses were based on the underlying question of the proposed failure
of the EMH to consistently hold, resulting in investors being able to generate statistically
significant positive abnormal returns in pharmaceutical stocks from the healthcare sector of the
NYSE due to the announcement of a pandemic by the WHO. Leading to the idea that an investor
can outperform the overall stock market through specific stock selection or specific market
timing on stock purchases because of an event (Wenjing, 2017). While the hypothesis did not
have to be correct, it chose either true or false outcomes. Therefore, this had two scientifically
testable predictions about the relationship between the stock ROR and the announcement of a
pandemic by the WHO. The first hypothesis looked for a direct relationship between stocks
ROR; before and after the announcement of a pandemic by the WHO. The second hypothesis
looked to see if the EMH was supported by the behavior of the overall market in the volume of
stock actually traded during the same periods.
These hypotheses were based on the work of Fama (1970) and Pilkington (2017), who
said the market is efficient and that prices are directly reflective of events and will trade at their
fair market value. Daniel and Hirshleifer (2015) argued that the market is affected by outside
events. This was the premise behind hypothesis one (H10), which stated there is no statistically
significant difference in the aggregate pharmaceutical sector stock(s) rate of return after
announcing a pandemic by the WHO.
The second hypothesis (H20) looked to support the work of Thaler and Shiller (2015)
who, like Charron (2015) and Daniel and Hirshleifer (2015), looked to explain the rational
market. The second hypothesis (H20) determined if a flaw existed in the EMH, which did not
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look at stock prices, but stock volume. When a stock is trading in larger than normal stock
volume, it would be an indicator of a flaw in the market that could be exploited and used to
predict the movement of a stock and hence a flaw in the EMH (Wenjing, 2017). This in itself is
the basis of supply and demand, which is an underlying basis of EMH. Supply and demand say
low availability and high demand with increase a stock price; whereas the opposite is true and
high availability and low demand will decrease the stock price. So, increased movement of the
volume of stock would indicate a potential area to exploit or an anomaly in the market (Wang,
2016). Therefore, (H2a) stated there is not a statistically significant difference in the volume of
aggregate pharmaceutical stock traded after the announcement of a pandemic by the WHO.
Summary of Research Method and Design
Although one could argue that there is great leniency in how data is interpreted, that
could not, in reality, be the case. However, one can have an unbiased opinion of what that data
reveals. A quantitative research project is very strict on interpreting and presenting it compared
to a qualitative research project. For this to take place, three main things have to co-exist. They
are the internal, external, and individual perspectives. The internal factors were the various data
from the various financial reports on the NYSE (2020) and company websites. Externally, the
data was reviewed and plugged into various formulas that complied with GAAP and statistical
formula rules. Lastly, the researcher had to ensure no bias when interpreting the statistical
model's findings. The data must be presented fairly and clearly.
Then a conclusion was drawn from this data that either supported or disproved the basic
assumptions of the research problem and answered the research question(s) and hypotheses of if
a positive abnormal return is found in the pharmaceutical companies of the NYSE when WHO
makes the announcement of a pandemic with a PHEIC. Even though as a researcher, I take an
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interpretive quantitative method perspective following the ideology of Babones (2016) and view
the data with no absolutes and open for interpretation. I presented all data collected and the
findings; however, the results came out. My presentation was inconsequential whether these
findings supported the research questions or hypothesis. As a researcher, I know that even
though my RQs or hypotheses are supported or not. All data and findings were used in the real
world from a practical vs. statistical significance use (Morgan et al., 2013; Peng, 2015; Trafimow
& Marks, 2015).
Population and Sampling
Since no new instrument was created, all data were collected from public data as
secondary data. As mentioned in the literature review, all data was noted as reliable and valid
due to the laws and regulations imposed upon publicly traded companies in the Unites States.
However, all data on its own did not provide the information sought after in this event study.
Therefore, various pieces of data were pulled from various sources and compiled to make useful
data and data tables for the calculation of this research. The notes of where and when this data
was collected can be seen in the reference section, with citations to those references located by
each data set.
Discussion of Population
Population in statistics is a large group with at least one common element (Morgan et al.,
2013; Peng, 2015). In finance, a population is the stock market of whatever country studied.
However, with a population of this size, there was too much data to be analyzed by one person or
a small group of people. Therefore, researchers dissect the overall population to study in a
research project. This small group from within the population is called a sample (Morgan et al.,
2013; Peng, 2015). A sample is a finite subset group of the overall population chosen by some
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process. There was a finite population and a finite sample of the population which were the same
at a count of 26. This was unique as the sample represented 100% of the population.
The NYSE has over 2,800 plus publicly traded companies, out of which 296 are
healthcare sector stocks listed as of March 2020 (NYSE, 2020). Forty-seven of those healthcare
sector stocks are pharmaceutical companies. These 47 can be seen in Appendix A: Alphabetized
Pharmaceutical Company List NYSE (2020). This list was narrowed down because 21 of those
companies did not exist in 2009. They now exist in 2020 (47-21=26) according to the NYSE
(2020) historical data in March of 2020. The 26 pharmaceutical companies used in this research
can be seen in Appendix B: Used Pharmaceutical Companies and have existed on the NYSE
from the year 2009 to the year 2020. This was based on April 13, 2009 (Swine Flu Event
Beginning Timeline) and March 2, 2020 (Covid-19 Event Ending Timeline).
The NYSE is stratified into 11 main sectors and further broken down by the parameters
of the companies within the sectors. Stratification breaks the larger group into subgroups for
classification purposes (thefreedictionary.com, nd). Pharmaceutical companies are one subgroup
of the overall healthcare sector. In theory, according to Fama (1970), the stock market is
efficient, and no one group, or sector will perform differently than any other group. This event
study challenged that efficiency notion and proposed that the pharmaceutical sector of the NYSE
would perform differently and generate a positive abnormal return compared to the overall
market represented by the S&P 500.
Discussion of Sampling
The population and sample are the same with 26 finite pharmaceutical companies that
have existed for the last 11 years from the healthcare sector of the NYSE based on data from the
NYSE historical data March 2020. Typically, the sample is smaller than the population. This is
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done for time and cost issues where the sample represents the population in research. However,
the sample size equaled the population; therefore, the results of the data had no variance, and the
population was reflected 100% accurately in the findings of the results. This factor alone
removed any uncertainty for the data and any guess about the reliability of the data for the 26
pharmaceutical companies that existed for the years 2009 to 2020 as of March 2020.
The entire list of pharmaceutical stocks was found in the NYSE historical data to choose
the companies (see Appendix A). Then, this list was narrowed down by the dates: April 13, 2009
(Swine Flu Event Beginning Timeline) and March 2, 2020 (Covid-19 Event Ending Timeline).
The 26 pharmaceutical companies used in Appendix B: Used Pharmaceutical Companies List as
mentioned in the population above. Next, the 26 companies were searched on the internet and
newspaper articles on the internet for potential extraneous variables (Creswell, 2007, 2014; Yin,
2013, 2018). In this case, the extraneous variable was any positive or negative newsworthy event
affecting the companies during April 13, 2009, to July 13, 2009 (Swine Flu Event Timeline) and
November 27, 2019, and March 2, 2020 (Covid-19 Event Timeline). No negative or positive
news events were found, such as lawsuits, crimes, mergers & acquisitions, environmental
pollutions, board of director changes, or scandals in a simple Internet search of company names.
This was not to be mistaken with the companies having lawsuits, crimes, mergers and
acquisitions, environmental pollutions, board of director changes, or scandals in the company’s
history. Each company had no findable negative or positive newsworthy event during the
aforementioned timeline that could be considered an extraneous variable that impacted the stock
price during the event windows (Heun et al., 2002).
This event study was rare because the total proposed population was small. Therefore,
this event study tested the entire population, which meant that the sample size and population
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were the same. Because the sample size was 100% of the population, the sample met or exceeded
the 95% percent confidence level and the 5% percent confidence interval required for a research
project (Morgan et al., 2013). Most research requires that the researcher find the sample size
concerning the population; so that the data can be valid and representative of the entire
population. This did not require a sample size calculation since the data represents 100% of the
pharmaceutical company’s population. Not to be confused with the entire population of
pharmaceutical companies on April 13, 2009, to July 13, 2009 (Swine Flu Event Timeline) and
November 27, 2019, and March 2, 2020 (Covid-19 Event Timeline).
Understanding the confidence level in research is the probability that the value of
research falls within a specific range (Morgan et al., 2013). Because there was a population of 26
companies and a sample size of 26 companies, the confidence level exceeded the expectation
that 95% percent of the population was represented in the research because it was at 100%. The
confidence interval is the degree of uncertainty associated with a research sample (Morgan et al.,
2013). The required confidence interval in research studies is 5%. One hundred percent of the
pharmaceutical companies (AKA: confidence level) in existence from April 13, 2009, to July 13,
2009 (Swine Flu Event Timeline) and November 27, 2019, and March 2, 2020 (Covid-19 Event
Timeline) from the NYSE list of pharmaceutical companies (NYSE, 2020) is represented in this
study with a degree of error less than 5% (AKA: confidence interval) from our representative
sample (Morgan et al., 2013).
Summary of Population and Sampling.
The sample of stocks chosen is 26 pharmaceutical companies from the NYSE (2020).
This population is a small group of all stocks on the NYSE and with the sample size being the
same as the total population with a greater than 95% percent confidence level and the 5% percent
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confidence interval requirement for a research project. A sampling method is a procedure for
selecting sample elements from an entire population of equities. In this study, these
pharmaceutical equities were chosen because of the hypothesized idea that pharmaceutical
companies would increase in value because they would be the ones to produce a treatment, cure,
or vaccine for a pandemic; which means they would act differently than other companies from
the stock market; including other companies in the healthcare sector. At the same time, this
relationship between the pharmaceutical companies' ROR and the volume was also hypothesized
either to support or disprove the EMH as proposed by Fama (1970).
Data Collection
Data collection is the procedure for collecting, measuring, and analyzing data using
validated research techniques. The most important step of data collection is to make sure the data
is information-rich, and that the data is reliable, allowing the data to be used for statistical
analysis. Because of this process, a data-driven decision was made for quantitative research. The
primary data collection was through online stock price history from the NYSE historical
database (2020) and Bloomberg (2020), where all data has a 90% or better rating in accuracy as
stated on the websites’ disclaimers. This data is called secondary data collection, as it was
collected from a primary source. This data is readily available with the internet and computers
accessing the internet to connect to those above-listed websites. Along with journals, government
records, and periodicals, this data gave an up-to-date picture of the needed information.
Instruments
There was no new instrument created for this quantitative research project. All
information gathered was from prior existing public records related to stock prices from the
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historical data of the NYSE (2020) Bloomberg (2020) and compiled in Microsoft Excel as
secondary data. This data can be viewed in the appendices, findings, and conclusion section.
Data Collection Techniques
The data collection techniques used were based on the research questions' ideas and what
data was needed for the research questions. Various public records were read and compiled in
Microsoft Excel as secondary data. Then the researcher translated all of the data to support or
disprove the research questions and hypotheses. They result in the ability of the researcher and a
reader of the research to conclude if the market model or MPT was a valid indicator of an
efficient market. Also, the researcher and the reader would conclude if pharmaceutical stocks
generated a statistically significant positive abnormal return.
All data for this project was done using Microsoft Excel. The reason was this research
project is about the average investor (Alrgaibat, 2015; Brigham & Houston, 2009; Dalbar
Associates, 2020; Fama & MacBeth, 1973; Frase & Ormiston, 2004; Freihat, 2019; Mossin,
1966; Ragsdale, 2015; Ramadan, 2014; Sharifzadeh, 2006; and Wenjing, 2017). This research
needed to be up to date, so the data analysis software must be up to date. According to Muenchen
(2019), Statistical Package for the Social Sciences (SPSS) and Statistical Analysis System (SAS)
statistics software use is declining, and other statistical software’s use is increasing in scientific
research, including dissertations. According to Microsoft (2020), Microsoft Excel is the most
popular spreadsheet and statistics software and is readily available and easy to use. It is also a
major tool used in the finance industry. The average person has access to Excel where the
average person might not have access to other statistics software without utilizing two or more
computer programs to do statistical calculations (Muenchen, 2019); therefore, making Microsoft
Excel a great tool to utilize and to analyze data from an average investor standpoint with no
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additional cost to the analyst (Alrgaibat, 2015; Brigham & Houston, 2009; Dalbar Associates,
2020; Fama & MacBeth, 1973; Frase & Ormiston, 2004; Freihat, 2019; Mossin, 1966; Ragsdale,
2015; Ramadan, 2014; Sharifzadeh, 2006; and Wenjing, 2017).
There was also another advantage to using Excel. Data had to be collected, stored, and
transposed before transferring to another program to run statistical formulas. Excel did all of the
above and more without using a secondary program like SPSS or SAS (Muenchen, 2019). By
using Excel, there was also a reduction of handling information and less likely that an error
occurred in data processing because it stayed in only one computer program and was handled
less by the researcher. Excel also made it easier to share data and findings from a research
perspective around the globe because of its popularity and availability.
Some research (Fairhurst, 2015; Melard, 2014) supported this idea that Excel is a reliable
statistical tool, but it also points to limitations with Excel in research. Excel Data Analysis is an
add-on tool for Excel with a conflicting finding compared to other statistical packages like SAS
or SPSS programs because Excel is based more on mathematical formulations. SAS and SPSS
are used to process statistical operations and problematic statistical analysis theories based on
computer programming. Excel also has limited use when going above 65,536 rows of data in
statistical calculations lacks non-parametric tests, post-tests, and some ANOVA’s. Plus, it can
take too long to redo the calculations with a non-programmed approach by using Excel compared
to SAS or SPSS.
Excel is spreadsheet software that is open to everyone and relatively inexpensive
(Fairhurst, 2015; Melard, 2014; Microsoft, 2020), whereas SAS and SPSS are statistical analysis
software programs that are very expensive and have fewer users. Excel has more likelihood of
copying and pasting errors with its manual processing than the programming aspect of SPSS and
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SAS software. There is no comparison between Excel, SPSS, SAS, and other statistical software
(Fairhurst, 2015; Melard, 2014). However, the purpose of quantitative research, statistical
findings, and data integrity was to ensure that the research reader and the research methods and
tools were appropriate for the research. This is a finance dissertation with a limited scope and
testing requirements based on the average investor and the average investor's computer ability,
skills, lack of computer programming skills, and costs. Excel meets or exceeds the limitations
requirement and was a reasonable choice for analyzing data for most academic and professional
research in finance (Fairhurst, 2015; Melard, 2014). This event studies hypothesis, research
questions, and the number of variables (stocks) being studied, using Microsoft Excel as the most
reliable and appropriate statistical analysis software.
Data Organization Techniques
Data organization is the method of sorting data so that it is useful. The organizational
data techniques employed were to sort data from categorization and logical viewpoint and then
show the relevant statistics and tables that were pulled and calculated from outside sources and
labeled for use. Table and figure data structure are described above or below each table or figure
and then explained.
Since all tables and figures came from audited NYSE records, all records were tested and
considered reliable and valid. This was also stated on the NYSE (2020) and Bloomberg (2020)
websites as all data had a 90% or better rating in accuracy. If any discrepancy was known, this
was described in the explanation of the table or figure. Then following the contextual framework
of Creswell (2007, 2014) and Yin (2013, 2018), a series of relationships were explored between
the collected data and reported without bias. Excel was used as an all-inclusive data management
tool since it can do a viable copying and data storage format and operates as statistical analysis
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software. Also, Excel is used because it leads credence to the idea that this method of cross
analyzing the same data with multiple methods should be easy and readily available to anyone
(average person/ investor) with a standard personal computer and the Microsoft Office Suite
without having to buy or rent another type of statistical software like SPSS.
The data collection process began by going to the NYSE historical data and looking up
the 26 pharmaceutical companies by name and then looking up the S&P 500 historical data from
the actual ticker symbol, which was ^GSPC (NYSE, 2020). This data was verified by comparing
it to Bloomberg's (2020) data. Once the company had been found, the actual dates needed for the
research were entered into the search parameters of the historical data. The two events were the
Swine Flu of 2009, which dates April 13, 2009, to July 13, 2009, and the Covid-19 pandemic of
2020 for November 27, 2019, to March 2, 2020. These dates are based on the date of the
pandemic announcement by WHO, which is June 11, 2009, and January 30, 2020, respectively.
These dates provided a total of 64 days of the timeline as shown in the Swine Flu timeline of
2009 and Coronavirus Pandemic 2020 (Covid-19) from the methodology.
Once the historical data and the dates for the events were obtained, all data was copied to
have two sets of the same data. With the second data set, the researcher had to remove some nonessential data from the pasted data that had no bearing or use. By having and working with a
copied set of data, any changes would be evident, and there was also an unedited original set of
data if questions arise by outside sources for review later if needed. There was a focus on the
following data from the historical data: date (Date), open price (Open), daily high price (High),
daily low price (Low), daily closing price (Close), Adjusted Closing price (Adj. Close), and
stock volume traded (Volume). The researcher removed the Open, High, and Low-price data for
all the companies because it had no bearing in this research. This left 64 pieces of daily data
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from the stock(s) historical data plus the heading for each of the 26 pharmaceutical companies
and the S&P 500 historical data for both pandemics. The 64 pieces coincided with the 42 days
pre-event, day of the event (T0) and 21 days post-event (42+1+21 = 64).
The next step was to get each timeline section's CAR (Cumulative Abnormal Return).
The median of each cumulative section of the volume and price worksheets were calculated to
get the CAR. To calculate the CAR, each grouping of 26 stocks had headers placed above them
with dates and numbers. The dates were the dates prior to, during and after the announcement of
a pandemic by the WHO. The announcement date was labeled T0. Then the other 63 days are
broken down by seven days before and after the announcement labeled T-1 and T1, respectively.
Then the 14 days before and after the seven days are labeled T-2 and T2, respectively. Finally,
the 21 days prior to the testing period is labeled (EP) for the Estimation Period. For simple
viewing, the following color pattern breaks down these periods. For quick reference, the number
of days in each section was posted above each heading above in Table 6 Color code for Excel
Data with a total of 64 days (21+14+7+1+7+14=64 days).
Table 6
Color Code for Excel Data
21 Days
EP

14 Days
T-2

7 Days
T-1

1 Day
T0

7 Days
T1

14 Days
T2

The next step was to calculate the median value (CAR) of the stock prices and or stock
volume for each of the 26 companies for both pandemics. The math formula of =MEDIAN
(??:??) is used to calculate the median value. The ??:?? represented the potential cell(s) reference
for the cell range in Excel used in the math formula. An example is the range of B2:B23;
reflected in the Excel formula as =MEDIAN (B2:B23). This process was repeated five times for
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each company's data set. A median value was not compiled on the T0 date since it was just one
day with one value. The CAR data was now six columns of data for the 26 companies. These can
be viewed in their entirety in Appendix E to Appendix H.
The final step was to run the t-Test on the data. A t-Test is used to determine whether two
variables were significantly different using statistical formulas (Morgan et al., 2013). The data in
this research was being used for hypothesis testing, which was the basis of inferential statistics,
which was used to ascertain the authenticity of a claim against a given variable. According to
statisticians, a one-tail t-test is used for hypothesis testing (Morgan et al., 2013; Peng, 2015;
Trafimow & Marks, 2015), but the data has to be the test's specific direction must be known. If
we do not know the direction (tail) of our t-Test or load the variables backward in statistical
formulas, the researcher will get the wrong answer. A two-tail t-test has its benefits, and the
researcher does not know a direction (tail) or does not make a difference in the results. Whereas
a two-sided t-Test is used to find out if a sample means it is more than and less than the
population mean (Morgan et al., 2013; Peng, 2015; Trafimow & Marks, 2015); and the result of
the tail of the test is directional concerning the way the variables are loaded in the statistical
software or how the statistics are calculated.
Excel does not have a one-tail t-Test built into the data analytics section as a single
function. The only way to run the one-tail t-Test is to run the two-tail t-Test (Microsoft, 2020).
The two-tail test results are double the value of a one-tail test and reflect both sides of the testing
results with a slight difference as noted in the p-value and were recommended when the
hypothesis said no change in findings. Alternatively, the direction of the tail of the test does not
have to be known. A tailed test (left or right) is based on the alternate hypothesis of greater than
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findings are a right-tailed test, and less than findings are a left-tailed test. This can be seen below
in

Figure 8
Two-Tail Bell Curve or (Gaussain Distribution), which shows a two-tailed test with 95%
of the data laying in the center and 5% of the data at the two ends split between two sides
equally.

Figure 7
One-Tail and Two-Tail Bell Curve
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Figure 9
One-Tail Test below shows just the one-tail of the test but notice the p-value at the top of the
curve at 95%, with the 5% reflected below on the left in red. Hence, a left-tailed test is pictured
in

Figure 9
One-Tail Test because the tail points to the left of the center.
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Figure 8
Two-Tail Bell Curve

Figure 9 could be inverted with the same numbers but would be called a right-tailed test
because the tail would point to the right of the center. This is slightly different from the twotailed test pictured in Figure 8: Two-Tail test because it shows both tails simultaneously.
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Figure 9
One-Tail Test

However, Figure 8 is slightly different because it has a p-value of 90% at the peak and
5% equally on each side of the bell curve (Gaussain Distribution) reflected in the red color area.
This is because it is not known the direction of the tail. It has to maintain a .05% p-value or
confidence interval for each direction. This is the case since the statistical outcome to the stock
price, or volume could be either a right-tail or a left-tail result because there could have been a
statistically significant gain or a statistically significant loss in stock prices and stock volume.
This t-Test is repeated for each of the testing periods of the stock price and the stock
volume for both pandemics yielding five sets of statistical findings per part of the event study.
These five data sets are based on the Estimation Period (EP) versus the five T-2, T-1, T0, T1 and
T2 testing periods. The t-Test results show the mean for each of the data sets for each variable,
the variance for each variable, the number of observations in each variable, the pooled variance

114
value, the hypothesized mean difference, the degrees of freedom (abbreviated as df), the t-value
(or t-Stat), and the probability values for the one-tail test, two-tail test and the t Critical one-tail
and the t Critical two-tail calculations.
The t Critical two-tail test findings will always be bigger than the t Critical one-tail
results because our data is skewed because of the change in p-value from the one-tailed or the
two-tailed test. Data from the two-tail test is used; as stated earlier, our statistical significance
could be from either a gain or loss reflected in either stock price or volume. The tail of the test is
usually referred to as a directional test or directional hypothesis (Morgan et al., 2013) and is
revealed in the two-tailed findings to be discussed in the interpretation of data section later.
The tail of the test is used in statistics to determine the region of distribution or if data is
more or less than a specific value. In statistics, if the data (tail or t-Stat) lies in the opposite
region of the test results, it will accept the alternate hypothesis, not the null hypothesis. This
depends on which side the variables are in the t-Test pop-up window. Since the hypothesis
testing with a potential for statistical significance in either direction, it is unknown which side the
data (variable) should be on. However, to run a two-tail test, the statistical software (Excel)
output will answer the question about the direction of the tail or if the data is statistically
significant. However, the two-tail test and the direction of the tail are two different statistical
tests and reveal two different sets of information to the reader of the test results (Morgan et al.,
2013; Peng, 2015; Trafimow & Marks, 2015).
To interpret the findings; look at the output data by comparing the two-tail p-value P
(T<=t) two-tail against our significance level or (alpha/ confidence level of 0.05), which we
typed (or defaulted) into the Excel calculation before the findings are shown.
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Figure 10
t-Test: Two-Sample Assuming Unequal Variances
EP vs. T2
14.0352381 15.06714
Mean
16.2315429 17.88117
Variance
211.018734 218.1455
Observations
25
25
Hypothesized Mean Difference
0
df
48
t Stat
-0.3981479
P(T<=t) one-tail
0.34614331
t Critical one-tail
1.6772242
P(T<=t) two-tail
0.69228661
t Critical two-tail
2.01063476

The p-value P (T<=t) two-tail is also called the significant or Sig in statistics. value
(Morgan et al., 2013; Peng, 2015; Trafimow & Marks, 2015). If the p-value P (T<=t) two-tail is
larger than the alpha, the rule is to not reject the null hypothesis and that there is no statistically
significant difference in the findings. If the confidence level (alpha) is bigger than the p-value P
(T<=t) two-tail, there is a statistically significant difference in the findings, then Reject the Null
Hypothesis and Accept the Alternate Hypothesis should be used.
By running a two-tail t-test Assuming Unequal Variances, the other revealed data could
clash with the findings. In Excel, if the t-Stat output is positive, the reported p-value P (T<=t)
two-tail is a right-tailed result, or the t-Stat is more positive. The opposite is also true. If the tStat is negative, the p-value P (T<=t) two-tail is a left-tailed output, or the t-Stat is more
negative. So, it is possible to have the results of a two-tailed test P(T<=t) two-tail if the tail is left
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tailed (negative numbers) to reject the Null Hypothesis, where the findings of the two-tailed test
(Positive Number) will not reject the Null Hypothesis by using the t-Stat result findings. There
could be conflicting information from the results of the two-tailed test that must be considered in
lieu of looking at the one-tailed test or two-tailed test findings since they are both present in the
statistical findings.
To understand the relationship between the t-Stat and the p-value P (T<=t) two-tail, a
researcher must return to the concept of hypothesis testing (one-tailed t-Test) and look at the t
critical finding for the one-tailed test and the two-tail test in relation to the 95% confidence
interval and 5% confidence level. The p-value P (T<=t) two-tail or P (T<=t) one-tail is the real
number that represents the 5% value in the statistical formula for the t-Test findings. The
question is, where does the t-Stat number lay concerning that p-value P (T<=t) one-tail or pvalue P (T<=t) two-tail result? Does the t-Stat lie in the center with 95% of the data making it not
statistically significant, or does it fall outside of the 5%, making it statistically significant? The
last factor is to remember that the t Critical number by default is a right-hand test number, an
absolute number, or always positive when shown in results. If it is a left-hand test, t Critical
number is negative. Hence, if the t-Critical number is a negative and the t-Stat is positive, they
do not lie in the same region and are conflicting because you are running a left-tailed test with
right-tailed results or vice versa. When interpreting the results, the researcher must hypothesize
that they are running the right-tailed test and then the left-tailed test by itself. Does the t-Stat
number support or disprove the findings of a tailed test (either right or left)?
For the example to explain the above statement in findings from the t-Test results are
being interpreted, and certain things like the tail direction of our tests based on our tests on t-Stat
positive or negative numbers are also known. Therefore, first, we look at the t-Stat and see
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whether it is positive or negative. In Figure 10, the number is negative, so it is a left tail test
result. The 5% value would be t Critical 2.01 for a right two-tailed test or -2.01 for a left twotailed test. Alternatively, the t Critical two-tail of 1.678 for the right one-tailed t-Test or -1.678
rounded for a left one-tailed t-Test. Then there was a comparison of the t-Stat to the number(s) in
the prior statement(s) individually. Is the t-Stat more or less than the t Critical value? Since -.398
tells us this is a left-tailed test. We use the negative value of the t-Critical, which is -1.678 or 2.01. Both the t-Stat and the t Critical are negative, so the findings of the tail of the test are still
not statistically significant, and one cannot reject the null hypothesis whether it is a two-tailed tTest or a one-tailed t-Test where the opposite could be true if the t-Stat were positive.
This interpretation of the findings is not running just one t-Test and calling a tail
direction. There are multiple t-Test results in the findings. What happens if the t-Stat is now
positive compared to negative in the above example (Example: .398)? For example, 4 out of 5 tTests have a negative t-Stat, and the fifth t-Test has a positive t-Stat. The researcher knows they
are running a left-tailed test based on the number of t-Test’s findings, so why is a positive
number in the t-Stat? The findings based on a one-tailed left t-Test (negative t-Stat findings
overall) have results that appear in the non-existing right-tailed t-test area for a hypothesized
single directional tailed test (shown below by a red box). Test results conflict with other t-Test
test results, and based on this, the null hypothesis has to be rejected, and the alternate hypothesis
accepted (Morgan et al., 2013; Peng, 2015; Trafimow & Marks, 2015). Further research is
required to explain test findings. This can be seen below in where the dot represents the positive
.398 in the red box opposite the left tailed test area.
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Figure 11
Left-Tailed t with Positive t

Summary of Data Collection
A successful data compilation and data compilation usage are more than just putting
random pieces of information together. There is so much data available that the human mind
cannot process it in reality. The data collection and analysis processes require summarizing
various information into a coherent flow. All of the original data was audited, tested, verified,
validated, and considered reliable with over 90% percent accuracy per the disclaimers on the
data on the primary website(s) for data collection. The data holds the same standard since it was
not changed in any form; just copied and pasted in Excel for analysis. Then the finding from this
event study, if presented logically, should hold the same standards since no information was
changed from the source and the presentation of said data in this research. A researcher needs to
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be careful if the researcher decides to use the one-tail test or the two-tail test and if the direction
of the tail is known. Using the two-tail test is a more conservative way to analyze data and will
pick up a larger difference in the variables; but can miss the smaller significant less than the
difference on the other side of the findings from the one-tailed test, which is half the results of
the two-tailed test findings because of the change in the p-value as noted in

Figure 9
One-Tail Test.
Data Analysis
The data analysis was based on Creswell's (2007, 2014) and Yin's (2013, 2018) research
and was quantitative and used secondary sources and a qualitative approach to put them all
together using the most logical flow and interpretations (Babones, 2016). The findings are
compiled, categorized, and presented logically using a causal relationship. This was
accomplished by bringing order, structure and meaning from various information in a qualitative
manner for quantitative data in an interpretive method (Babones, 2016). The data collected
included stock prices, ROR, and outstanding company share volume traded. After compiling the
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equity data for these assumptions, data was analyzed, and the t-Test results were interpreted
based on the probability value (p) using statistics p-value P (T<=t) two-tail and the t-Stat results.
Variables Used in the Study
This event study had an independent, dependent, extraneous, and intervening variable(s)
(Creswell, 2007, 2014; Yin, 2013, 2018). An independent variable is a variable that affects the
dependent variable and is not affected by a dependent variable (Creswell, 2007, 2014; Yin.,
2013, 2018). An independent variable is a reason for a change in the dependent variable. The
announcement of a pandemic was the proposed independent variable that affected the dependent
variable of the pharmaceutical stock prices of the healthcare sector of the NYSE. Other variables
in the research were extraneous variables (Creswell, 2007, 2014; Yin, 2013, 2018). In every
research project, some variables can affect both the independent and dependent variables.
This event study attempted to mention some extraneous variables, but these variables
were not studied and may or may not have affected the outcome. Extraneous variables are only
mentioned because the researcher knew other factors could cause the stock market to react a
certain way. However, this event study did not look at those factors but was mentioned as other
events during the timeline. There was no possible way to know if the extraneous variable listed
affected pharmaceutical stock(s), the healthcare sector, or any other sector of the NYSE.
However, the events took place during the time window and could have affected the event study.
The last element was an intervening variable. An intervening variable is different from
the dependent variable, the independent variable, and the extraneous variable. An intervening
variable is needed to help the independent variable affect the dependent variable (Creswell,
2007, 2014; Yin, 2013, 2018). This event study has an intervening variable of the World Health
Organization (WHO). This was because the announcement of a pandemic by the WHO was the
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determining factor of if a disease/ pathogen/epidemic became a pandemic and potentially did or
did not affect the stock price or stock trading volume. The relationship of the variables to each
other can be seen below in Figure 12.
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Figure 12 Variable Relationship

Summary of Data Analysis
Data analysis is a process of transforming and modeling various pieces of information in
a useful manner to discover information not presented in the original data hopefully. This is the
same basic principle with painting. Not until each brushstroke and color is applied (explained)
can one see what the artist wants to show you. Various pieces of financial information were
collected and painted a picture. If the pharmaceutical sector of the stock market does not
generate a significant abnormal return, then investors have one more piece of information of
what not to do and where not to invest during a pandemic for statistically significant results
financially.
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Reliability and Validity
Except in the application of statistics, the terms’ reliability and validity are
interchangeable, except they have different meanings. Reliability is the consistency, and validity
is whatever was used to measure something; measured what it was supposed to measure
(Creswell, 2007, 2014; Yin, 2013, 2018). These terms are not synonymous. An example is a
thermometer. Due to outside testing, one knows the thermometer is one degree off. Every time
the boiling water is measured, it gives the same temperature; therefore, it is reliable. However, it
is not valid; because it is unknown if it is a degree off and, therefore, gives the wrong
temperature (Creswell, 2007, 2014).
Reliability
The reliability of this event study was based on four principles. They were
understandability, relevance, comparability, and reliability. The understandability was based on
the information being presented clearly, with supporting information supplied so that there was
no clarification of meanings needed. The information was relevant because it met the needs of
the research project and the college writing requirements without omission or misstatement of
facts. This might be used either as proof of support for or against the idea that a pandemic
affected the United States stock market ROR of the pharmaceutical sector (Creswell, 2007,
2014). This research is comparable to the actual documents used for research, and all relevant
data is shown. Finally, there is reliability because the document is free of bias, has no errors, and
is not misleading. The facts presented are faithfully represented as true, state the underlying
substance of events, and prudently present all estimates, claims and disclosures. This makes
reliability a consistent measurement.
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The data reliability should be well established as it is publicly published information. The
data was audited with strict government oversight that states it has a 90% chance of accuracy and
a standard value of 1.6 error rate for the entire data population per the original posting websites
disclaimers. All data was also categorized according to the GAAP standards for accounting. The
non-sampling error was also addressed as information was always collected and available during
calculations. Notes were made on all statistical data when there was a lag or change in
information. This event study had made every attempt to report all such known lags an
adjustment if they had a bearing or effect when the data was recorded and used.
Validity.
The validity hinges on factors influencing the findings of a study beyond the researcher's
control (Creswell, 2007). Van Manen (2014) stated that a study must suspend personal bias.
Miles et al. (2013) put forth that validity is a contested term among qualitative researchers and
offers another term instead, academic rigor. To address these issues of validity:
•

The researcher’s role and relationship to the study have been addressed.

•

The research questions and the design of the study were aligned.

•

There was meaningful parallelism between the data presented and the research questions
and hypotheses.

•

Quality checks had been made for errors and deceit.

•

Peer and colleague reviews had taken place.

•

Data presented was linked to prior research work.

•

Any areas of uncertainty were identified.

•

When possible, math and finding had been duplicated.

•

Positive as well as negative information had been presented.
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Summary of Reliability and Validity
Heeding the words of Creswell (2007, 2014) and Yin (2013, 2018), issues of validity and
reliability were addressed by having work checked by others to review the accuracy of data, the
analysis, interpretations of data, and the conclusion drawn. The reliability and validity of the data
are as important as the research outcome. This section of the research project should have made a
case for the reliability and validity of the data and the findings from the research.
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Section 3: Application to Professional Practice and Implications for Change
Over the last century, the finance industry has given the world countless scandals and
stories about financial professionals who have deceived investors, employees, and governmental
agencies. In many cases, greed is the underlying factor (NYSE, 2020). However, most
inappropriate behavior lies in unethical practices and a lack of education about the basic
principles of finance. This event study expanded upon the efficient market hypothesis and helped
clarify how to handle chaotic times in the market during a pandemic. It also expanded on
knowing where to invest one’s money to get a good rate of return. By knowing the basics of
finance and encouraging higher ethical standards, financiers can take a leading role in the fair
and transparent behavior of the equities market.
Overview of the Study
This event study looked to combine popular fiancé theories into a comprehensive study
that dissected the behavior of the pharmaceutical sector of the NYSE. It was also done to
determine if the same information in different ways resulted in an abnormal return generated by
the stock market's pharmaceutical sector during a pandemic. Using the market theory and MPT,
the researcher looked to see if stock market ROR generated a positive abnormal return in the
pharmaceutical sector of the NYSE during the last two pandemics. By doing this research,
another anomaly in the stock market or prove Fama’s (1970) theory that the whole market is
efficient or not would be found. Either way, the bigger picture of finance has provided another
part in the financial knowledge of how or where someone should invest their funds during a
pandemic.
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Presentation of the Findings
The following part shows the research findings concerning the data, literature review, and
proposed research questions. Each finding is presented and how the data was interpreted from
the research design method. Also, the data is presented how it was described in the data
collection section as described above and referenced with each interpretation.
Introduction to Findings
The researcher was looking to examine the effect of the announcement of a pandemic on
26 stocks from the pharmaceutical sector of the NYSE and to see if the pandemics generated a
positive abnormal return in the pharmaceutical sector stocks; resulting in the EMH failing again
in data from the last two pandemics to affect the NYSE. It must be pointed out is that every
pandemic studied coincided with other major events in the United States. Every pandemic was in
the year of a United States presidential election. Coincidentally, there have also been epidemics
that align with elections, even though not pandemics. These epidemics/ pandemics are the SARS
epidemic of 2004, the Avian Flu of 2008, MERCER of 2012, ZIKA of 2016 and now the Corona
Pandemic (COVID-19) of 2020 (WHO, 2020).
Other research has shown the effects of presidential events on stock prices (Daniel &
Hirshleifer, 2015; Elbe, 2008; Karolyi & Martell, 2010; Wang, 2016). However, because of the
dates of the pandemics, there is no actual proof of an election having any effect on this event
study, except to say that the pandemics took place in or during the years of the United States
presidential elections. As noted in the literature review, President Donald Trump was impeached
and acquitted during the start of the Covid-19 outbreak of 2020. At the point of the writings,
there is no research to say if this did or did not affect the NYSE. Another factor that must be kept
in mind is that eight of the 26 pharmaceutical companies are included in the S&P 500 list. As of
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March 2020, they were Abbott Laboratories, Allergan plc, Bristol-Myers Squibb Company, Eli
Lilly and Company, Johnson and Johnson, Merck and Company, Inc., Perrigo Company, and
Pfizer, Inc. The S&P 500 is a stock market index that measures the stock performance of 505 of
the largest companies listed on stock exchanges in the United States (NYSE, 2020). Out of these
505 companies, 61 are healthcare-related companies per their description in the S&P and NYSE
(NYSE, 2020). In some ways, comparing the pharmaceutical stock to the S&P 500 is appropriate
because some of the pharmaceutical companies in this study are in the S&P 500 data.
Research Questions and Hypotheses
Research Question 1
RQ1. What is the difference between the pharmaceutical stocks’ rate of return before and after
the announcement of a pandemic by the WHO?
Research Question 2
RQ2. What is the difference in the volume of pharmaceutical stock traded before and after the
announcement of a pandemic by the WHO?
Hypotheses 1.
H10 – There is no statistically significant difference in the pharmaceutical stocks’ rate of return
after the announcement of a pandemic by the WHO.
H1a - There is a statistically significant difference in the pharmaceutical stocks’ rate of returns
after the announcement of a pandemic by the WHO.
Hypotheses 2.
H20 – There is no statistically significant difference in the volume of pharmaceutical stock traded
after the announcement of a pandemic by the WHO.
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H2a - There is a statistically significant difference in the volume of pharmaceutical stock traded
after the announcement of a pandemic by the WHO.
Results and Findings
Findings for Research Question 1
Research Question 1 asked if there was a difference between the pharmaceutical stocks’
rate of return (ROR) before and after announcing a pandemic by the World Health Organization
(WHO). This question is answered by hypothesis 1, which says there is no statistically
significant difference in the pharmaceutical stocks’ rate of return after announcing a pandemic
by the WHO. The ideas behind these hypotheses and research questions were based on Fama
(1970) and Pilkington (2017), who stated that the market is efficient, prices are directly reflective
of events and will trade at their fair market value. Daniel and Hirshleifer (2015) argued that the
market is affected by outside events. This is the premise behind hypothesis one (H10), which
states there is no statistically significant difference in the aggregate pharmaceutical sector
stock(s) rate of return after announcing a pandemic by the WHO. The complete cumulative table
for the findings below can be seen in Appendix E Swine Flu of 2009 Price CAR Table and
Appendix F: Covid-19 of 2020 Price CAR Table.
The two-tailed t-Test for the stock rate of return is shown in the following five figures for
the Swine Flu of 2009 and five figures for the Covid-19 of 2020 findings.
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SWINE FLU of 2009
Figure 13
t-Test Two-Sample Assuming Unequal Variances EP vs. T-2

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

13.95
14.37
15.974 16.3338
204.0678 195.4415
25
25
0
48
-0.090005
0.464329
1.677224
0.928658
2.010635

Figure 14
t-Test Two-Sample Assuming Unequal Variances EP vs. T-1

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

13.95
15.974
204.067833
25
0
48
-0.1649524
0.4348371
1.6772242
0.86967419
2.01063476

14.46
16.628
188.9193
25
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Figure 15
t-Test Two-Sample Assuming Unequal Variances EP vs. T0
13.95
Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

14.4
15.974 16.8264
204.0678 188.3741
25
25
0
48
-0.215142
0.415284
1.677224
0.830568
2.010635

Figure 16
t-Test Two-Sample Assuming Unequal Variances EP vs. T1

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

13.95
14.84
15.974
16.5664
204.067833 176.04133
25
25
0
48
-0.1519256
0.43994121
1.6772242
0.87988242
2.01063476
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Figure 17
t-Test Two-Sample Assuming Unequal Variances EP vs. T2

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

13.95
15.105
15.974
18.179
204.0678 238.7895
25
25
0
48
-0.523898
0.30138
1.677224
0.60276
2.010635

The complete cumulative table for the findings below can be seen in Appendix: F
COVID-19 of 2020 Price CAR Table.
COVID 19 of 2020
Figure 18
t-Test Two-Sample Assuming Unequal Variances EP vs. T-2

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

85.61
86.02
50.7572 51.6368
2273.63 2421.122
25
25
0
48
-0.06419
0.474544
1.677224
0.949088
2.010635
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Figure 19
t-Test Two-Sample Assuming Unequal Variances EP vs. T-1
Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

85.61
89.73
50.7572
52.68
2273.63 2428.6039
25
25
0
48
-0.1402
0.444544
1.677224
0.889088
2.010635

Figure 20
t-Test: Two-Sample Assuming Unequal Variances
EP vs. T0
85.61
Mean
50.7572
Variance
2273.63
Observations
25
Hypothesized Mean Difference
0
df
48
t Stat
-0.12527
P(T<=t) one-tail
0.450416
t Critical one-tail
1.677224
P(T<=t) two-tail
0.900832
t Critical two-tail
2.010635

89.16
52.4776
2441.57
25
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Figure 21
t-Test Two-Sample Assuming Unequal Variances EP vs. T1

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

85.61
88.23
50.7572
53.2252
2273.63 2513.4473
25
25
0
48
-0.17835
0.429598
1.677224
0.859197
2.010635

Figure 22
t-Test Two-Sample Assuming Unequal Variances EP vs. T2

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

85.61
87.955
50.7572 52.6754
2273.63 2533.702
25
25
0
48
-0.13833
0.44528
1.677224
0.890559
2.010635

The output data needs to be compared by the two-tail p-value P (T<=t) two-tail against
our significance level or (alpha/ confidence level of 0.05). If the p-value P (T<=t) two-tail is
larger than the alpha, to not reject the null hypothesis and that there is no statistically significant
difference in the research findings are correct o interpret the findings above for stock ROR. In all
ten of the figures (Figure 12 thru Figure 22), all of the p-values P (T<=t) two-tail are larger than
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the alpha. For the Swine Flu, the p-value P (T<=t) two-tail ranges from .92 to .60, respectively.
In the Covid-19 figures, they range from .94 to .89, respectively. Since the findings are not
statistically significant, a conclusion can be made that the answer to research question 1 is Not a
Statistically Significant Difference between the pharmaceutical stocks’ rate of return before and
after the announcement of a pandemic by the WHO.
If the t-Stat output is positive, the reported p-value P (T<=t) two-tail is a right-tailed
result or positive. In contrast, the opposite is also true. If the t-Stat is negative, the p-value P
(T<=t) two-tail is a left-tailed output. This is a completely different set of findings from the
statistical analysis because the t-Stat and the p-value P (T<=t) two-tail are different statistical
tests than a t-Test and measure different things. All of the results of the t-Stat are negative. This
is a left-tailed test. According to statistics (Morgan et al., 2013; Peng, 2015; Trafimow & Marks,
2015), the researcher should not reject the null hypothesis based on the negative t-Stat finding in
a left-tailed test. Therefore, this data set supports the prior statements to not reject the null
hypothesis and notes that the findings are not statistically significant.
Table 7 is a left tail test because of the negative t-Stat numbers. Table 7 has one strange
anomaly (noted by ****), which can be seen in the highlighted cells adjacent to the ****. This is
the change in numbers in EP vs. T2 from Table 7
Swine Flu t-Stat and Two-Tail Test Price Data of -.5239 for t-Stat and .60276 for the
two-tailed test though not statistically significant. All other numbers in the t-Stat range from .09001 to -.21514. However, EP vs. T2 jumped to -.5239, which is over twice the other numbers,
with the highest being -0.21514. The two-tailed test changed to .60276, with the other numbers
being in the range of 0.830568 to 0.928658, which is a .26 minimum drop in the findings result
(though not statistically significant).
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Table 7
Swine Flu t-Stat and Two-Tail Test Price Data
SWINE FLU of 2009 PRICE
EP vs. T-2

t Stat

-0.09001 P(T<=t) two-tail

0.928658

EP vs. T-1

t Stat

-0.16495 P(T<=t) two-tail

0.869674

EP vs. T0

t Stat

-0.21514 P(T<=t) two-tail

0.830568

EP vs. T1

t Stat

-0.15193 P(T<=t) two-tail

0.879882

Ep vs. T2

t Stat

-0.52390 P(T<=t) two-tail

0.602760 ****

A similar finding is found in in EP vs. T-2 t-Stat is -.06419, which deviates from the
other t-Stats, which range from -.12527 EP vs. T0 to -.17835 in EP vs. T1.
Table 8
Covid-19 t-Stat and Two-Tail Test Price Data
COVID 19 of 2020 PRICE
EP vs. T-2

t Stat

-0.06419 P(T<=t) two-tail

0.949088 ****

EP vs. T-1

t Stat

-0.14020 P(T<=t) two-tail

0.889088

EP vs. T0

t Stat

-0.12527 P(T<=t) two-tail

0.900832

EP vs. T1

t Stat

-0.17835 P(T<=t) two-tail

0.859197

Ep vs. T2

t Stat

-0.13833 P(T<=t) two-tail

0.890559

As mentioned earlier, the results for RQ1 were based on the findings from the two-tailed
t-Test and the one-tailed t-Test, which is used for hypothesis testing (Morgan et al., 2013). Only
run a two-tailed test can be run to get the one-tailed results. Since there are two data sets, the two
sets must be presented and discussed in the findings.
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The findings in Table 9: Swine Flu of 2009 Price One-Tail vs. Two-Tail Comparison and
Table 10: Covid-19 of 2020 Price One-Tail vs. Two-tail Comparison show that the results are
still the same one-tail test is half of the two-tailed test findings. A conclusion can be drawn that
the findings are not statistically significant, and the answer to RQ 1 is still that there is not a
statistically significant difference between the pharmaceutical stocks’ rate of return before and
after the announcement of a pandemic by the WHO. However, all findings are positive, and there
are two abnormalities in the test results, though not statistically significant towards this research.
Table 9
Swine Flu of 2009 Price One-Tail Vs. Two-Tail Comparison
Swine Flu of 2009 Price One-Tail vs. Two-Tail
P(T<=t) one-tail

0.464329 P(T<=t) two-tail

0.928658

P(T<=t) one-tail

0.434837 P(T<=t) two-tail

0.869674

P(T<=t) one-tail

0.415284 P(T<=t) two-tail

0.830568

P(T<=t) one-tail

0.439941 P(T<=t) two-tail

0.879882

P(T<=t) one-tail

0.301380 P(T<=t) two-tail

0.602760

Table 10
Covid-19 of 2020 Price One-Tail vs. Two-tail Comparison
Covid-19 of 2020 Price One-Tail vs. Two-Tail
P(T<=t) one-tail

0.474544 P(T<=t) two-tail

0.949088

P(T<=t) one-tail

0.444544 P(T<=t) two-tail

0.889088

P(T<=t) one-tail

0.450416 P(T<=t) two-tail

0.900832

P(T<=t) one-tail

0.429598 P(T<=t) two-tail

0.859197

P(T<=t) one-tail

0.445280 P(T<=t) two-tail

0.890559
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Findings for Research Question 2
Research Question 2 asked, what is the difference in the volume of pharmaceutical stock
traded before and after the announcement of a pandemic by the WHO? This question is answered
by hypothesis 2, which says there is a statistically significant difference in the volume of
pharmaceutical stock traded after the announcement of a pandemic by the WHO. The second
hypothesis (H20) supports the work of Thaler and Shiller (2015) who, like Charron (2015) and
Daniel and Hirshleifer (2015), explained the rational market. The second hypothesis (H20)
determined if a flaw existed in the EMH, which did not look at stock prices, but stock volume.
When a stock is trading in larger than normal stock volume, it would be an indicator of a flaw in
the market that could be exploited and used to predict the movement of a stock and hence a flaw
in the EMH (Wenjing, 2017). This in itself is the basis of supply and demand, which is an
underlying basis of EMH. Supply and demand say low availability and high demand with
increase a stock price; whereas the opposite is true and high availability and low demand will
decrease the stock price. Increased movement of the volume of stock would indicate a potential
area to exploit or an anomaly in the market (Wang, 2016). The complete cumulative table for the
findings below can be seen in Appendix G: Swine Flu of 2009 Volume CAR Table and
Appendix H: Covid-19 of 2020 Volume CAR Table.
The results of the two-tailed t-Test for stock volume are shown in the following five
figures for the Swine Flu of 2009 and five figures for the Covid-19 of 2020 findings:
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SWINE FLU of 2009
Figure 23
t-Test Two-Sample Assuming Unequal Variances EP vs. T-2

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-2168300
4844448.077
5.95443E+14
26
0
37
-0.429829091
0.334906498
1.68709362
0.669812997
2.026192463

26900
9331309.615
2.23769E+15
26

Figure 24
t-Test Two-Sample Assuming Unequal Variances EP vs. T-1
-2168300
Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-1872000

4844448.077 2881226.923
5.95443E+14 2.16464E+14
26
26
0
41
1.382516069
0.08714908
1.682878002
0.17429816
2.01954097
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Figure 25
t-Test Two-Sample Assuming Unequal Variances EP vs. T0

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-2168300
4844448.077
5.95443E+14
26
0
50
-0.15934113
0.437021019
1.675905025
0.874042037
2.008559112

-1673500
5914400
5.76877E+14
26

Figure 26
t-Test Two-Sample Assuming Unequal Variances EP vs. T1

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-2168300
-1239900
4844448.077 6507023.077
5.95443E+14 1.10963E+15
26
26
0
46
-0.205303297
0.419120499
1.678660414
0.838240997
2.012895599
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Figure 27
t-Test Two-Sample Assuming Unequal Variances EP vs. T2

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-2168300
4844448.077
5.95443E+14
26
0
45
0.281312167
0.389880258
1.679427393
0.779760516
2.014103389

-114500
3184423.077
3.09926E+14
26

The complete cumulative table for the findings below can be seen in Appendix: H
COVID-19 of 2020 Volume CAR Table.
COVID-19 of 2020
Figure 28
t-Test Two-Sample Assuming Unequal Variances EP vs. T-2

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

47050
-1746444.231
8.42662E+13
26
0
34
-1.338914123
0.094741145
1.690924255
0.189482291
2.032244509

646800
4280317.308
4.42522E+14
26
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Figure 29
t-Test Two-Sample Assuming Unequal Variances EP vs. T-1

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

47050
263500
-1746444.231 2121742.308
8.42662E+13 1.29201E+14
26
26
0
48
-1.34998272
0.091676739
1.677224196
0.183353478
2.010634758

Figure 30
t-Test Two-Sample Assuming Unequal Variances EP vs. T0

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

47050
-1746444.231
8.42662E+13
26
0
28
-1.332550387
0.09671148
1.701130934
0.19342296
2.048407142

1333800
8982176.923
1.6011E+15
26
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Figure 31
t-Test Two-Sample Assuming Unequal Variances EP vs. T1
47050
Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-252900

-1746444.231 5448569.231
8.42662E+13 7.29463E+14
26
26
0
31
0.661755908
0.256508526
1.695518783
0.513017052
2.039513446

Figure 32
t-Test Two-Sample Assuming Unequal Variances EP vs. T2

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

47050
-1746444.231
8.42662E+13
26
0
27
-1.201583288
0.119979537
1.703288446
0.239959073
2.051830516

465400
9451363.462
2.17377E+15
26

Before interpretation of the findings of stock volume, there is one noticeable difference in
Figures 23 thru 32 above. This difference is the number of observations in these figures
compared to the numbers in stock price. There are 26 observations in the stock volume which is
one more than the number of observations in stock price at 25 observations in Figures 13 thru 22.
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In the stock volume data, a new number was added; the overall volume of stock traded on the
S&P 500 compared to the number of stock trades in the pharmaceutical sector of the NYSE.
To interpret these findings for stock volume, the output data in the figures compare the
two-tail p-value P (T<=t) two-tail against the significance level or (alpha/ confidence level of
0.05). If the p-value P (T<=t) two-tail is larger than the alpha. The results mean not reject the
null hypothesis and that there is no statistically significant difference. In all 10 of the figures
(Figure 23 thru Figure 32), all of the p-values P (T<=t) two-tail are larger than the alpha of .05.
For the Swine Flu, the p-value P (T<=t) two-tail ranges from .66 to .87. In the Covid-19 figures,
it ranges from .18 to .51. Since the findings are not statistically significant, a conclusion can be
drawn that the answer to research question 2 is not a statistically significant difference between
the pharmaceutical stocks’ volume before and after the announcement of a pandemic by the
WHO.
With these findings of stock volume, there is another anomaly in the data. In the Swine
Flu results, the EP vs. T-1 (Figure 24
t-Test Two-Sample Assuming Unequal Variances EP vs. T-1) made a drop (though not
statistically significant) to .17 from .6698 in Figure 23
t-Test Two-Sample Assuming Unequal Variances EP vs. T-2 in the p-value P (T<=t)
two-tail. At the same time, the t-Stat goes positive from a negative and back to a negative in
Figure 24
t-Test Two-Sample Assuming Unequal Variances EP vs. T-1. Swine flu also has t-Stat
values that change concerning other t-Stat results, but the p-value P (T<=t) two-tail does not
change in relation to other p-values P (T<=t) two-tail by a strong degree in EP vs. T2 data in
Figure 32
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t-Test Two-Sample Assuming Unequal Variances EP vs. T2. In the Covid-19 findings, an
opposite spike occurred in the EP vs. T1 findings (though not statistically significant) where the
data went to a .51 (Figure 31
t-Test Two-Sample Assuming Unequal Variances EP vs. T1) from .19 in EP vs. T0
(Figure 30
t-Test Two-Sample Assuming Unequal Variances EP vs. T0) and returned to .23 in EP
vs. T2 (Figure 32
t-Test Two-Sample Assuming Unequal Variances EP vs. T2) results. This is best seen in
Table 11
Swine Flu of 2009 t-Stat and Two-Tail Volume Test Data and Table 12
Covid-19 of 2020 t-Stat vs. Two-Tail Volume Test Data below.
Table 11
Swine Flu of 2009 t-Stat and Two-Tail Volume Test Data
SWINE FLU of 2009 VOLUME
EP vs. T-2

t Stat

-0.42983 P(T<=t) two-tail

0.669813

EP vs. T-1

t Stat

1.382516 P(T<=t) two-tail

0.174298 ****

EP vs. T0

t Stat

-0.15934 P(T<=t) two-tail

0.874042

EP vs. T1

t Stat

-0.20530 P(T<=t) two-tail

0.838241

Ep vs. T2

t Stat

0.281312 P(T<=t) two-tail

0.779761 ****

Table 12
Covid-19 of 2020 t-Stat vs. Two-Tail Volume Test Data
COVID 19 of 2020 VOLUME
EP vs. T-2

t Stat

-1.33891 P(T<=t) two-tail

0.189482

EP vs. T-1

t Stat

-1.34998 P(T<=t) two-tail

0.183353

EP vs. T0

t Stat

-1.33255 P(T<=t) two-tail

0.193423

EP vs. T1

t Stat

0.661756 P(T<=t) two-tail

0.513017 ****
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Ep vs. T2

t Stat

-1.20158 P(T<=t) two-tail

0.239959

As mentioned in the data organization techniques above, if the t-Stat output is positive,
the reported p-value P (T<=t) two-tail is a right-tailed result, or positive. If the t-Stat is negative,
the p-value P (T<=t) two-tail is a left-tailed output or negative. From the findings of the t-Stat
test in the figures and table above, there are a completely different set of findings in the statistical
analysis of the data. All of the results of the t-Stat were negative except where the anomaly was
pointed out for EP vs. T-1 in the Swine Flu of 1.382516, EP vs. T2 in the Swine Flu data of
.281312, and EP vs. T1 in the Covid-19 data of .661756, where all of the t-Stats became positive.
According to statistics (Morgan et al., 2013; Peng, 2015; Trafimow & Marks, 2015), the null
should be rejected based on this set of data with positive numbers t-Stat. This is because this data
is based on a left-tailed t-Test, and positive numbers are now seen in the findings of the t-Stat. As
mentioned in the literature review, it is possible to have the results of a two-tailed t-Test get
contradicted by the findings in the t-Stat test findings concerning a one-tailed t-Test. The rule for
a t-Stat test in statistics are: if it is left tailed test, the researcher is to reject the null hypothesis,
where the findings of the p-value P (T<=t) two-tail test assuming unequal variances will not
reject the null hypotheses based off of the same set of data (Morgan et al., 2013; Peng, 2015;
Trafimow & Marks, 2015).
As mentioned in the findings from Research Question 1, a comparison of the data from
Table 7
Swine Flu t-Stat and Two-Tail Test Price Data, A similar finding is found in in EP vs. T2 t-Stat is -.06419, which deviates from the other t-Stats, which range from -.12527 EP vs. T0 to
-.17835 in EP vs. T1.
Table 8
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Covid-19 t-Stat and Two-Tail Test Price Data, Table 9
Swine Flu of 2009 Price One-Tail Vs. Two-Tail Comparison, and Table 10
Covid-19 of 2020 Price One-Tail vs. Two-tail Comparison the data does not always
show the same anomaly. This can be seen with a price vs. volume comparison for the same
pandemic data, which can be seen below in
Table 13
Swine Flu Price and Volume Comparison and
Table 14
Covid-19 Price and Volume Comparison with the differences noted by a yellow coloring
in the cell and the asterisks ****. As seen in
Table 13
Swine Flu Price and Volume Comparison for the Swine Flu volume has an anomaly that
is not reflected in the price for EP vs. T-1 price. The opposite is half true for an anomaly in
Swine Flu price that is not reflected in Swine Flu volume for EP vs. T2 in volume compared to
price in
Table 13
Swine Flu Price and Volume Comparison. This is a half-true statement because it is
reflected in the T2 t-Stat but not the T2 two-tail test results.
Table 13
Swine Flu Price and Volume Comparison
SWINE FLU of 2009 PRICE
EP vs. T-2

t Stat

-0.09001 P(T<=t) two-tail

0.928658

EP vs. T-1

t Stat

-0.16495 P(T<=t) two-tail

0.869674

EP vs. T0

t Stat

-0.21514 P(T<=t) two-tail

0.830568

148

EP vs. T1

t Stat

-0.15193 P(T<=t) two-tail

Ep vs. T2

t Stat

-0.5239 P(T<=t) two-tail

0.879882
0.60276 ****

SWINE FLU of 2009 VOLUME
EP vs. T-2

t Stat

-0.42983 P(T<=t) two-tail

0.669813

EP vs. T-1

t Stat

1.382516 P(T<=t) two-tail

0.174298 ****

EP vs. T0

t Stat

-0.15934 P(T<=t) two-tail

0.874042

EP vs. T1

t Stat

-0.2053 P(T<=t) two-tail

0.838241

Ep vs. T2

t Stat

0.281312 P(T<=t) two-tail

0.779761 ****

Table 14
Covid-19 Price and Volume Comparison
COVID 19 of 2020 VOLUME
EP vs. T-2

t Stat

-1.33891 P(T<=t) two-tail

0.189482

EP vs. T-1

t Stat

-1.34998 P(T<=t) two-tail

0.183353

EP vs. T0

t Stat

-1.33255 P(T<=t) two-tail

0.193423

EP vs. T1

t Stat

0.661756 P(T<=t) two-tail

0.513017 ****

Ep vs. T2

t Stat

-1.20158 P(T<=t) two-tail

0.239959

COVID 19 of 2020 PRICE
EP vs. T-2

t Stat

-0.06419 P(T<=t) two-tail

0.949088 ****

EP vs. T-1

t Stat

-0.14020 P(T<=t) two-tail

0.889088

EP vs. T0

t Stat

-0.12527 P(T<=t) two-tail

0.900832

EP vs. T1

t Stat

-0.17835 P(T<=t) two-tail

0.859197

Ep vs. T2

t Stat

-0.13833 P(T<=t) two-tail

0.890559

Then in the Covid-19 data from
Table 14
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Covid-19 Price and Volume Comparison, there is one strange outlier of EP vs. T1 in the
Covid-19 volume that is not reflected at all in the Covid-19 price. According to the supply and
demand principle, there should be a correlation between volume and price (Wenjing, 2017) and
the numbers in Covid-19 price should have changed and been different than the other t-stats and
p-values P (T<=t) two-tail of the data for volume findings in our test findings as shown in the
results.
As mentioned in RQ1, is there a difference in using the one-tailed t-Test results compared
to the two-tailed t-Test results for the finding for RQ2? The answer would still be no. The answer
to research question 2 is that there is still not a statistically significant difference between the
pharmaceutical stocks’ volume before and after the announcement of a pandemic by the WHO,
as demonstrated below in the one-tail vs. two-tail comparison in Table 15
Swine Flu of 2009 Volume One-Tail vs. Two-Tail Comparison and Table 16
Covid-19 of 2020 Volume One-Tail vs. Two-Tail Comparison. However, all findings are
still positive and with some data coming close to being statistically significant in the one-tail test
results at a .087 in Swine Flu volume and .095 in Covid-19 volume.
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Table 15
Swine Flu of 2009 Volume One-Tail vs. Two-Tail Comparison

P(T<=t) one-tail
P(T<=t) one-tail
P(T<=t) one-tail
P(T<=t) one-tail
P(T<=t) one-tail

Swine Flu of 2009 Volume One-Tail vs. Two-Tail
0.334906 P(T<=t) two-tail
0.087149 P(T<=t) two-tail
0.437021 P(T<=t) two-tail
0.419120 P(T<=t) two-tail
0.389880 P(T<=t) two-tail

0.669813
0.174298
0.874042
0.838241
0.779761

Table 16
Covid-19 of 2020 Volume One-Tail vs. Two-Tail Comparison

P(T<=t) one-tail
P(T<=t) one-tail
P(T<=t) one-tail
P(T<=t) one-tail
P(T<=t) one-tail

Covid-19 of 2020 Volume One-Tail vs. Two-Tail
0.094741 P(T<=t) two-tail
0.091677 P(T<=t) two-tail
0.096711 P(T<=t) two-tail
0.256509 P(T<=t) two-tail
0.119980 P(T<=t) two-tail

0.189482
0.183353
0.193423
0.513017
0.239959

Findings for Research Question 2 Part 2
All data and how it is presented must address the question, “Did adding a new variable
for stock volume change the outcome of the data?” The answer to this question would be yes.
This is most notably seen in the variance data of stock volume compared to stock price for both
pandemics noted by the word variance in the test findings. Large variances in data findings
indicate the findings are very far from the mean number of the data set, noted by the word mean
in each figure. In Figure 23 to Figure 32, the mean number is very large, ranging from 1,746,444.231 to 9,451,363.462. Therefore, the data for stock volume was computed again in
Excel without the S&P 500 data to see if it changed the outcome of the statistics. The complete
cumulative table for the findings below can be seen in Appendix: G Swine Flu of 2009 Volume
CAR Table, except the data from the S&P 500 is removed from these calculations where a red
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coloring notes the S&P data on the table. The following figures show the results of the t-Test
without the S&P data below.
Swine Flu of 2009
Figure 33
t-Test Two-Sample Assuming Unequal Variances EP vs. T-2. No S&P 500 Data

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-2168300
59426
1.40868E+11
25
0
47
0.042311102
0.483214968
1.677926722
0.966429936
2.011740514

26900
54562
1.89515E+11
25

Figure 34
t-Test Two-Sample Assuming Unequal Variances EP vs. T-1. No S&P 500 Data

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-2168300
-1872000
59426
2724
1.40868E+11 2.26142E+11
25
25
0
46
0.467981873
0.321003674
1.678660414
0.642007348
2.012895599
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Figure 35
t-Test Two-Sample Assuming Unequal Variances EP vs. T0. No S&P 500 Data

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-2168300
59426
1.40868E+11
25
0
24
-1.2895307
0.104751474
1.71088208
0.209502947
2.063898562

-1673500
1294176
2.27802E+13
25

Figure 36
t-Test Two-Sample Assuming Unequal Variances EP vs. T1. No S&P 500 Data

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-2168300
59426
1.40868E+11
25
0
31
0.391595233
0.349018135
1.695518783
0.69803627
2.039513446

-1239900
-23096
9.6934E+1
1
25
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Figure 37
t-Test Two-Sample Assuming Unequal Variances EP vs. T2. No S&P 500 Data

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

-2168300
59426
1.40868E+11
25
0
30
1.394346971
0.086727063
1.697260887
0.173454126
2.042272456

-114500
-261800
1.18597E+12
25

The complete cumulative table for the findings below can be seen in Appendix: H
COVID-19 of 2020 Volume CAR Table, except for the data from the S&P 500 is removed from
these calculations.
Covid-19 of 2020
Figure 38
t-Test Two-Sample Assuming Unequal Variances EP vs. T-2. No S&P 500 Data
47050
Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

52698
1.10929E+11
25
0
46
-0.973675171
0.167655209
1.678660414
0.335310419
2.012895599

646800
155530
1.6792E+11
25
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Figure 39
t-Test Two-Sample Assuming Unequal Variances EP vs. T-1 No S&P 500 Data

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

47050
52698
1.10929E+11
25
0
38
1.164885093
0.125663172
1.68595446
0.251326344
2.024394164

263500
-104588
3.4485E+11
25

Figure 40
t-Test Two-Sample Assuming Unequal Variances EP vs. T0. No S&P 500 Data
47050
Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

52698
1.10929E+11
25
0
24
-0.921250395
0.183044067
1.71088208
0.366088134
2.063898562

1333800
1231464
4.08189E+13
25
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Figure 41
t-Test Two-Sample Assuming Unequal Variances EP vs. T1. No S&P 500 Data

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

47050
-252900
52698
-157712
1.10929E+11 1.70881E+12
25
25
0
27
0.779887776
0.221120136
1.703288446
0.442240271
2.051830516

Figure 42
t-Test Two-Sample Assuming Unequal Variances EP vs. T2. No S&P 500 Data

Mean
Variance
Observations
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

47050
52698
1.10929E+11
25
0
33
-1.56776446
0.063238177
1.692360309
0.126476354
2.034515297

465400
308818
5.56286E+11
25

Before interpretation of the findings of stock volume again, the number of observations in
each t-Test is decreased by one to 25 for Figure 33 to Figure 42 from 26 in Figure 23 to Figure
32. All data from the S&P 500 stock volume has been removed from these findings. Also, the
mean number has decreased, as well as the df results and the findings variance score in each
figure from Figure 33 to Figure 42. Following the same rules as before, the findings for stock
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volume were examined at the output data in the figures by comparing the two-tail p-value P
(T<=t) two-tail against our significance level or (alpha/ confidence level of 0.05). If the p-value
P (T<=t) two-tail is larger than the alpha, then one should not reject the null hypothesis and that
there is no statistically significant difference in the research findings. In all 10 of the figures
(Figure 33 thru Figure 42), all of the p-values P (T<=t) two-tail are larger than the alpha of .05.
For the Swine Flu, the p-value P (T<=t) two-tail ranges from .17 to .966). The Covid-19 figures
range from .12 to .44. Since it is known that the findings are not statistically significant, a
conclusion can be made that the answer to research question 2 is that there is still not a
statistically significant difference between the pharmaceutical stocks’ volume before and after
the announcement of a pandemic by the WHO.
With these findings of stock volume, there is another of anomalies. In the Swine Flu
results, the EP vs. T0 (
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Figure 35
t-Test Two-Sample Assuming Unequal Variances EP vs. T0. No S&P 500 Data) made a strange
drop (though not statistically significant) of .46798 to -1.2895 for the t-Stat. Then this number
returns to .3915 in EP vs. T1 for the t-Stat (Figure 36
t-Test Two-Sample Assuming Unequal Variances EP vs. T1. No S&P 500 Data). In EP vs. T-2
and EP vs. T2, the numbers now range from .0423 to 1.39. They are all positive, except for EP
vs. T0 for t-Stat results. Swine Flu in the two-tail test results also dropped to .2095 and .17345 in
EP vs. T0 and EP vs. T2, respectively. In the Covid-19 findings, an opposite positive spike
occurred in the EP vs. T-1 findings (though not statistically significant) where the data went from
a -.9736 (Figure 38
t-Test Two-Sample Assuming Unequal Variances EP vs. T-2. No S&P 500 Data) to 1.16488.
Then it changed back to -.9212 in EP vs. T0 (Figure 40
t-Test Two-Sample Assuming Unequal Variances EP vs. T0. No S&P 500 Data). This time the
data also made another spike in EP vs. T1 (Figure 41
t-Test Two-Sample Assuming Unequal Variances EP vs. T1. No S&P 500 Data) to .77989 and
returned to -1.5677 in EP vs. T2 (Figure 42
t-Test Two-Sample Assuming Unequal Variances EP vs. T2. No S&P 500 Data). The two-tail
test results in EP vs. T2 dropped to 0.1265. As seen in Table 17
SWINE FLU of 2009 Volume No S&P 500 Data and
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Table 18
COVID-19 of 2020 Volume No S&P 500 Data with the irregularities noted by a yellow color
and an asterisk **** mark at the end of each row. If the t-Stat output is positive, the reported pvalue P (T<=t) two-tail is a right-tailed result, or positive. If the t-Stat is negative, the p-value P
(T<=t) two-tail is a left-tailed output or negative. From the findings of the t-Stat test in
Table 13
Swine Flu Price and Volume Comparison and
Table 14
Covid-19 Price and Volume Comparison plus Figures 33 to 42 above, there are a completely
different set of findings in the statistical analysis of the data in Table 17
SWINE FLU of 2009 Volume No S&P 500 Data and
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Table 18
COVID-19 of 2020 Volume No S&P 500 Data.
Table 17
SWINE FLU of 2009 Volume No S&P 500 Data

EP vs. T-2
EP vs. T-1
EP vs. T0
EP vs. T1
Ep vs. T2

SWINE FLU of 2009 VOLUME No S&P 500
P(T<=t) twot Stat
0.0423111 tail
0.96642994 ****
P(T<=t) twot Stat
0.467981783 tail
0.642007348
P(T<=t) twot Stat
-1.2895307 tail
0.20950295 ****
P(T<=t) twot Stat
0.391595233 tail
0.69803627
P(T<=t) twot Stat
1.39434697 tail
0.17345413 ****
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Table 18
COVID-19 of 2020 Volume No S&P 500 Data

EP vs. T-2
EP vs. T-1
EP vs. T0
EP vs. T1
Ep vs. T2

COVID 19 of 2020 VOLUME NO S&P 500
t Stat
-0.97367517 P(T<=t) two-tail 0.335310419
t Stat
1.16488509 P(T<=t) two-tail
0.25132634 ****
t Stat
-0.9212504 P(T<=t) two-tail
0.36688134
t Stat
0.77988778 P(T<=t) two-tail
0.44224027 ****
t Stat
-1.56776446 P(T<=t) two-tail
0.12647635 ****

All of the results of the t-Stat are almost opposite the findings of the first stock volume
that included S&P 500 data except where the anomaly was pointed out in Table 11
Swine Flu of 2009 t-Stat and Two-Tail Volume Test Data and Table 12
Covid-19 of 2020 t-Stat vs. Two-Tail Volume Test Data. The data for the Swine Flu shows
outliers in EP vs. T-2, EP vs. T0, and EP vs. T2 (though not statistically significant). The same
basic idea holds for the Covid-2019 volume (
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Table 18
COVID-19 of 2020 Volume No S&P 500 Data), except it shows EP vs. T-1, EP vs. T1 and Ep
vs. T2 anomalies. This is best seen in a side-by-side comparison of the two sets of data in
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Table 19
Swine Flu of 2009 Volume with and without the S&P 500 Data and Table 20
Covid-19 of 2020 Volume with and without the S&P 500 Data below with the irregularities
noted by a yellow color and an asterisk **** mark at the end of each row.
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Table 19
Swine Flu of 2009 Volume with and without the S&P 500 Data

EP vs. T-2
EP vs. T-1
EP vs. T0
EP vs. T1
Ep vs. T2

SWINE FLU of 2009 VOLUME NO S&P 500
t Stat
0.042311102 P(T<=t) two-tail
t Stat
0.467981873 P(T<=t) two-tail
t Stat
-1.2895307 P(T<=t) two-tail
t Stat
0.391595233 P(T<=t) two-tail
t Stat
1.39434697 P(T<=t) two-tail

0.96642936 ****
0.642007348
0.209502947 ****
0.69803627
0.173454126 ****

SWINE FLU of 2009 VOLUME
EP vs. T-2

t Stat

-0.42983 P(T<=t) two-tail

0.669813

EP vs. T-1

t Stat

1.382516 P(T<=t) two-tail

0.174298 ****

EP vs. T0

t Stat

-0.15934 P(T<=t) two-tail

0.874042

EP vs. T1

t Stat

-0.2053 P(T<=t) two-tail

0.838241

Ep vs. T2

t Stat

0.281312 P(T<=t) two-tail

0.779761 ****

Table 20
Covid-19 of 2020 Volume with and without the S&P 500 Data
COVID 19 of 2020 VOLUME NO S&P 500
EP vs. T-2

t Stat

-0.973675171 P(T<=t) two-tail

EP vs. T-1

t Stat

1.164885093 P(T<=t) two-tail

EP vs. T0

t Stat

-0.921250395 P(T<=t) two-tail

EP vs. T1

t Stat

0.77988776 P(T<=t) two-tail

0.44224027 ****

Ep vs. T2

t Stat

-1.56776446 P(T<=t) two-tail

0.12647635 ****

EP vs. T-2
EP vs. T-1
EP vs. T0
EP vs. T1
Ep vs. T2

t Stat
t Stat
t Stat
t Stat
t Stat

COVID 19 of 2020 VOLUME
-1.33891 P(T<=t) two-tail
-1.34998 P(T<=t) two-tail
-1.33255 P(T<=t) two-tail
0.661756 P(T<=t) two-tail
-1.20158 P(T<=t) two-tail

0.335310419
0.251326344 ****
0.36688134

0.189482
0.183353
0.193423
0.513017 ****
0.239959
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According to statistics (Morgan et al., 2013; Peng, 2015; Trafimow & Marks, 2015), the
researcher should reject the null hypotheses based on this set of data with positive numbers t-Stat
for a left tailed test. It was again possible to have the results of a two-tailed test contradictory to
the findings in the t-Stat test compared to the direction of the left-tailed test. The rule for a t-Stat
test in statistics are: if it is left tailed test, the researcher is to reject the null hypothesis, where the
findings of the p-value P (T<=t) two-tail test assuming unequal variances will not reject the null
hypotheses based off of the same set of data (Morgan et al., 2013; Peng, 2015; Trafimow &
Marks, 2015). However, this time, the conclusion is based on positive numbers that are now
negative and negative numbers that are now positive because of removing the S&P 500 data
from our data before running the t-Test.
From this data in
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Table 19
Swine Flu of 2009 Volume with and without the S&P 500 Data and Table 20
Covid-19 of 2020 Volume with and without the S&P 500 Data, a conclusion can be made
conclude that there is an anomaly in EP vs. T2 in the Swine Flu data and EP vs. T1 with and with
the S&P 500 data in the Covid-19 data. A deviation occurring in the stock volume traded is not
reflected in stock price compatible with the overall S&P 500 data. Another conclusion is that the
other inconsistencies in the data for stock volume in
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Table 19
Swine Flu of 2009 Volume with and without the S&P 500 Data and Table 20
Covid-19 of 2020 Volume with and without the S&P 500 Data is probably caused by the data
from the S&P 500 which would require further research beyond the scope of this event study.
The inference by removing the S&P 500 data is that the overall market is dropping, and the
pharmaceutical stock is increasing by looking at the results of the t-Test and reflects in the
corresponding t-Stat data because the t-Stat got bigger (positive) or became a smaller negative
number (Ex.-.42983 EP vs. T-2 Swine Flu to 0.0423111 Ep vs. T-2 Swine Flu without the S&P
500 data).
The final point to make with this stock volume and price data is tied to another point
made in the literature review. Krzeczewski (2017) reported that pharmaceutical companies are
considered defensive stocks. Defensive stocks (food, medicines, and utilities) tend to do well
during economic downtowns in the stock market than cyclical stocks that tend to do well due to
upswings in the overall economy. People typically do not cut back on their food, medicines, or
electricity consumption during a downturn in the economy (Krzeczewski, 2017). As mentioned
with each interpretation of data, if the t-Stat output is positive, it is a right-tailed result. If the tStat is negative, it is a left-tailed output or negative (Morgan et al., 2013; Peng, 2015; Trafimow
& Marks, 2015). From the data in
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Table 19
Swine Flu of 2009 Volume with and without the S&P 500 Data) and Table 20
Covid-19 of 2020 Volume with and without the S&P 500 Data), a researcher must point out that
the findings without the S&P 500 data have either positive or more positive results compared to
the data with the S&P 500 data. For instance, in EP vs. T0 the t-Stat went from -1.33255 to .921250395 (Table 20
Covid-19 of 2020 Volume with and without the S&P 500 Data), an increase of 1.240429605.
These statistical (though not statistically significant) results back up Krzeczewski’s (2017) and
Palache et al.’s (2017) findings because pharmaceutical stock prices and volume are either
positive or more positive without the S&P 500 data. The stock price movement and the stock
volume movement are positive except where the incongruity/ outliers are mentioned in the prior
findings.
This gives credence to the idea that both the stock volume and the stock price moved in a
positive direction (though not statistically significant) during the testing periods, proving that the
pharmaceutical stocks were doing well or better than the surrounding overall market data as
reflected by the S&P 500 data in the research which is shown and removed from the data in
Figure 23 to Figure 42. Just like RQ1 and RQ2 Part 1, the researcher must address the issue of
the one-tailed t-Test vs. the two-tailed t-Test findings as seen below in Table 21
Swine Flu of 2009 Volume One-Tail vs. Two-Tail Comparison Part II) and Table 22
Covid-19 of 2020 Volume One-Tail vs. Two-Tail Comparison Part II). There is no statistical
difference in the results of the two tests that change my t-Test results findings. A conclusion can
be made that the answer to research question 2 is that there is still not a statistically significant
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difference between the pharmaceutical stocks’ volume before and after the announcement of a
pandemic by the WHO even after removing the data from the S&P 500 data from my
calculation. However, all t-Test findings are positive.
Table 21
Swine Flu of 2009 Volume One-Tail vs. Two-Tail Comparison Part II
Swine Flu of 2009 Volume One-Tail vs. Two-Tail
P(T<=t) one-tail

0.483215 P(T<=t) two-tail

0.96643

P(T<=t) one-tail

0.321004 P(T<=t) two-tail

0.642007

P(T<=t) one-tail

0.104751 P(T<=t) two-tail

P(T<=t) one-tail

0.349018 P(T<=t) two-tail

0.209503
0.698036

P(T<=t) one-tail

0.086727 P(T<=t) two-tail

0.173454

Table 22
Covid-19 of 2020 Volume One-Tail vs. Two-Tail Comparison Part II

P(T<=t) one-tail
P(T<=t) one-tail
P(T<=t) one-tail
P(T<=t) one-tail
P(T<=t) one-tail

Covid-19 of 2020 Volume One-Tail vs. Two-Tail
0.167655 P(T<=t) two-tail
0.125663 P(T<=t) two-tail
0.183044 P(T<=t) two-tail
0.22112 P(T<=t) two-tail
0.063238 P(T<=t) two-tail

0.33531
0.251326
0.366088
0.44224
0.126476

Return on Investment
The return on investment (ROI) needs some clarification concerning the research findings
because this is a fixed design event study using a causal-comparative ex post facto quantitative
method. It is exploratory and deductive (Babones, 2016; Creswell, 2014; Yin, 2018). The
qualitative research method alone is not appropriate because it has a hypothesis. The quantitative
method alone is also not appropriate for this research because the research is comparing and
interpreting data from multiple theories on one event, looking for data not presented in one set of
findings from one theory (Babones, 2016; Creswell, 2014; Yin, 2018).
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The ROR can be expected from an asset(s) investment, where the ROI is how much one
plans to get back from an investment purchased (Alrgaibat, 2015; Freihat, 2019; Wenjing, 2017).
This event study has analyzed the pharmaceutical sector of the NYSE for two specific periods
(Swine Flu of 2009 [April 13, 2009, to July 13, 2009] and the Covid-19 of 2020 with the dates of
[November 27, 2019, to March 2, 2020]. The findings for both research questions based on the
hypotheses were not statistically significant. However, the question of did the pharmaceutical
sector provided any data about its ROR of the pharmaceutical stock has been addressed. The
answer is yes. According to Dalbar Associates (2020), the average investor can expect a 5.19%
return on their investment yearly from their 20-year study. Compared to their NYSE return of
9.85% from the same 20-year study (Dalbar Associates, 2020). This is slightly different from the
NYSE’s actual return of -40.9% to 31.3%, as shown in Appendix C: NYSE Composite Index
Annual ROR and the NYSE statement of the average return being 10% (NYSE, 2020).
The findings were not statistically significant, but the data showed that some stocks made
gains while others had losses during both pandemics, with the entire segment average at the
bottom. This can be seen in Figure 43
Average Percentage of Return of Swine Flu 2009 and Figure 44
Average Percentage of Return of Covid-19 of 2020.
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Figure 43
Average Percentage of Return of Swine Flu 2009
COMPANY NAME

T-2

T-1

T0

T1

T2

1

Abbott Laboratories

3.01%

3.66%

3.23%

6.38%

8.28%

2

Synthetic Biologics, Inc

5.00%

2.50%

25.00%

5.00%

-2.50%

3

iBio, Inc.

0.00%

0.00%

5.00%

-10.00%

3.75%

4

Johnson & Johnson

5.90%

7.59%

7.99%

6.92%

9.17%

5

Bausch Health Companies Inc.

13.01%

7.86%

16.31%

11.84%

21.12%

6

Novartis AG

7.25%

6.72%

8.01%

12.23%

8.96%

7

Lannett Co Inc

6.05%

-0.18%

5.79%

7.02%

19.74%

8

Takeda Pharmaceutical Company Limited

0.00%

0.00%

0.00%

0.00%

9

Oragenics Inc.

0.00%
30.77%

-7.69%

-23.08%

-15.38%

111.54%

10 Perrigo Company

5.98%

4.07%

3.60%

4.37%

7.76%

11 Allergan plc.

0.59%

1.07%

-0.64%

0.79%

11.38%

12 Emergent Biosolutions, Inc.

8.47%

27.12%

32.86%

34.84%

30.27%

13 Merck & Company, Inc.

6.20%

7.53%

8.01%

3.86%

11.39%

14 GlaxoSmithKline PLC

8.19%

9.36%

14.78%

19.18%

16.35%

15 Eli Lilly and Company

5.54%

4.73%

4.73%

1.85%

2.34%

16 Dr. Reddy’s Laboratories Ltd

18.43%

29.61%

39.58%

37.16%

51.71%

17 NovaBay Pharmaceuticals, Inc.

-3.16%

-8.70%

-7.91%

-14.23%

-14.62%

18 Pfizer, Inc.

11.81%
12.06%

8.09%

8.98%

9.87%

9.65%

-16.47%

-12.94%

-14.12%

-13.82%

20 Teva Pharmaceutical Industries Limited

1.91%

8.11%

10.28%

8.11%

10.81%

21 Bristol-Myers Squibb Company

1.13%

-0.36%

0.00%

-0.44%

0.55%

22 Astrazeneca PLC

15.82%

15.96%

18.43%

24.07%

25.24%

23 Prestige Consumer Healthcare Inc.

10.57%

12.26%

14.21%

4.97%

5.51%

24 Taro Pharmaceutical Industries Ltd.

0.13%

0.13%

-2.04%

-1.02%

-4.08%

56.67% 106.67% 126.67% 100.00%

66.67%

19 China Pharma Holdings, Inc.

25 Palatin Technologies, Inc.
26 Novartis AG
AVERAGE PERCENT RETURN

8.96%

10.41%

11.09%

11.09%

14.25%

5.95%

9.23%

12.23%

9.78%

15.82%
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Figure 44
Average Percentage of Return of Covid-19 of 2020
COMPANY NAME

T-2

T-1

1

Abbott Laboratories

0.48%

4.81%

4.15%

3.06%

2.74%

2

Synthetic Biologics, Inc

21.43%

28.57%

23.81%

30.95%

17.86%

3

iBio, Inc.

6.25%

16.67%

20.83%

50.00%

39.58%

4

Johnson & Johnson

2.98%

5.25%

6.39%

7.45%

5.18%

5

Bausch Health Companies Inc.

-1.28%

-0.48%

-3.34%

-3.89%

-9.87%

6

Novartis AG

1.73%

2.32%

3.10%

3.00%

3.75%

7

Lannett Co Inc

-5.77%

-0.67%

-6.55%

-4.00%

-0.11%

8

Takeda Pharmaceutical Company Limited
Oragenics Inc.

-2.12%
16.67%

-3.21%
18.52%

-1.43%
11.11%

-7.80%

9

-1.97%
11.11%
-4.83%

11.18%

8.18%

10.41%

10.67%

11 Allergan plc.

1.80%

0.52%

-0.35%

2.04%

5.69%

12 Emergent Biosolutions, Inc.

1.79%

3.91%

2.19%

13.59%

16.49%

13 Merck & Company, Inc.

2.24%

-1.93%

-2.77%

-3.68%

-7.84%

14 GlaxoSmithKline PLC

1.70%

2.33%

1.80%

-2.35%

-5.95%

15 Eli Lilly and Company

10.93%

15.14%

17.39%

19.74%

16.56%

16 Dr. Reddy’s Laboratories Ltd

0.96%

4.93%

8.80%

8.82%

9.91%

17 NovaBay Pharmaceuticals, Inc.

6.78%

5.08%

3.39%

-1.69%

-3.39%

18 Pfizer, Inc.

1.60%

4.19%

-2.83%

-0.89%

-6.20%

19 China Pharma Holdings, Inc.

1.22%

20.85%

25.68%

29.66%

25.65%

-5.97%

2.51%

3.11%

21.49%

26.86%

21 Bristol-Myers Squibb Company

3.47%

3.84%

2.25%

5.09%

4.79%

22 Astrazeneca PLC

3.29%

2.44%

1.26%

1.89%

-0.18%

23 Prestige Consumer Healthcare Inc.

3.51%

24 Taro Pharmaceutical Industries Ltd.

-7.76%

25 Palatin Technologies, Inc.

-6.25%

6.75%
10.68%
11.25%

6.51%
13.21%
16.25%

6.44%
17.25%
18.75%

8.41%
21.98%
26.88%

1.85%

7.04%

6.66%

10.84%

10.24%

1.12%

4.02%

3.02%

6.13%

4.53%

10 Perrigo Company

20 Teva Pharmaceutical Industries Limited

26 Novartis AG
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Figure 43

T0

T1

T2

3.70%
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Average Percentage of Return of Swine Flu 2009) and Figure 44
Average Percentage of Return of Covid-19 of 2020) are the returns of each stock
compared against the EP, which is not shown since it would reflect a 0% gain. From the data
above, the average return for T1 is better than the average investor’s return of 5.19%, according
to Dalbar’s 20-year study (Dalbar Associates, 2020) at 9.78% for the Swine Flu of 2009 and
6.13% for Covid-19 of 2020 respectively as shown and bold at the bottom of the figures. The
other periods showed mixed above or below the average threshold set by Dalbar Associates’
(2020) 20-year study of 5.19%, depending on which event one looks.
However, picking individual stocks based on this data could yield better results, but this
is beyond the scope of this event study. For the more experienced or professional investor (Fama,
2013; Markowitz, 1952; Mauck & Salzsieder, 2015), this data could be used for stop-loss
investing or short-selling stocks to get a better ROR which is beyond the scope of this event
study. The pharmaceutical stock shows data reflecting positive average returns over short
periods. The data shows the practically significant data using interpretivism from a positivist
perspective (Babone, 2016) though not statistically significant use of this market segment data
and answering the question of stock ROR during a fourteen- and seven-day period before after
the announcement of a PHEIC by the WHO.
Efficient Market Hypothesis (EMH) Problem
The final topic of the interpretation of the data is the Efficient Market Hypothesis (EMH),
as proposed by Fama (1970). The topic of EMH is the underlying general problem, though not a
specific research question or a specific hypothesis. The first research question and hypothesis
(H10) made the following statements. The ideas behind these hypotheses and research questions
are based on Fama (1970) and Pilkington (2017), who said the market is efficient and that prices
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are directly reflective of events trading at their fair market value. Daniel and Hirshleifer (2015)
argued that the market is affected by outside events. The second hypothesis (H20) determined if a
flaw existed in the EMH, not stock prices, but stock volume. When a stock is trading in larger
than normal stock volume, it would be an indicator of a flaw in the market that could be
exploited and used to predict the movement of a stock and hence a flaw in the EMH (Wenjing,
2017). This is the basis of supply and demand, which is an underlying basis of EMH.
In the findings of both research questions, the researcher can statistically prove some
conflicting data but cannot prove statistical significance in the research findings for the research
questions or the research hypotheses. Because of this conflicting data, the researcher using
interpretivism from a positivist perspective (Babone, 2016) can say the EMH has not been
validated, and there is a possible flaw in the EMH based on the data in this research event study
where volume moved. The stock price did not correspond to the results, validating Wenjing’s
(2017) findings. This is not bias, a search for an interpretation that validates the research, but a
statement of fact. This is also in the wording of Fama (1970), as well as Pilkington (2017), Wang
(2016), and Daniel and Hirshleifer (2015). Fama’s idea of EMH is that the market is efficient.
This is backed up by research by Pilkington (2017), Wang (2016) and Daniel and Hirshleifer
(2015). Fama did not say the market is statistically significantly efficient. Fama stated that the
market is efficient. The data above shows that there is some practically significant useful data
where the stock prices increased and where volume increased from each study individually based
on t-Test results
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Table 19
Swine Flu of 2009 Volume with and without the S&P 500 Data and Table 20
Covid-19 of 2020 Volume with and without the S&P 500 Data. However, supply and
demand suggest that low availability and high demand will increase stock prices, but the
opposite is true. High availability and low demand will decrease the stock price (Wenjing, 2017).
Therefore, the anomalies in stock volume traded should have had the same effect on stock price
in the same periods. This did not happen with the findings where volume moved, but the price
did not move accordingly. This is because giving credence to Wenjing (2017) who reported this
anomaly exists (volume does not affect price) and can be exploited by investors. Therefore,
according to Wenjing (2017) and this event study, the market is non-efficient using
interpretivism from a positivist perspective (Babone, 2016). This is because the volume of stock
traded did not change the stock price; leading to the conclusion that the market is not efficient,
indicating that Fama (1970), Wang (2016), Pilkington (2017), and Daniel and Hirshleifer (2015)
are all wrong in their research and findings.
Relationship of Hypotheses to Research Questions.
A research question is simply an idea of something to be tested through formal research
that has not been tested before. A hypothesis is a statement of a tentative relationship between
two variables in a research study. If there is a prediction between two variables, a researcher has
proposed a hypothesis. This event study proposes a relationship between the announcement of a
pandemic and two things 1) proposal is the rate of return (ROR) of the pharmaceutical sector of
the NYSE and 2) proposal changes in the volume of stock traded which shows a flaw not seen in
the stock price ROR. The general problem was the possible failure of the EMH to consistently
hold, resulting in investors being able to generate statistically significant abnormal returns in the
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medical sector of the NYSE. Both the research question and hypotheses are necessary for
research, where the research question proposes an idea to be tested, and the hypothesis is the
testable measure of the research question.
Summary of the Findings.
No matter what question is asked or what point of view is taken on the subject, there is
always a point that validates the subject and someone who has a point that counteracts those
statements. This event study has provided the following information: no statistically significant
findings in either research question or hypothesis in stock price ROR or stock volume
movement. However, the data shows that one cannot fully accept or reject the null hypothesis in
the research questions. This is because there is conflicting evidence in the findings of the data
from the analysis of the t-Tests p-value P (T<=t) two-tail above and the t-Stat results. According
to statistics (Morgan et al., 2013; Peng, 2015; Trafimow & Marks, 2015); a researcher in order to
fully reject the null hypothesis, the data does have to align, and both the p-value P (T<=t) twotail and t-Stat data have to conform to statistical requirements.
If the data does not conform to statistical requirements, further analysis must be done to
explain the differences in the statistical data. The data results conflict with statistical
requirements and the specific set of parameters. The explanation of the differences is beyond the
scope of this event study and is an area of further research to explain why this conflicting data
exists between volume and stock price. This event study has also validated other researchers
from the literature review. In the findings, the work of Wenjing (2017) was found to have been
proven true as stock volume moved, but at the same time, the stock price did not move to the
degree of movement in volume. Also, Krzeczewski's (2017) efficiency was proven true because
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the pharmaceutical stocks moved opposite the overall S&P 500 data and moved in a positive or
positive direction though all of this support and findings are not statically significant.
A final note is added to the findings. There is the potential possibility for unintentional
bias. This note is based on the word efficiency. Whether interpreted as technical or fundamental
(Thaler & Shiller, 2015), efficiency is the relationship between information and price. Technical
efficiency says the information is instantaneously reflected in stock prices; therefore, an investor
or a researcher cannot use the information to forecast stock prices. Fundamental efficiency says
the price of a stock is intrinsic and reflects value through information; therefore, only
information related to the stock's intrinsic value makes the price move.
There would have been a problem producing this proposal if efficiency is true. This
dissertation was in November of 2019 (before December 13th, 2019) because there had to be a
change in the dissertation topic. The topics of pandemics from information readily available on
the internet almost four months before the WHO's announcement of the COVID-19
(Coronavirus) of 2020. This was also approved for research before the WHO announced the
Covid-19 pandemic in 2019. This final note in findings is noted for the potential of a conflict of
interest; in theory or practice depending on interpretation; the researcher did something which
contradicts the EMH, which this research attempted to validate or disprove. The actual creation
is potential proof that the EMH does not hold, and there are inefficiencies in the market from a
technical and fundamental basis. This event study prior to the actual second pandemic occurred
because, at the time of the event topic approval, this second event (Covid-19) had yet to occur as
a pandemic. This was mentioned as a potential bias and its possible impact on this research.
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Applications to Professional Practice
Professional practice is a schematic that outlines the beliefs, values, theories, and
operations systems for any given industry. It can also be synonymous with a code of professional
responsibility (thefreedictionary.com, nd). In the concept of this event study, the professional
practice was two-fold. Professional practice is first, the responsibility to act by the SEC to
enforce rules and laws about financial reporting for the benefit of the people of the United States
and all investors in these companies; whether they are in the United States or somewhere else on
the globe but choose to invest in the NYSE.
Secondly, the professional practice has its foundation for this quantitative study is the
obligation and commitment of the chief financial officers, company presidents, accountants,
financiers, and anyone responsible for reporting financial data about a company to treat its
expenses and financial condition and avoid financial risk to stay in business and operate in the
future. Professionalism by these decision-makers is and has a traditional tenant of being ethical
and derives its beneficence from the act of helping both citizens and the companies by doing
good and avoiding evil (Whitehead, 1925).
Donati (2014) said that moral responsibility is acted upon by the degree of freedom
allowed. Donati made it difficult for one to see where the influence of one thing is entangled in
the effect on the other. Therefore, one is culpable of ethical injustice to some degree by the
complicit nature of the unknown influence. Since a man cannot serve two masters, the supervisor
must choose his professional moral obligation between the economics and finances of a decision
and the moral and ethical responsibilities of those under their care. Rogers (2003) argued that a
moral issue must be fixed before someone says the issue is an ethical problem. For people will be
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lovers of self, lovers of money, proud, arrogant, abusive, disobedient to their parents, ungrateful,
unholy.” (2 Timothy 3:2 KJV).
Recommendations for Action
When looking at money, one thinks of what one has, what one wants (Vining et al.,
2019), what one needs (Doyal & Gough, 1991). One thinks others have that they do not (Cofsky,
1993). This brings people to a feeling of inequality and maybe disparity. Parkinson’s Law says
that expenses rise to meet one’s income, or work grows the more time one tries to work and
stops working (Parkinson, 1955).
The research results showed no statistically significant findings in the data related to this
event study. However, it also showed us that a researcher could neither accept nor reject the null
hypothesis. However, it also shows something else beyond the scope of the event study. It has
also proven that where someone has a point of view, there is also another point of view. This
event study focused on statistical significance in the data. Statistical significance implies there is
no random set of chance in the data (Fisher, 1925; Morgan et al., 2013; Peng, 2015; Trafimow &
Marks, 2015), but another term that must be used is practical significance to the data. Practical
significance is a term that refers to the magnitude of the difference, which is also known as the
effect size (Peng, 2015). Finding data is practically significant when the difference between the
data sets is large enough to be meaningful in real life, where the term meaningful may be
subjective and dependent on the person using it and in what context.
Some practically significant data was revealed by looking at the pharmaceutical
companies that focused on vaccines only, compared to the pharmaceutical sector as a whole,
which was needed for meaningful sample size and population. Even the data presented in figures
10 thru 39 above showed large gains in ROR (but not statistically significant) during short
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periods not present in the EPs (Estimation Period[s]). The skewness of the data reveals some
positive skewness which means the data is positive in the research results but not statistically
significant in overall research findings. This leads to whether this information is practically
significant, even though it is not statistically significant for the real world. Whether or not this
information is relevant is dependent on the average investor (Dalbar Associates, 2020) and how
or what is one’s goal is during a time. This factor was not measured since it had no bearing on
the findings, but it was mentioned in the data and an area of further research.
Recommendations for Further Study
Areas of further study could be the argument of the rational assumptions of the efficient
market in the 21st century and defining efficiency and its relation to the average investor(s)
(Dalbar Associates, 2020). Are investors rational or irrational, and is information about stocks
priced readily available and free to the public? What would have been the results of the data if
Cohens D an ANOVA or Gaussian Statistical Model (Morgan et al., 2013) was a statistical
model of the research instead of using a t-Test for data analysis? What is the difference between
the practical and statistical significance of the findings, and would those findings be relevant to
the average investor (Dalbar Associates, 2020) in the 21st Century? Could further breaking down
the 26 pharmaceutical companies to a smaller subset with the companies that focus on vaccines
and not the topics of pharmaceutical companies have changed the findings to a statistically
significant level?
Other facts to consider in finance are transaction costs from buying and selling stocks
which change stock prices and, therefore, the ROI; making equities cost more than any model.
Some taxes have to be paid on selling assets when money is made, which depends on the
investor's income because of taxes and tax brackets. This is another hidden cost (beyond
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purchase price) associated with owning an asset. Another factor is that information is not always
readily available and free. Information can be interpreted differently depending on the researcher
or the person hearing the information (bias). Lastly, people do not always make rational
decisions. There is some luck and chance involved in buying and selling equity (Sharpe, 1964).
Can an investor or company profit from the information, either known or hypothesized,
like data from an event study? From a technical efficiency perspective, the stock price changes
because of an event. From a fundamental perspective and all available research, one can see that
events affect stock market price in the technical efficiency sense. The more information one has
from a research perspective; the more one can predict stock prices at a technical level when the
normal investor reacts rationally or irrationally to the market. Ironically, this was validated by
the people who issued the Nobel Prize(s) in Finance. Because Fama (2013) and Shiller (2013)
have both received Nobel Prizes, one researcher says you cannot beat the market, and the other
says you can beat the market, respectively. So, who is right? It depends on the Nobel Committee,
the research reader depending on the information one has in front of you, and the investor's
decision.
Reflections
Money is a strange and wonderful thing. It builds empires; yet can destroy them as well.
It is the key to happiness; the chains bind them and take happiness away from others. It is the
thing of dreams when you can have so much, but it takes away to sleep when it is about all you
think about. In modern society, happiness is usually linked to money, and maybe someone would
say money equals happiness. However, this is the inherent problem with money. It is a mindset
that leads many down a futile path, does not suit them, or makes them miserable. The King
James Version of the Bible validates this with Acts 8:20: “But Peter said unto him, thy money
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perishes with thee because thou hast thought that the gift of God might be purchased with
money.”
The misery, of course, is not pertinent in this event study related to finance. However, it
is an area of finance that could be explored. All of these statistics and data do not measure
everything like individual happiness (Adams, 1963; Whitehead, 1925) from doing things like
community participation, volunteer work, spending time with family, and parenting, to name a
few. This leads us back to the money issue and the value (Whitehead, 1925) one places on
money or the value places on one’s life (Whitehead, 1920, 1925, 1927, 1929a, 1929b, 1933,
1938, 1948, 1951a, 1951b, 1978, 1996).
One does not have to be a doctor or have an MBA to understand what makes a successful
equity investment. An equity investment is successful if one ends up with more money than one
started with after investing. The extra money is their ROI. However, there are all sorts of ways to
measure ROI. Two of the most common return formulas are ROI which shows what percentage a
person gets from their original investment where ROR shows how they got their ROI, and the
investment grows annually from start to finish while considering the time value of money.
It is a good idea not to draw any fixed conclusions about the effects of pandemics upon
stock-market performance. Any stock market can and will react unpredictably to the unknown.
Also, no event should be studied in isolation but viewed in conjunction with other market
conditions. From an investment standpoint, it is hard to accept or mitigate the effects of an
epidemic/ pandemic on the market. Investors should remember the benefits of long-term
investing. This can be seen above because the S&P 500 over a period of time the stock market
always recovers and does better the longer the stock market is observed.
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The final factor to consider is probability. Probability deals with predicting the likelihood
of future events, whereas statistics involves the analysis of past events (Peng, 2015). Probability
is a theoretical branch of mathematics that studies the consequences of mathematical definitions,
and statistics is primarily an applied branch of mathematics, which tries to make sense of
observations in the real world using mathematical formulas. Just because a result of a study is
not statistically significant does not imply that it is not random, just that the probability of the
findings being random is greatly reduced. Finally, statistical significance in past data and the
results of that data, whether statistically significant or not, may not reflect ongoing or future
market conditions and variables and the practical use of said data even though it is not statically
significant.
Summing up can be done by reflecting on a few verses from the Bible. The first principle
is that God is the source of everything, including money. “My God shall supply all your need
according to his riches in glory by Christ Jesus” (Philippians 4:19 KJV). “I lead in the way of
righteousness, amid the paths of judgment: that I may cause those that love me to inherit
substance; and I will fill their treasures.” (Proverbs 8:20-21) Then 2 Corinthians 9:8 says: “and
God can make all grace abound toward you; that ye, always having all sufficiency in all things,
may abound to every good work. Whenever we need money or possessions, prayer is the answer.
Look to the Lord because He will provide it according to His will.”
However, with having everything (money), one must remember that an evil sin can occur,
and that sin is greed. Generally, greed is a selfish desire for wealth. It is that point at which a
person desires more than needed or what God views needed. Greed can be traced back to the Old
Testament in the Bible. “He that is greedy of gain troubleth his own house; but he that hateth
gifts shall live” (Proverbs 15:27). “He that loveth silver shall not be satisfied with silver, nor he
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that loveth abundance with increase: this is also vanity.” (Ecclesiastes 5:10). No man can serve
two masters: for either he will hate the one and love the other, or else he will hold to the one and
despise the other. Ye cannot serve God and mammon” (Matthew 6:24). Finally, Luke 12:15, “He
said unto them, take heed, and beware of covetousness: for a man’s life consists not in the
abundance of the things he possesseth.”. Of course, having has nothing to do with greed, but has
also had to do with giving, which is a biblical principle that is mentioned in Luke 6:38, “Give,
and it shall be given unto you; good measure, pressed down, and shaken together, and running
over, shall men give unto your bosom. With the same measure that ye mete withal, it shall be
measured to you again.” “One purpose of tithing was to teach the people of Israel to put God first
in their lives” (Deuteronomy 14:23).
Summary and Study Conclusions
This event study acknowledges Wilber's (1998) ideology from The Eye of Spirit. I do not
believe that any human mind can 100% error. So instead of asking which approach is right and
which approach is wrong, we assume each approach is true but partial and then try to figure out
how to fit these partial truths together, integrate them, pick one and get rid of the others. This
event study was trying to help the average investor (Dalbar Associates, 2020) and the
experienced manager. This event study looked to add research to the topic of the EMH (Fama,
1970, 1976) and provide data as to how and why the market reacts the way it does. Hopefully,
this research will be used by someone to benefit them and their investments during the next
pandemic, which according to history, will happen again. The question is when the next
pandemic will happen and the extent to which it will have a practically or statistically significant
effect on the stock market.
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Appendix A: Alphabetized Pharmaceutical Company List NYSE (2020)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

COMPANY NAMES IN ALPHABETICAL ORDER
Abbott Laboratories
AbbVie Inc.
Actinium Pharmaceuticals, Inc.
AgeX Therapeutics, Inc.
Allergan plc.
Amneal Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc.
Arcus Biosciences, Inc.
Astrazeneca PLC
Bausch Health Companies Inc.
Biohaven Pharmaceutical Holding Company Ltd.
BioPharmX Corporation
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company
Can-Fite Biopharma Ltd
Catalent, Inc.
China Pharma Holdings, Inc.
CorMedix Inc.
Dr. Reddy's Laboratories Ltd
Elanco Animal Health Incorporated
Eli Lilly and Company
Emergent Biosolutions, Inc.
GlaxoSmithKline PLC
iBio, Inc.
Johnson & Johnson
Kadmon Holdings, Inc.
Lannett Co Inc
Mallinckrodt plc
Matinas Biopharma Holdings, Inc.
Merck & Company, Inc.
Myovant Sciences Ltd.
NovaBay Pharmaceuticals, Inc.
Novartis AG
Novo Nordisk A/S
Oragenics Inc.
Palatin Technologies, Inc.
Perrigo Company
Pfenex Inc.

STOCK
Symbol
ABT
ABBV
ATNM
AGE
AGN
AMRX
AMPE
RCUS
AZN
BHC
BHVN
BPMX
BMY
BMY
CANF
CTLT
CPHI
CRMD
RDY
ELAN
LLY
EBS
GSK
IBIO
JNJ
KDMN
LCI
MNK
MTNB
MRK
MYOV
NBY
NVS.
NVO
OGEN
PTN
PRGO
PFNX

202
39
40
41
42
43
44
45
46
47

Pfizer, Inc.
Prestige Consumer Healthcare Inc.
Synthetic Biologics, Inc
Takeda Pharmaceutical Company Limited
Taro Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited
Zoetis Inc.
Zomedica Pharmaceuticals Corp.
Zymeworks Inc.

PFE
PBH
SYN
TAK
TARO
TEVA
ZTS
ZOM
ZYME
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Appendix B: Used Pharmaceutical Company List

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Company Name
Abbott Laboratories
Allergan plc.
AstraZeneca PLC
Bausch Health Companies Inc.
Bristol-Myers Squibb Company
China Pharma Holdings, Inc.
Dr. Reddy's Laboratories Ltd
Eli Lilly and Company
Emergent Biosolutions, Inc.
GlaxoSmithKline PLC
iBio, Inc.
Johnson & Johnson
Lannett Co Inc
Merck & Company, Inc.
NovaBay Pharmaceuticals, Inc.
Novartis AG
Novo Nordisk AS
Oragenics Inc.
Palatin Technologies, Inc.
Perrigo Company
Pfizer, Inc.
Prestige Consumer Healthcare Inc.
Synthetic Biologics, Inc
Takeda Pharmaceutical Company Limited
Taro Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited
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Appendix C: NYSE Composite Index Annual ROR %
NYSE Composite Index: Annual Returns
YEAR
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979

ROR
-12.40%
22.10%
10.40%
-11.20%
-4.30%
12.60%
15.70%
-18.50%
-29.80%
31.00%
16.60%
-9.50%
5.70%
10.60%

YEAR
ROR
YEAR
ROR
1980 31.10%
1994
-3.10%
1981 -10.10% 1995 31.30%
1982 13.90%
1996 19.10%
1983 17.50%
1997 30.30%
1984
1.30%
1998 16.60%
1985 26.20%
1999
9.10%
1986 14.00%
2000
1.00%
1987
-0.30%
2001 -10.20%
1988 13.00%
2002 -19.80%
1989 24.80%
2003 29.30%
1990
-7.50%
2004 12.20%
1991 27.10%
2005
7.00%
1992
4.70%
2006 17.90%
1993
7.90%
2007
6.60%

YEAR
ROR
2008 -40.90%
2009 24.80%
2010 10.80%
2011
-6.10%
2012 12.90%
2013 23.20%
2014
4.20%
2015
-6.40%
2016
9.00%
2017 14.50%
2018 11.20%
2019 28.88%
2020
4.40%
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Appendix D: Five Year Monthly BETAs of Pharmaceutical Companies March 2020

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Company Name
Abbott Laboratories
Allergan plc.
Astrazeneca PLC
Bausch Health Companies Inc.
Bristol-Myers Squibb Company
China Pharma Holdings, Inc.
Dr. Reddy's Laboratories Ltd
Eli Lilly and Company
Emergent Biosolutions, Inc.
GlaxoSmithKline PLC
iBio, Inc.
Johnson & Johnson
Lannett Co Inc
Merck & Company, Inc.
NovaBay Pharmaceuticals, Inc.
Novartis AG
Novo Nordisk AS
Oragenics Inc.
Palatin Technologies, Inc.
Perrigo Company
Pfizer, Inc.
Prestige Consumer Healthcare Inc.
Synthetic Biologics, Inc
Takeda Pharmaceutical Company Limited
Taro Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited

BETA (β)
5 Year
Monthly
0.92
1.31
0.22
1.22
0.72
0.98
-0.23
0.17
1.11
0.41
-7.11
0.66
1.72
0.56
3.97
0.46
0.42
0.65
1.61
1.24
0.60
0.78
1.79
1.05
0.88
1.58
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Appendix E: SWINE FLU of 2009 PRICE CAR TABLE
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Appendix F: COVID-19 of 2020 PRICE CAR TABLE
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Appendix G: SWINE FLU of 2009 VOLUME CAR TABLE
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Appendix H: COVID-19 of 2020 VOLUME CAR TABLE

